<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE patent-document
  PUBLIC "-//MXW//DTD patent-document XML//EN" "http://www.matrixware.com/dtds/patents/v1.2/patent-document.dtd"><patent-document ucid="US-6060478-A" country="US" doc-number="6060478" kind="A" lang="EN" date="20000509" family-id="26696935" date-produced="20090603" status="new"><bibliographic-data><publication-reference fvid="72310006" ucid="US-6060478-A" status="new"><document-id status="new" format="original"><country>US</country><doc-number>6060478</doc-number><kind>A</kind><date>20000509</date></document-id></publication-reference><application-reference ucid="US-1500198-A" appl-type="1" us-art-unit="161" us-series-code="9 " status="new" is-representative="NO"><document-id format="epo" status="new"><country>US</country><doc-number>1500198</doc-number><kind>A</kind><date>19980128</date></document-id></application-reference><priority-claims status="new"><priority-claim ucid="US-1500198-A" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>1500198</doc-number><kind>A</kind><date>19980128</date></document-id></priority-claim><priority-claim ucid="US-2329096-P" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>2329096</doc-number><kind>P</kind><date>19960724</date></document-id></priority-claim><priority-claim ucid="US-89924297-A" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>89924297</doc-number><kind>A</kind><date>19970723</date></document-id></priority-claim></priority-claims><technical-data status="new"><classification-ipc status="new"><edition>7</edition><main-classification>A61K  31/505</main-classification><further-classification>C07D 487/04</further-classification></classification-ipc><classifications-ipcr><classification-ipcr status="new">C07D 487/00        20060101C I20051008RMEP        </classification-ipcr><classification-ipcr status="new">C07D 487/04        20060101A I20051008RMEP        </classification-ipcr></classifications-ipcr><classification-national country="US" status="new"><main-classification>5142285</main-classification><further-classification>544281</further-classification><further-classification>51425216</further-classification><further-classification>544180</further-classification><further-classification>5142338</further-classification><further-classification>514241</further-classification><further-classification>5142593</further-classification></classification-national><classification-ecla status="new"><classification-symbol scheme="EC">C07D 487/04+239C+231C</classification-symbol><classification-symbol scheme="EC">C07D 487/04+251C+231C</classification-symbol><classification-symbol scheme="EC">C07D 487/04+251C+249C</classification-symbol><classification-symbol scheme="ICO">M07D487:04</classification-symbol></classification-ecla><invention-title lang="EN" load-source="us" status="new">Azolo triazines and pyrimidines</invention-title><citations><patent-citations><patcit ucid="DE-4243279-A1" status="new"><document-id format="epo" status="new"><country>DE</country><doc-number>4243279</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="EP-0269859-A2" status="new"><document-id format="epo" status="new"><country>EP</country><doc-number>0269859</doc-number><kind>A2</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="EP-0300688-A1" status="new"><document-id format="epo" status="new"><country>EP</country><doc-number>0300688</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="EP-0373891-A2" status="new"><document-id format="epo" status="new"><country>EP</country><doc-number>0373891</doc-number><kind>A2</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="EP-0374448-A1" status="new"><document-id format="epo" status="new"><country>EP</country><doc-number>0374448</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="EP-0395144-A1" status="new"><document-id format="epo" status="new"><country>EP</country><doc-number>0395144</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="EP-0455545-A1" status="new"><document-id format="epo" status="new"><country>EP</country><doc-number>0455545</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="EP-0503099-A1" status="new"><document-id format="epo" status="new"><country>EP</country><doc-number>0503099</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="EP-0521622-A1" status="new"><document-id format="epo" status="new"><country>EP</country><doc-number>0521622</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="EP-0531901-A2" status="new"><document-id format="epo" status="new"><country>EP</country><doc-number>0531901</doc-number><kind>A2</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="EP-0576350-A1" status="new"><document-id format="epo" status="new"><country>EP</country><doc-number>0576350</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="EP-0591528-A1" status="new"><document-id format="epo" status="new"><country>EP</country><doc-number>0591528</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="EP-0594149-A2" status="new"><document-id format="epo" status="new"><country>EP</country><doc-number>0594149</doc-number><kind>A2</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="EP-0662477-A1" status="new"><document-id format="epo" status="new"><country>EP</country><doc-number>0662477</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="EP-0714898-A1" status="new"><document-id format="epo" status="new"><country>EP</country><doc-number>0714898</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="EP-0729758-A2" status="new"><document-id format="epo" status="new"><country>EP</country><doc-number>0729758</doc-number><kind>A2</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="EP-0773023-A1" status="new"><document-id format="epo" status="new"><country>EP</country><doc-number>0773023</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="EP-0778277-A1" status="new"><document-id format="epo" status="new"><country>EP</country><doc-number>0778277</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="EP-0812831-A1" status="new"><document-id format="epo" status="new"><country>EP</country><doc-number>0812831</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="JP-42011753-A" status="new"><document-id format="epo" status="new"><country>JP</country><doc-number>42011753</doc-number><kind>A</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="JP-61057587-A" status="new"><document-id format="epo" status="new"><country>JP</country><doc-number>61057587</doc-number><kind>A</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="US-3910907-A" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>3910907</doc-number><kind>A</kind></document-id><sources><source name="SEA" created-by-npl="N"/><source name="UNKNOWN" created-by-npl="N"/></sources></patcit><patcit ucid="US-3920652-A" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>3920652</doc-number><kind>A</kind></document-id><sources><source name="SEA" created-by-npl="N"/><source name="UNKNOWN" created-by-npl="N"/></sources></patcit><patcit ucid="US-3995039-A" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>3995039</doc-number><kind>A</kind></document-id><sources><source name="SEA" created-by-npl="N"/><source name="UNKNOWN" created-by-npl="N"/></sources></patcit><patcit ucid="US-4021556-A" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>4021556</doc-number><kind>A</kind></document-id><sources><source name="SEA" created-by-npl="N"/><source name="UNKNOWN" created-by-npl="N"/></sources></patcit><patcit ucid="US-4567263-A" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>4567263</doc-number><kind>A</kind></document-id><sources><source name="SEA" created-by-npl="N"/><source name="UNKNOWN" created-by-npl="N"/></sources></patcit><patcit ucid="US-4892576-A" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>4892576</doc-number><kind>A</kind></document-id><sources><source name="SEA" created-by-npl="N"/><source name="UNKNOWN" created-by-npl="N"/></sources></patcit><patcit ucid="US-4990647-A" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>4990647</doc-number><kind>A</kind></document-id><sources><source name="SEA" created-by-npl="N"/><source name="UNKNOWN" created-by-npl="N"/></sources></patcit><patcit ucid="US-4997940-A" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>4997940</doc-number><kind>A</kind></document-id><sources><source name="SEA" created-by-npl="N"/><source name="UNKNOWN" created-by-npl="N"/></sources></patcit><patcit ucid="US-5089499-A" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>5089499</doc-number><kind>A</kind></document-id><sources><source name="SEA" created-by-npl="N"/><source name="UNKNOWN" created-by-npl="N"/></sources></patcit><patcit ucid="US-5137887-A" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>5137887</doc-number><kind>A</kind></document-id><sources><source name="SEA" created-by-npl="N"/><source name="UNKNOWN" created-by-npl="N"/></sources></patcit><patcit ucid="US-5397774-A" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>5397774</doc-number><kind>A</kind></document-id><sources><source name="SEA" created-by-npl="N"/><source name="UNKNOWN" created-by-npl="N"/></sources></patcit><patcit ucid="US-5428044-A" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>5428044</doc-number><kind>A</kind></document-id><sources><source name="SEA" created-by-npl="N"/><source name="UNKNOWN" created-by-npl="N"/></sources></patcit><patcit ucid="US-5463071-A" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>5463071</doc-number><kind>A</kind></document-id><sources><source name="SEA" created-by-npl="N"/><source name="UNKNOWN" created-by-npl="N"/></sources></patcit><patcit ucid="US-5464847-A" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>5464847</doc-number><kind>A</kind></document-id><sources><source name="SEA" created-by-npl="N"/><source name="UNKNOWN" created-by-npl="N"/></sources></patcit><patcit ucid="US-5484760-A" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>5484760</doc-number><kind>A</kind></document-id><sources><source name="SEA" created-by-npl="N"/><source name="UNKNOWN" created-by-npl="N"/></sources></patcit><patcit ucid="US-5486531-A" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>5486531</doc-number><kind>A</kind></document-id><sources><source name="SEA" created-by-npl="N"/><source name="UNKNOWN" created-by-npl="N"/></sources></patcit><patcit ucid="US-5723608-A" status="new"><document-id format="epo" status="new"><country>US</country><doc-number>5723608</doc-number><kind>A</kind></document-id><sources><source name="UNKNOWN" created-by-npl="N"/><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1992010098-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1992010098</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1992020642-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1992020642</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1994009017-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1994009017</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1994013643-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1994013643</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1994013644-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1994013644</doc-number><kind>A1</kind></document-id><sources><source name="SEA"  created-by-npl="N"/></sources></patcit><patcit ucid="WO-1994013661-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1994013661</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1994013676-A1" status="new"><document-id format="epo"  status="new"><country>WO</country><doc-number>1994013676</doc-number><kind>A1</kind></document-id><sources><source name="SEA"  created-by-npl="N"/></sources></patcit><patcit ucid="WO-1994013677-A1"  status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1994013677</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1995000507-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1995000507</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1995011880-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1995011880</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1995032710-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1995032710</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1995033727-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1995033727</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1995033750-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1995033750</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1995034563-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1995034563</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1995035298-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1995035298</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1996019452-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1996019452</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1996023783-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1996023783</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1996035689-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1996035689</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1996039388-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1996039388</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1996039400-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1996039400</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1997000868-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1997000868</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1997014684-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1997014684</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1997029109-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1997029109</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1997029110-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1997029110</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1998008821-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1998008821</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1998008846-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1998008846</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit><patcit ucid="WO-1998008847-A1" status="new"><document-id format="epo" status="new"><country>WO</country><doc-number>1998008847</doc-number><kind>A1</kind></document-id><sources><source name="SEA" created-by-npl="N"/></sources></patcit></patent-citations><non-patent-citations><nplcit status="new"><text>Am. J. Psychiatry (Banki, et al.) 144:873 877 (1987).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Am. J. Psychiatry (Banki, et al.) 144:873-877 (1987).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Arch. Gen. Psychiatry (Nemeroff, et al.) 45:577 579 (1988).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Arch. Gen. Psychiatry (Nemeroff, et al.) 45:577-579 (1988).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Arch. Gen. Psychiatry (Sapolsky) 46:1047 1051 (1989).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Arch. Gen. Psychiatry (Sapolsky) 46:1047-1051 (1989).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Arch. Pharm. (Weinheim) 320, 487 491 (1987).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Arch. Pharm. (Weinheim) 320, 487-491 (1987).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Biol. Psychiatry (Arato, et al.) 25:355 359 (1989).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Biol. Psychiatry (Arato, et al.) 25:355-359 (1989).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Biol. Psychiatry (France, et al.) 23:86 88 (1988).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Biol. Psychiatry (France, et al.) 23:86-88 (1988).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Brain Research Reviews (Dunn, Berridge) 15:71 100 (1990).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Brain Research Reviews (Dunn, Berridge) 15:71-100 (1990).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Bull. Soc. Chim. Belg. (Maquestiau, Taghret, Eynde) vol. 101/No. 2/1992.</text><sources><source name="SEA" created-by-npl="N"/><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Chemical Abstracts, vol. 67, No. 28, 1967, abstract # 108663r.</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Chemical Abstracts, vol. 67, No. 28, 1967, abstract 108663r.</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Chemical Abstracts, vol. 68, No. 28, 1968, abstract # 114635v.</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Chemical Abstracts, vol. 68, No. 28, 1968, abstract 114635v.</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Chemical Abstracts, vol. 74, No. 28, 1971, abstract # 22867t.</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Chemical Abstracts, vol. 74, No. 28, 1971, abstract # 22872r.</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Chemical Abstracts, vol. 74, No. 28, 1971, abstract 22867t.</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Chemical Abstracts, vol. 74, No. 28, 1971, abstract 22872r.</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Comprehensive Organic Synthesis (Trost, Fleming) 3:481 520 (1991).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Comprehensive Organic Synthesis (Trost, Fleming) 3:481-520 (1991).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Comprehensive Organic Synthesis (Trost, Fleming) 7:762 769 (1991).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Comprehensive Organic Synthesis (Trost, Fleming) 7:762-769 (1991).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Corticotropin Releasing Factor: Basic and Clinical Studies of a Neuropeptide (De Souza, Nemeroff) p. 221 224 (1990).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Corticotropin Releasing Factor: Basic and Clinical Studies of a Neuropeptide (De Souza, Nemeroff) p. 221-224 (1990).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Hormones and Behavior (Berridge, Dunn) 21:393 401 (1987).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Hormones and Behavior (Berridge, Dunn) 21:393-401 (1987).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Hospital Practice (De Souza) p. 59 71 (1988).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Hospital Practice (De Souza) p. 59-71 (1988).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>J. Heterocyclic Chem. (O Brien, et al.) 22:601 634 (1985).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>J. Heterocyclic Chem. (O'Brien, et al.) 22:601-634 (1985).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>J. Med. Chem. (Senga, et al.) 25:243 249 (1982).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>J. Med. Chem. (Senga, et al.) 25:243-249 (1982).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>J. Med. Chem. (Senga, Novinson, Wilson) 24:610 613 (1981).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>J. Med. Chem. (Senga, Novinson, Wilson) 24:610-613 (1981).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Journal f.prakt. Chemie. (Joshi, Dubey) Band 321, Heft 2, p. 341 344 (1979).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Journal f.prakt. Chemie. (Joshi, Dubey) Band 321, Heft 2, p. 341-344 (1979).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Journal of Medicinal Chemistry (Springer, et al.) vol. 19, No. 2, p. 291 296 (1976).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Journal of Medicinal Chemistry (Springer, et al.) vol. 19, No. 2, p. 291-296 (1976).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Journal of Neuroscience (De Souza, et al.) vol. 5, No. 12, p. 3189 3203 (1985).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Journal of Neuroscience (De Souza, et al.) vol. 5, No. 12, p. 3189-3203 (1985).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Life Sciences (Britton, Koob, Rivier, Vale) 31:363 367 (1982).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Life Sciences (Britton, Koob, Rivier, Vale) 31:363-367 (1982).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Life Sciences (Morley, et al.) 41:527 544 (1987).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Life Sciences (Morley, et al.) 41:527-544 (1987).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Neuropsychopharmacology (Grigoriadis, et al.) vol. 2, No. 1, p. 53 60 (1989).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Neuropsychopharmacology (Grigoriadis, et al.) vol. 2, No. 1, p. 53-60 (1989).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>New Eng. J. Med. (Gold, et al.) vol. 314, No. 21, p. 1329 1335 (1986).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>New Eng. J. Med. (Gold, et al.) vol. 314, No. 21, p. 1329-1335 (1986).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Perspectives on Behavioral Medicine (Koob) 2:39 52 (1985).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Perspectives on Behavioral Medicine (Koob) 2:39-52 (1985).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Physiological Reviews (Blalock) vol. 69, No. 1, p. 1 33 (1989).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Physiological Reviews (Blalock) vol. 69, No. 1, p. 1-33 (1989).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Proc. Natl. Acad. Sci. (Rivier, Spiess, Vale) 80:4851 4855 (1983).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Proc. Natl. Acad. Sci. (Rivier, Spiess, Vale) 80:4851-4855 (1983).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Psychopharmacology (Britton, et al.) 86:170 174 (1985).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Psychopharmacology (Britton, et al.) 86:170-174 (1985).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Psychopharmacology (Britton, Lee, Koob) 94:306 311 (1988).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Psychopharmacology (Britton, Lee, Koob) 94:306-311 (1988).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Psychopharmacology (Swerdlow, Geyer, Vale, Koob) 88:147 152 (1986).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Psychopharmacology (Swerdlow, Geyer, Vale, Koob) 88:147-152 (1986).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Recent Progress in Hormone Research (Vale, et al.) 39:245 271 (1983).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Recent Progress in Hormone Research (Vale, et al.) 39:245-271 (1983).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Regulatory Peptides (Berridge, Dunn) 16:83 93 (1986).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Regulatory Peptides (Berridge, Dunn) 16:83-93 (1986).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Remington s Pharmaceutical Sciences (Gennaro, ed.) 17 th ed. P. 1418 1419 (1985).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Remington's Pharmaceutical Sciences (Gennaro, ed.) 17.sup.th ed. P. 1418-1419 (1985).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Science (Nemeroff, et al.) 226:1342 (1984).</text><sources><source name="SEA" created-by-npl="N"/><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Science, (Vale, et al.) 213:1394 1397 (1981).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Science, (Vale, et al.) 213:1394-1397 (1981).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Synapse (Battaglia, Webster, De Souza), 1:572 581 (1987).</text><sources><source name="SEA" created-by-npl="N"/></sources></nplcit><nplcit status="new"><text>Synapse (Battaglia, Webster, De Souza), 1:572-581 (1987).</text><sources><source name="UNKNOWN" created-by-npl="N"/></sources></nplcit></non-patent-citations></citations><field-of-search status="new"><classification-national country="US" status="new"><text>514/245;246;258;241</text></classification-national><classification-national country="US" status="new"><text>544/180;194;281</text></classification-national></field-of-search></technical-data><related-documents status="new"><relation type="continuation-in-part"><child-doc ucid="US-01500198"><document-id status="new" format="original"><country>US</country><doc-number>01500198</doc-number><date>19980128</date></document-id></child-doc><parent-doc ucid="US-89924297" psta="unknown"><document-id status="new" format="original"><country>US</country><doc-number>89924297</doc-number><date>19970723</date></document-id></parent-doc></relation></related-documents><parties><applicants><applicant format="epo" status="new"><addressbook><name>DU PONT PHARM CO</name><address><country>US</country></address></addressbook></applicant><applicant format="intermediate" status="new"><addressbook><name>DUPONT PHARMACEUTICALS</name></addressbook></applicant></applicants><inventors><inventor format="epo" status="new"><addressbook><name>ARVANITIS ARGYRIOS GEORGIOS</name><address><country>US</country></address></addressbook></inventor><inventor format="epo" status="new"><addressbook><name>CHORVAT ROBERT</name><address><country>US</country></address></addressbook></inventor><inventor format="epo" status="new"><addressbook><name>GILLIGAN PAUL</name><address><country>US</country></address></addressbook></inventor><inventor format="intermediate" status="new"><addressbook><name>ARVANITIS; ARGYRIOS GEORGIOS</name></addressbook></inventor><inventor format="intermediate" status="new"><addressbook><name>CHORVAT; ROBERT</name></addressbook></inventor><inventor format="intermediate" status="new"><addressbook><name>GILLIGAN; PAUL</name></addressbook></inventor><inventor format="original" status="new"><addressbook><last-name>Arvanitis</last-name><first-name>Argyrios Georgios</first-name><address><city>Kennett Square</city><state>PA</state><country>US</country></address></addressbook></inventor><inventor format="original" status="new"><addressbook><last-name>Chorvat</last-name><first-name>Robert</first-name><address><city>West Chester</city><state>PA</state><country>US</country></address></addressbook></inventor><inventor format="original" status="new"><addressbook><last-name>Gilligan</last-name><first-name>Paul</first-name><address><city>Wilmington</city><state>DE</state><country>US</country></address></addressbook></inventor></inventors><assignees><assignee format="original" status="new"><addressbook><name>DUPONT PHARMACEUTICALS</name><address><city>Wilmington</city><state>DE</state><country>US</country></address></addressbook></assignee></assignees><agents><agent format="original" status="new"><addressbook><last-name>Rubin</last-name><first-name>Kenneth B.</first-name></addressbook></agent></agents><examiners><examiner examiner-level="primary" sequence="1" format="original" status="new"><addressbook><last-name>Ford</last-name><first-name>John M.</first-name><address><country>US</country></address></addressbook></examiner></examiners></parties></bibliographic-data><abstract lang="EN" load-source="us" status="new"><p>Corticotropin releasing factor (CRF) antagonists of formula I or II: ##STR1## and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.</p></abstract><description lang="EN" load-source="us" status="new"><?description-type Parent Case Text?><p>This is a continuation-in-part of application Ser. No. 08/899,242 filed Jul. 23, 1997, which claims benefit of provisional application 60/023,290, filed Jul. 24, 1996.</p><?description-type Brief Summary?><heading>FIELD OF THE INVENTION</heading><p>This invention relates a treatment of psychiatric disorders and neurological diseases including major depression, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress, by administration of certain [1,5-a]-pyrazolo-1,3,5-triazines, [1,5-a]-1,2,3-triazolo-1,3,5-triazines, [1,5-a]-pyrazolo-pyrimidines and [1,5-a]-1,2,3-triazolo-pyrimidines.</p><heading>BACKGROUND OF THE INVENTION</heading><p>Corticotropin releasing factor (herein referred to as CRF), a 41 amino acid peptide, is the primary physiological regulator of proopiomelanocortin (POMC)-derived peptide secretion from the anterior pituitary gland [J. Rivier et al., Proc. Nat. Acad. Sci. (USA) 80:4851 (1983); W. Vale et al., Science 213:1394 (1981)]. In addition to its endocrine role at the pituitary gland, immunohistochemical localization of CRF has demonstrated that the hormone has a broad extrahypothalamic distribution in the central nervous system and produces a wide spectrum of autonomic, electrophysiological and behavioral effects consistent with a neurotransmitter or neuromodulator role in brain [W. Vale et al., Rec. Prog. Horm. Res. 39:245 (1983); G. F. Koob, Persp. Behav. Med. 2:39 (1985); E. B. De Souza et al., J. Neurosci. 5:3189 (1985)]. There is also evidence that CRF plays a significant role in integrating the response of the immune system to physiological, psychological, and immunological stressors [J. E. Blalock, Physiological Reviews 69:1 (1989); J. E. Morley, Life Sci. 41:527 (1987)].</p><p>Clinical data provide evidence that CRF has a role in psychiatric disorders and neurological diseases including depression, anxiety-related disorders and feeding disorders. A role for CRF has also been postulated in the etiology and pathophysiology of Alzheimer's disease, Parkinson's disease, Huntington's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis as they relate to the dysfunction of CRF neurons in the central nervous system [for review see E. B. De Souza, Hosp. Practice 23:59 (1988)].</p><p>In affective disorder, or major depression, the concentration of CRF is significantly increased in the cerebral spinal fluid (CSF) of drug-free individuals [C. B. Nemeroff et al., Science 226:1342 (1984); C. M. Banki et al., Am. J. Psychiatry 144:873 (1987); R. D. France et al., Biol. Psychiatry 28:86 (1988); M. Arato et al., Biol Psychiatry 25:355 (1989)]. Furthermore, the density of CRF receptors is significantly decreased in the frontal cortex of suicide victims, consistent with a hypersecretion of CRF [C. B. Nemeroff et al., Arch. Gen. Psychiatry 45:577 (1988)]. In addition, there is a blunted adrenocorticotropin (ACTH) response to CRF (i.v. administered) observed in depressed patients [P. W. Gold et al., Am J. Psychiatry 141:619 (1984); F. Holsboer et al., Psychoneuroendocrinology 9:147 (1984); P. W. Gold et al., New Eng. J. Med. 314:1129 (1986)]. Preclinical studies in rats and non-human primates provide additional support for the hypothesis that hypersecretion of CRF may be involved in the symptoms seen in human depression [R. M. Sapolsky, Arch. Gen. Psychiatry 46:1047 (1989)]. There is preliminary evidence that tricyclic antidepressants can alter CRF levels and thus modulate the numbers of CRF receptors in brain [Grigoriadis et al., Neuropsychopharmacology 2:53 (1989)].</p><p>There has also been a role postulated for CRF in the etiology of anxiety-related disorders. CRF produces anxiogenic effects in animals and interactions between benzodiazepine/non-benzodiazepine anxiolytics and CRF have been demonstrated in a variety of behavioral anxiety models [D. R. Britton et al., Life Sci. 31:363 (1982); C. W. Berridge and A. J. Dunn Regul. Peptides 16:83 (1986)]. Preliminary studies using the putative CRF receptor antagonist a-helical ovine CRF (9-41) in a variety of behavioral paradigms demonstrate that the antagonist produces "anxiolytic-like" effects that are qualitatively similar to the benzodiazepines [C. W. Berridge and A. J. Dunn Horm. Behav. 21:393 (1987), Brain Research Reviews 15:71 (1990)]. Neurochemical, endocrine and receptor binding studies have all demonstrated interactions between CRF and benzodiazepine anxiolytics providing further evidence for the involvement of CRF in these disorders. Chlordiazepoxide attenuates the "anxiogenic" effects of CRF in both the conflict test [K. T. Britton et al., Psychopharmacology 86:170 (1985); K. T. Britton et al., Psychopharmacology 94:306 (1988)] and in the acoustic startle test [N. R. Swerdlow et al., Psychopharmacology 88:147 (1986)] in rats. The benzodiazepine receptor antagonist (Ro15-1788), which was without behavioral activity alone in the operant conflict test, reversed the effects of CRF in a dose-dependent manner while the benzodiazepine inverse agonist (FG7142) enhanced the actions of CRF [K. T. Britton et al., Psychopharmacology 94:306 (1988)].</p><p>The mechanisms and sites of action through which the standard anxiolytics and antidepressants produce their therapeutic effects remain to be elucidated. It has been hypothesized however, that they are involved in the suppression of the CRF hypersecretion that is observed in these disorders. Of particular interest is that preliminary studies examining the effects of a CRF receptor antagonist (α-helical CRF.sub.9-41) in a variety of behavioral paradigms have demonstrated that the CRF antagonist produces "anxiolytic-like" effects qualitatively similar to the benzodiazepines [for review see G. F. Koob and K. T. Britton, In: Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide, E. B. De Souza and C. B. Nemeroff eds., CRC Press p221 (1990)].</p><p>Several publications describe corticotropin releasing factor antagonist compounds and their use to treat psychiatric disorders and neurological diseases. Examples of such publications include DuPont Merck PCT application US94/11050, Pfizer WO 95/33750, Pfizer WO 95/34563, Pfizer WO 95/33727 and Pfizer EP 0778 277 A1.</p><p>Insofar as is known, [1,5-a]-pyrazolo-1,3,5-triazines, [1,5-a]-1,2,3-triazolo-1,3,5-triazines, [1,5-a]-pyrazolo-pyrimidines and [1,5-a]-1,2,3-triazolo-pyrimidines, have not been previously reported as corticotropin releasing factor antagonist compounds useful in the treatment of psychiatric disorders and neurological diseases. However, there have been publications which teach some of these compounds for other uses.</p><p>For instance, EP 0 269 859 (Ostuka, 1988) discloses pyrazolotriazine compounds of the formula ##STR2## where R.sup.1 is OH or alkanoyl, R.sup.2 is H, OH, or SH, and R.sup.3 is an unsaturated heterocyclic group, naphthyl or substituted phenyl, and states that the compounds have xanthine oxidase inhibitory activity and are useful for treatment of gout.</p><p>EP 0 594 149 (Ostuka, 1994) discloses pyrazolotriazine and pyrazolopyrimidine compounds of the formula ##STR3## where A is CH or N, R.sup.0 and R.sup.3 are H or alkyl, and R.sup.1 and R.sup.2 are H, alkyl, alkoxyl, alkylthio, nitro, etc., and states that the compounds inhibit androgen and are useful in treatment of benign prostatic hypertrophy and prostatic carcinoma.</p><p>U.S. Pat. No. 3,910,907 (ICI, 1975) discloses pyrazolotriazines of the formula: ##STR4## where R.sup.1 is CH.sub.3, C.sub.2 H.sub.5 or C.sub.6 H.sub.5, X is H, C.sub.6 H.sub.5, m-CH.sub.3 C.sub.6 H.sub.4, CN, COOEt, Cl, I or Br, Y is H, C.sub.6 H.sub.5, o-CH.sub.3 C.sub.6 H.sub.4, or p-CH.sub.3 C.sub.6 H.sub.4, and Z is OH, H, CH.sub.3, C.sub.2 H.sub.5, C.sub.6 H.sub.5, n-C.sub.3 H.sub.7, i-C.sub.3 H.sub.7, SH, SCH.sub.3, NHC.sub.4 H.sub.9, or N(C.sub.2 H.sub.5).sub.2, and states that the compounds are c-AMP phosphodiesterase inhibitors useful as bronchodilators.</p><p>U.S. Pat. No. 3,995,039 discloses pyrazolotriazines of the formula: ##STR5## where R.sup.1 is H or alkyl, R.sup.2 is H or alkyl, R.sup.3 is H, alkyl, alkanoyl, carbamoyl, or lower alkylcarbamoyl, and R is pyridyl, pyrimidinyl, or pyrazinyl, and states that the compounds are useful as bronchodilators.</p><p>U.S. Pat. No. 5,137,887 discloses pyrazolotriazines of the formula ##STR6## where R is lower alkoxy, and teaches that the compounds are xanthine oxidase inhibitors and are useful for treatment of gout.</p><p>U.S. Pat. No. 4,892,576 discloses pyrazolotriazines of the formula ##STR7## where X is O or S, Ar is a phenyl, naphthyl, pyridyl or thienyl group, R.sub.6 -R.sub.8 are H, alkyl, etc., and R.sub.9 is H, alkyl, phenyl, etc. The patent states that the compounds are useful as herbicides and plant growth regulants.</p><p>U.S. Pat. No. 5,484,760 and WO 92/10098 discloses herbicidal compositions containing, among other things, a herbicidal compound of the formula ##STR8## where A can be N, B can be CR.sub.3, R.sub.3 can be phenyl or substituted phenyl, etc., R is --N(R.sub.4)SO.sub.2 R.sub.5 or --SO.sub.2 N(R.sub.6)R.sub.7 and R.sub.1 and R.sub.2 can be taken together to form ##STR9## where X, Y and Z are H, alkyl, acyl, etc. and D is O or S.</p><p>U.S. Pat. No. 3,910,907 and Senga et al., J. Med. Chem., 1982, 25, 243-249, disclose triazolotriazines cAMP phosphodiesterase inhibitors of the formula ##STR10## where Z is H, OH, CH.sub.3, C.sub.2 H.sub.5, C.sub.6 H.sub.5, n-C.sub.3 H.sub.7, iso-C.sub.3 H.sub.7, SH, SCH.sub.3, NH(n-C.sub.4 H.sub.9), or N(C.sub.2 H.sub.5).sub.2, R is H or CH.sub.3, and R.sub.1 is CH.sub.3 or C.sub.2 H.sub.5. The reference lists eight therapeutic areas where inhibitors of cAMP phosphodiesterase could have utility: asthma, diabetes mellitus, female fertility control, male infertility, psoriasis, thrombosis, anxiety, and hypertension.</p><p>WO95/35298 (Otsuka, 1995) discloses pyrazolopyrimidines and states that they are useful as analgesics. The compounds are represented by the formula ##STR11## where Q is carbonyl or sulfonyl, n is 0 or 1, A is a single bond, alkylene or alkenylene, R.sup.1 is H, alkyl, etc., R.sup.2 is naphthyl, cycloalkyl, heteroaryl, substituted phenyl or phenoxy, R.sup.3 is H, alkyl or phenyl, R.sup.4 is H, alkyl, alkoxycarbonyl, phenylalkyl, optionally phenylthio-substituted phenyl, or halogen, R.sup.5 and R.sup.6 are H or alkyl.</p><p>EP 0 591 528 (Otsuka,1991) discloses anti-inflammatory use of pyrazolopyrimidines represented by the formula ##STR12## where R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are H, carboxyl, alkoxycarbonyl, optionally substituted alkyl, cycloalkyl, or phenyl, R.sub.5 is SR.sub.6 or NR.sub.7 R.sub.8, R.sub.6 is pyridyl or optionally substituted phenyl, and R.sub.7 and R.sub.8 are H or optionally substituted phenyl.</p><p>Springer et al, J. Med. Chem., 1976, vol. 19, no. 2, 291-296 and Springer U.S. Pat. Nos. 4021,556 and 3,920,652 disclose pyrazolopyrimidines of the formula ##STR13## where R can be phenyl, substituted phenyl or pyridyl, and their use to treat gout, based on their ability to inhibit xanthine oxidase.</p><p>Joshi et al., J. Prakt. Chemie, 321, 2, 1979, 341-344, discloses compounds of the formula ##STR14## where R.sup.1 is CF.sub.3, C.sub.2 F.sub.5, or C.sub.6 H.sub.4 F, and R.sup.2 is CH.sub.3, C.sub.2 H.sub.5, CF.sub.3, or C.sub.6 H.sub.4 F.</p><p>Maquestiau et al., Bull. Soc. Belg., vol. 101, no. 2, 1992, pages 131-136 discloses a pyrazolo[1,5-a]pyrimidine of the formula ##STR15##</p><p>Ibrahim et al., Arch. Pharm. (weinheim) 320, 487-491 (1987) discloses pyrazolo[1,5-a]pyrimidines of the formula ##STR16## where R is NH2 or OH and Ar is 4-phenyl-3-cyano-2-aminopyrid-2-yl.</p><p>Other references which disclose azolopyrimidines inclued EP 0 511 528 (Otsuka, 1992), U.S. Pat. No. 4,997,940 (Dow, 1991), EP 0 374 448 (Nissan, 1990), U.S. Pat. No. 4,621,556 (ICN, 1997), EP 0 531 901 (Fujisawa, 1993), U.S. Pat. No. 4,567,263 (BASF, 1986), EP 0 662 477 (Isagro, 1995), DE 4 243 279 (Bayer, 1994), U.S. Pat. No. 5,397,774 (Upjohn, 1995), EP 0 521 622 (Upjohn, 1993), WO 94/109017 (Upjohn, 1994), J. Med. Chem., 24, 610-613 (1981), and J. Het. Chem., 22, 601 (1985).</p><heading>SUMMARY OF THE INVENTION</heading><p>In accordance with one aspect, the present invention provides novel compounds, pharmaceutical compositions and methods which may be used in the treatment of affective disorder, anxiety, depression, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal disease, anorexia nervosa or other feeding disorder, drug or alcohol withdrawal symptoms, drug addiction, inflammatory disorder, fertility problems, disorders, the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, or a disorder selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic, phobias, obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; fatigue syndrome; stress-induced headache; cancer, human immunodeficiency virus (HIV) infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases such as ulcers, irritable bowel syndrome, Crohn's disease, spastic colon, diarrhea, and post operative ilius and colonic hypersensitivity associated by psychopathological disturbances or stress; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiarrhetic hormone (ADH); obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage (e.g., cerebral ischemia such as cerebral hippocampal ischemia); excitotoxic neuronal damage; epilepsy; cardiovascular and hear related disorders including hypertension, tachycardia and congestive heart failure; stroke; immune dysfunctions including stress induced immune dysfunctions (e.g. stress induced fevers, porcine stress syndrome, bovine shipping fever, equine paroxysmal fibrillation, and dysfunctions induced by confinement in chickens, sheering stress in sheep or human-animal interaction related stress in dogs); muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; chemical dependencies and addictions (e a., dependencies on alcohol, cocaine, heroin, benzodiazepines, or other drugs); drug and alcohol withdrawal symptoms; osteoporosis; psychosocial dwarfism and hypoglycemia in a mammal.</p><p>The present invention provides novel compounds which bind to corticotropin releasing factor receptors, thereby altering the anxiogenic effects of CRF secretion. The compounds of the present invention are useful for the treatment of psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in a mammal.</p><p>According to another aspect, the present invention provides novel compounds of Formulae (1) and (2) (described below) which are useful as antagonists of the corticotropin releasing factor. The compounds of the present invention exhibit activity as corticotropin releasing factor antagonists and appear to suppress CRF hypersecretion. The present invention also includes pharmaceutical compositions containing such compounds of Formulae (1) and (2), and methods of using such compounds for the suppression of CRF hypersecretion, and/or for the treatment of anxiogenic disorders.</p><p>According to yet another aspect of the invention, the compounds provided by this invention (and especially labelled compounds of this invention) are also useful as standards and reagents in determining the ability of a potential pharmaceutical to bind to the CRF receptor.</p><heading>DETAILED DESCRIPTION OF INVENTION</heading><p>[1] The present invention comprises a method of treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals comprising administering to the mammal a therapeutically effective amount of a compound of Formulae (1) or (2): ##STR17## and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof, wherein:</p><p>A is N or CR;</p><p>Z is N or CR.sup.2 ;</p><p>Ar is selected from phenyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, benzothienyl, benzofuranyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, indanyl, 1,2-benzopyranyl, 3,4-dihydro-1,2-benzopyranyl, tetralinyl, each Ar optionally substituted with 1 to 5 R.sup.4 groups and each Ar is attached to an unsaturated carbon atom;</p><p>R is independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.7 cycloalkylalkyl, halo, CN, C.sub.1 -C.sub.4 haloalkyl;</p><p>R.sup.1 is independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, halo, CN, C.sub.1 -C.sub.4 haloalkyl, C.sub.1 -C.sub.12 hydroxyalkyl, C.sub.2 -C.sub.12 alkoxyalkyl, C.sub.2 -C.sub.10 cyanoalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, NR.sup.9 R.sup.10, C.sup.1 -C.sub.4 alkyl-NR.sup.9 R.sup.10, NR.sup.9 COR.sup.10, OR.sup.11, SH or S(O).sub.n R.sup.12 ;</p><p>R.sup.2 is selected from H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, C.sub.1 -C.sub.4 hydroxyalkyl, halo, CN, --NR.sup.6 R.sup.7, NR.sup.9 COR.sup.10, --NR.sup.6 S(O).sub.n R.sup.7, S(O).sub.n NR.sup.6 R.sup.7, C.sub.1 -C.sub.4 haloalkyl, --OR.sup.7, SH or --S(O).sub.n R.sup.12 ;</p><p>R.sup.3 is selected from:</p><p>--H, OR.sup.7, SH, S(O).sub.n R.sup.13, COR.sup.7, CO.sub.2 R.sup.7, OC(O)R.sup.13, NR.sup.8 COR.sup.7, N(COR.sup.7).sub.2, NR.sup.8 CONR.sup.6 R.sup.7, NR.sup.8 CO.sub.2 R.sup.13 NR.sup.6 R.sup.7, NR.sup.6a R.sup.7a, N(OR.sup.7)R.sup.6, CONR.sup.6 R.sup.7, aryl, heteroaryl and heterocyclyl, or</p><p>--C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.5 -C.sub.8 cycloalkenyl, C.sub.4 -C.sub.12 cycloalkylalkyl or C.sub.6 -C.sub.10 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl and heterocyclyl;</p><p>R.sup.4 is independently selected at each occurrence from:</p><p>C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, NO.sub.2, halo, CN, C.sub.1 -C.sub.4 haloalkyl, NR.sup.6 R.sup.7, NR.sup.8 COR.sup.7, NR.sup.8 CO.sub.2 R.sup.7, COR.sup.7, OR.sup.7, CONR.sup.6 R.sup.7, CO(NOR.sup.9)R.sup.7, CO.sub.2 R.sup.7, or S(O).sub.n R.sup.7, where each such C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.6 cycloalkyl and C.sub.4 -C.sub.12 cycloalkylalkyl are optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, NO.sub.2, halo, CN, NR.sup.6 R.sup.7, NR.sup.8 COR.sup.7, NR.sup.8 CO.sub.2 R.sup.7, COR.sup.7 OR.sup.7, CONR.sup.6 R.sup.7, CO.sub.2 R.sup.7, CO(NOR.sup.9)R.sup.7, or S(O).sub.n R.sup.7 ;</p><p>R.sup.6 and R.sup.7, R.sup.6a and R.sup.7a are independently selected at each occurrence from:</p><p>--H,</p><p>--C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.1 -C.sub.10 haloalkyl with 1-10 halogens, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, C.sub.5 -C.sub.10 cycloalkenyl, or C.sub.6 -C.sub.14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl,</p><p>-aryl, aryl(C.sub.1 -C.sub.4 alkyl), heteroaryl, heteroaryl(C.sub.1 -C.sub.4 alkyl), heterocyclyl or heterocyclyl(C.sub.1 -C.sub.4 alkyl);</p><p>alternatively, NR.sup.6 R.sup.7 and NR.sup.6a R.sup.7a are independently piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine, each optionally substituted with 1-3 C.sub.1 -C.sub.4 alkyl groups;</p><p>R.sup.8 is independently selected at each occurrence from H or C.sub.1 -C.sub.4 alkyl;</p><p>R.sup.9 and R.sup.10 are independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, or C.sub.3 -C.sub.6 cycloalkyl;</p><p>R.sup.11 is selected from H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, or C.sub.3 -C.sub.6 cycloalkyl;</p><p>R.sup.12 is C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 haloalkyl;</p><p>R.sup.13 is selected from C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, aryl, aryl (C.sub.1 -C.sub.4 alkyl)-, heteroaryl or heteroaryl (C.sub.1 -C.sub.4 alkyl)-;</p><p>R.sup.14 is selected from C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, or C.sub.4 -C.sub.12 cycloalkylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, and C.sub.1 -C.sub.6 alkylthio, C.sub.1 -C.sub.6 alkylsulfinyl and C.sub.1 -C.sub.6 alkylsulfonyl;</p><p>R.sup.15 and R.sup.16 are independently selected at each occurrence from H, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.10 cycloalkyl, C.sub.4 -C.sub.16 cycloalkylalkyl, except that for S(O).sub.n R.sup.15, R.sup.15 cannot be H;</p><p>aryl is phenyl or naphthyl, each optionally substituted with 1 to 5 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.16 R.sup.15, and CONR.sup.16 R.sup.15 ;</p><p>heteroaryl is pyridyl, pyrimidinyl, triazinyl, furanyl, pyranyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, isoxazolyl, pyrazolyl, 2,3-dihydrobenzothienyl or 2,3-dihydrobenzofuranyl, each being optionally substituted with 1 to 5 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, --COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.16 R.sup.15 and CONR.sup.16 R.sup.15 ;</p><p>heterocyclyl is saturated or partially saturated heteroaryl, optionally substituted with 1 to 5 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.15 R.sup.16, and CONR.sup.16 R.sup.15 ;</p><p>n is independently at each occurrence 0, 1 or 2,</p><p>[2] Preferred methods of the present invention are methods in wherein in the compound of Formulae (1) or (2), Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, each optionally substituted with 1 to 4 R.sup.4 substituents.</p><p>[3] Further preferred methods of the above invention are methods wherein, in the compound of Formulae (1) or (2), A is N, Z is CR.sup.2, Ar is 2,4-dichlorophenyl, 2,4-dimethylphenyl or 2,4,6-trimethylphenyl, R.sup.1 and R.sup.2 are CH.sub.3, and R.sup.3 is NR.sup.6a R.sup.7a.</p><p>[4] The present invention comprises compounds of Formulae (1) or (2): ##STR18## and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein:</p><p>A is N or CR;</p><p>Z is N or CR.sup.2 ;</p><p>Ar is selected from phenyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, benzothienyl, benzofuranyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, indanyl, 1,2-benzopyranyl, 3,4-dihydro-1,2-benzopyranyl, tetralinyl, each Ar optionally substituted with 1 to 5 R.sup.4 groups and each Ar is attached to an unsaturated carbon atom;</p><p>R is independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.7 cycloalkylalkyl, halo, CN, C.sub.1 -C.sub.4 haloalkyl;</p><p>R.sup.1 is independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, halo, CN, C.sub.1 -C.sub.4 haloalkyl, C.sub.1 -C.sub.12 hydroxyalkyl, C.sub.2 -C.sub.12 alkoxyalkyl, C.sub.2 -C.sub.10 cyanoalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, NR.sup.9 R.sup.10, C.sub.1 -C.sub.4 alkyl-NR.sup.9 R.sup.10, NR.sup.9 COR.sup.10, OR.sup.11, SH or S(O).sub.n R.sup.12 ;</p><p>R.sup.2 is selected from H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, C.sub.1 -C.sub.4 hydroxyalkyl, halo, CN, --NR.sup.6 R.sup.7, NR.sup.9 COR.sup.10, --NR.sup.6 S(O).sub.n R.sup.7, S(O).sub.n NR.sup.6 R.sup.7, C.sub.1 -C.sub.4 haloalkyl, --OR.sup.7, SH or --S(O).sub.n R.sup.12 ;</p><p>R.sup.3 is selected from:</p><p>--H, OR.sup.7, SH, S(O).sub.n R.sup.13, COR.sup.7, CO.sub.2 R.sup.7, OC(O)R.sup.13, NR.sup.8 COR.sup.7, N(COR.sup.7).sub.2, NR.sup.8 CONR.sup.6 R.sup.7, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.6 R.sup.7, NR.sup.6a R.sup.7a, N(OR.sup.7)R.sup.6, CONR.sup.6 R.sup.7, aryl, heteroaryl and heterocyclyl, or</p><p>--C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.5 -C.sub.8 cycloalkenyl, C.sub.4 -C.sub.12 cycloalkylalkyl or C.sub.6 -C.sub.10 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl and heterocyclyl;</p><p>R.sup.4 is independently selected at each occurrence from:</p><p>C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, NO.sub.2, halo, CN, C.sub.1 -C.sub.4 haloalkyl, NR.sup.6 R.sup.7, NR.sup.8 COR.sup.7, NR.sup.8 CO.sub.2 R.sup.7, COR.sup.7, OR.sup.7, CONR.sup.6 R.sup.7, CO(NOR.sup.9)R.sup.7, CO.sub.2 R.sup.7, or S(O).sub.n R.sup.7, where each such C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.6 cycloalkyl and C.sub.4 -C.sub.12 cycloalkylalkyl are optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, NO.sub.2, halo, CN, NR.sup.6 R.sup.7, NR.sup.8 COR.sup.7, NR.sup.8 CO.sub.2 R.sup.7, COR.sup.7 OR.sup.7, CONR.sup.6 R.sup.7, CO.sub.2 R.sup.7, CO(NOR.sup.9)R.sup.7, or S(O).sub.n R.sup.7 ;</p><p>R.sup.6 and R.sup.7, R.sup.6a and R.sup.7a are independently selected at each occurrence from:</p><p>--H,</p><p>--C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.1 -C.sub.10 haloalkyl with 1-10 halogens, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, C.sub.5 -C.sub.10 cycloalkenyl, or C.sub.6 -C.sub.14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl,</p><p>-aryl, aryl (C.sub.1 -C.sub.4 alkyl), heteroaryl, heteroaryl (C.sub.1 -C.sub.4 alkyl), heterocyclyl or heterocyclyl (C.sub.1 -C.sub.4 alkyl),</p><p>alternatively, NR.sup.6 R.sup.7 and NR.sup.6a R.sup.7a are independently piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine, each optionally substituted with 1-3 C.sub.1 -C.sub.4 alkyl groups;</p><p>R.sup.8 is independently selected at each occurrence from H or C.sub.1 -C.sub.4 alkyl;</p><p>R.sup.9 and R.sup.10 are independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, or C.sub.3 -C.sub.6 cycloalkyl;</p><p>R.sup.11 is selected from H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, or C.sub.3 -C.sub.6 cycloalkyl;</p><p>R.sup.12 is C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 haloalkyl;</p><p>R.sup.13 is selected from C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, aryl, aryl(C.sub.1 -C.sub.4 alkyl)-, heteroaryl or heteroaryl(C.sub.1 -C.sub.4 alkyl)-;</p><p>R.sup.14 is selected from C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, or C.sub.4 -C.sub.12 cycloalkylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, and C.sub.1 -C.sub.6 alkylthio, C.sub.1 -C.sub.6 alkylsulfinyl and C.sub.1 -C.sub.6 alkylsulfonyl;</p><p>R.sup.15 and R.sup.16 are independently selected at each occurrence from H, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.10 cycloalkyl, C.sub.4 -C.sub.16 cycloalkylalkyl, except that for S(O).sub.n R.sup.15, R.sup.15 cannot be H;</p><p>aryl is phenyl or naphthyl, each optionally substituted with 1 to 5 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 Rl.sup.5, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.16 R.sup.15, and CONR.sup.16 R.sup.15 ;</p><p>heteroaryl is pyridyl, pyrimidinyl, triazinyl, furanyl, pyranyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, isoxazolyl, pyrazolyl, 2,3-dihydrobenzothienyl or 2,3-dihydrobenzofuranyl, each being optionally substituted with 1 to 5 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, --COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.16 R.sup.15, and CONR.sup.16 R.sup.15 ;</p><p>heterocyclyl is saturated or partially saturated heteroaryl, optionally substituted with 1 to 5 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.15 R.sup.16, and CONR.sup.16 R.sup.15 ;</p><p>n is independently at each occurrence 0, 1 or 2,</p><p>with the provisos that:</p><p>(1) when A is N, Z is CR.sup.2, R.sup.2 is H, R.sup.3 is --OR.sup.7 or --OCOR.sup.13, and R.sup.7 is H, then R.sup.1 is not H, OH or SH;</p><p>(2) when A is N, Z is CR.sup.2, R.sup.1 is CH.sub.3 or C.sub.2 H.sub.5, R.sup.2 is H, and R.sup.3 is OH, H, CH.sub.3, C.sub.2 H.sub.5, C.sub.6 H.sub.5, n-C.sub.3 H.sub.7, i-C.sub.3 H.sub.7, SH, SCH.sub.3, NHC.sub.4 H.sub.9, or N(C.sub.2 H.sub.5).sub.2, then Ar is not phenyl or m-CH.sub.3 -phenyl;</p><p>(3) when A is N, Z is CR.sup.2, R.sup.2 is H, and Ar is pyridyl, pyrimidinyl or pyrazinyl, and R.sup.3 is NR.sup.6a R.sup.7a, then R.sup.6a and R.sup.7a are not H or alkyl;</p><p>(4) when A is N, Z is CR.sup.2, and R.sup.2 is SO.sub.2 NR.sup.6 R.sup.7, then R.sup.3 is not OH or SH;</p><p>(5) when A is CR and Z is CR.sup.2, then R.sup.2 is not --NR.sup.6 SO.sub.2 R.sup.7 or --SO.sub.2 NR.sup.6 R.sup.7 ;</p><p>(6) when A is N, Z is CR.sup.2 and R.sup.2 is --NR.sup.6 SO.sub.2 R.sup.7 or --SO.sub.2 NR.sup.6 R.sup.7, then R.sup.3 is not OH or SH;</p><p>(7) when A is N, Z is CR.sup.2, R.sup.1 is methyl or ethyl, R.sup.2 is H, and R.sup.3 is H, OH, CH.sub.3, C.sub.2 H.sub.5, C.sub.6 H.sub.5, n-C.sub.3 H.sub.7, iso-C.sub.3 H.sub.7, SH, SCH.sub.3, NH(n-C.sub.4 H.sub.9), or N(C.sub.2 H.sub.5).sub.2, then Ar is not unsubstituted phenyl or m-methylphenyl;</p><p>(8) when A is CR, Z is CR.sup.2, R.sup.2 is H, phenyl or alkyl, R.sup.3 is NR.sup.8 COR.sup.7 and Ar is phenyl or phenyl substituted with phenylthio, then R.sup.7 is not aryl, aryl(C.sub.1 -C.sub.4 alkyl), heteroaryl, heteroaryl(C.sub.1 -C.sub.4 alkyl), heterocyclyl or heterocycly(C.sub.1 -C.sub.4 alkyl);</p><p>(9) when A is CR, Z is CR.sup.2, R.sup.2 is H or alkyl, Ar is phenyl, and R.sup.3 is SR.sup.13 or NR.sup.6a R.sup.7a, then R.sup.13 is not aryl or heteroaryl and R.sup.6a and R.sup.7a are not H or aryl; or</p><p>(10) when A is CH, Z is CR.sup.2, R.sup.1 is OR.sup.11, R.sup.2 is H, R.sup.3 is OR.sup.7, and R.sup.7 and R.sup.11 are both H, then Ar is not phenyl, p-Br-phenyl, p-Cl-phenyl, p-NHCOCH.sub.3 -phenyl, p-CH3-phenyl, pyridyl or naphthyl;</p><p>(11) when A is CH, Z is CR.sup.2, R.sup.2 is H, Ar is unsubstituted phenyl, and R.sup.3 is CH.sub.3, C.sub.2 H.sub.5, CF.sub.3 or C.sub.6 H.sub.4 F, then R.sub.1 is not CF.sub.3 or C.sub.2 F.sub.5 ;</p> <p>(12) when A is CR, R is H, Z is CR.sup.2, R.sup.2 is OH, and R.sup.1 and R.sup.3 are H, then Ar is not phenyl;</p><p>(13) when A is CR, R is H, Z is CR.sup.2, R.sup.2 OH or NH.sub.2, R.sup.1 and R.sup.3 are CH.sub.3, then Ar is not 4-phenyl-3-cyano-2-aminopyrid-2-yl.</p><p>[5] Preferred compounds of the above invention are compounds of Formulae (1) and (2) and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof with the additional provisos that: (1) when A is N, R.sup.1 is H, C.sub.1 -C.sub.4 alkyl, halo, CN, C.sub.1 -C.sub.12 hydroxyalkyl, C.sub.1 -C.sub.4 alkoxyalkyl or SO.sub.2 (C.sub.1 -C.sub.4 alkyl), R.sup.3 is NR.sup.6a R.sup.7a and R.sup.6a is unsubstituted C.sub.1 -C.sub.4 alkyl, then R.sup.7a is not phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, furanyl, benzofuranyl, benzothiazolyl, indolyl or C.sub.3 -C.sub.6 cycloalkyl; and (2) A is N, R.sup.1 is H, C.sub.1 -C.sub.4 alkyl, halo, CN, C.sub.1 -C.sub.12 hydroxyalkyl, C.sub.1 -C.sub.4 alkoxyalkyl or SO.sub.2 (C.sub.1 -C.sub.4 alkyl), R.sup.3 is NR.sup.6a R.sup.7a and R.sup.7a is unsubstituted C.sub.1 -C.sub.4 alkyl, then R.sup.6a is not phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, furanyl, benzofuranyl, benzothiazolyl, indolyl or C.sub.3 -C.sub.6 cycloalkyl.</p><p>[6] Preferred compounds of the above invention also include compounds of Formulae (1) and (2) and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, each optionally substituted with 1 to 4 R.sup.4 substituents.</p><p>[7]. Preferred compounds of the above invention also include compounds of Formulae (1) and (2) and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein A is N, Z is CR.sup.2, Ar is 2,4-dichlorophenyl, 2,4-dimethylphenyl or 2,4,6-trimethylphenyl, R.sup.1 and R.sup.2 are CH.sub.3, and R.sup.3 is NR.sup.6a R.sup.7a.</p> <p>[11] More preferred compounds of the above invention are compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein A is N.</p> <p>[12] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof.</p> <p>[13] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R.sup.4 substituents.</p><p>[14] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R.sup.3 is NR.sup.6a R.sup.7a or OR.sup.7.</p><p>[15] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R.sup.4 substituents, and R.sup.3 is NR.sup.6a R.sup.7a or OR.sup.7.</p><p>[16] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Z is CR.sup.2.</p><p>[17] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R.sup.4 substituents.</p><p>[18] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R.sup.3 is NR.sup.6a R.sup.7a or OR.sup.7.</p><p>[19] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R.sup.6a is independently selected from:</p><p>--H,</p><p>--C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.1 -C.sub.10 haloalkyl with 1-10 halogens, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, C.sub.5 -C.sub.10 cycloalkenyl, or C.sub.6 -C.sub.14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl,</p><p>-aryl, aryl (C.sub.1 -C.sub.4 alkyl)-, heteroaryl, heteroaryl (C.sub.1 -C.sub.4 alkyl)-, heterocyclyl or heterocyclyl(C.sub.1 -C.sub.4 alkyl)-; and</p><p>R.sup.7a is independently selected at each occurrence from:</p><p>--H,</p><p>--C.sub.5 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.1 -C.sub.10 haloalkyl with 1-10 halogens, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, C.sub.5 -C.sub.10 cycloalkenyl, or C.sub.6 -C.sub.14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl,</p><p>-aryl, aryl (C.sub.1 -C.sub.4 alkyl), heteroaryl, heteroaryl (C.sub.1 -C.sub.4 alkyl), heterocyclyl or heterocyclyl (C.sub.1 -C.sub.4 alkyl);</p><p>alternatively, NR.sup.6 R.sup.7 and NR.sup.6a R.sup.7a are independently piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine, each optionally substituted with 1-3 C.sub.1 -C.sub.4 alkyl groups.</p><p>[20] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R.sup.6a and R.sup.7a are identical and are selected from:</p><p>--C.sub.1 -C.sub.4 alkyl or C.sub.3 -C.sub.6 cycloalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, --COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl, and -aryl or heteroaryl.</p><p>[21] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R.sup.6a is selected from:</p><p>--H,</p><p>--C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.1 -C.sub.10 haloalkyl with 1-10 halogens, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, C.sub.5 -C.sub.10 cycloalkenyl, or C.sub.6 -C.sub.14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15 aryl, heteroaryl or heterocyclyl,</p><p>-aryl, aryl (C.sub.1 -C.sub.4 alkyl), heteroaryl, heteroaryl(C.sub.1 -C.sub.4 alkyl), heterocyclyl or heterocyclyl(C.sub.1 -.sub.4 alkyl);</p><p>R.sup.7a is selected from:</p><p>--C.sub.1 -C.sub.4 alkyl and each such C.sub.1 -C.sub.4 alkyl is substituted with 1-3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl.</p><p>[22] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein one of R.sup.6a and R.sup.7a is selected from:</p><p>--C.sub.3 -C.sub.6 cycloalkyl, each such C.sub.3 -C.sub.6 cycloalkyl optionally substituted with 1-3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl,</p><p>-aryl,</p><p>-heteroaryl or</p><p>-heterocyclyl,</p><p>and the other of R.sup.6a and R.sup.7a is unsubstituted C.sub.1 -C.sub.4 alkyl.</p><p>[23] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R.sup.6a and R.sup.7a are independently H or C.sub.1 -C.sub.10 alkyl, each such C.sub.1 -C.sub.10 alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, R.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl.</p><p>[24] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R.sup.4 substituents, and R.sup.3 is NR.sup.6a R.sup.7a or OR.sup.7.</p><p>[25] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R.sup.6a is independently selected from:</p><p>--H,</p><p>--C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.1 -C.sub.10 haloalkyl with 1-10 halogens, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, C.sub.5 -C.sub.10 cycloalkenyl, or C.sub.6 -C.sub.14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl,</p><p>-aryl, aryl (C.sub.1 -C.sub.4 alkyl)-, heteroaryl, heteroaryl (C.sub.1 -C.sub.4 alkyl), heterocyclyl or heterocyclyl (C.sub.1 -C.sub.4 alkyl);</p><p>R.sup.7a is independently selected at each occurrence from:</p><p>--H,</p><p>--C.sub.5 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.1 -C.sub.10 haloalkyl with 1-10 halogens, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, C.sub.5 -C.sub.10 cycloalkenyl, or C.sub.6 -C.sub.14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl,</p><p>-aryl, aryl (C.sub.1 -C.sub.4 alkyl), heteroaryl, heteroaryl (C.sub.1 -C.sub.4 alkyl), heterocyclyl or heterocyclyl (C.sub.1 -C.sub.4 alkyl),</p><p>alternatively, NR.sup.6 R.sup.7 and NR.sup.6a R.sup.7a are independently piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine, each optionally substituted with 1-3 C.sub.1 -C.sub.4 alkyl groups.</p><p>[26] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R.sup.6a and R.sup.7a are identical and are selected from:</p><p>--C.sub.1 -C.sub.4 alkyl or C.sub.3 -C.sub.6 cycloalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, --COR.sup.15, CO.sub.2 R.sup.15,OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl, and -aryl or heteroaryl.</p><p>[27] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R.sup.6a and R.sup.7a are identical and are</p><p>--C.sub.1 -C.sub.4 alkyl, each such C.sub.1 -C.sub.4 alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, --COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl.</p><p>[28] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R.sup.6a is selected from:</p><p>--H,</p><p>--C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.1 -C.sub.10 haloalkyl with 1-10 halogens, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, C.sub.5 -C.sub.10 cycloalkenyl, or C.sub.6 -C.sub.14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl,</p><p>-aryl, aryl (C.sub.1 -C.sub.4 alkyl), heteroaryl, heteroaryl (C.sub.1 -C.sub.4 alkyl), heterocyclyl or heterocyclyl (C.sub.1 -C.sub.4 alkyl);</p><p>R.sup.7a is:</p><p>--C.sub.1 -C.sub.4 alkyl and each such C.sub.1 -C.sub.4 alkyl is substituted with 1-3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl.</p><p>[29] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein one of R.sup.6a and R.sup.7a is selected from:</p><p>--C.sub.3 -C.sub.6 cycloalkyl, each such C.sub.3 -C.sub.6 cycloalkyl optionally substituted with 1-3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl,</p><p>-aryl,</p><p>-heteroaryl or</p><p>-heterocyclyl,</p><p>and the other of R.sup.6a and R.sup.7a is unsubstituted C.sub.1 -C.sub.4 alkyl.</p><p>[30] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R.sup.6a and R.sup.7a are independently H or C.sub.1 -C.sub.10 alkyl, each such C.sub.1 -C.sub.10 alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, R.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl.</p><p>[31] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein</p><p>--Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R.sup.4 substituents,</p><p>--R.sup.3 is NR.sup.6a R.sup.7a or OR.sup.7 and</p><p>--R.sup.1 and R.sup.2 are independently selected from H, C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl.</p><p>[32] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R.sup.6a is independently selected from:</p><p>--H,</p><p>--C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.1 -C.sub.10 haloalkyl with 1-10 halogens, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, C.sub.5 -C.sub.10 cycloalkenyl, or C.sub.6 -C.sub.14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl,</p><p>-aryl, aryl (C.sub.1 -C.sub.4 alkyl)-, heteroaryl, heteroaryl (C.sub.1 -C.sub.4 alkyl), heterocyclyl or heterocyclyl (C.sub.1 -C.sub.4 alkyl);</p><p>R.sup.7a is independently selected at each occurrence from:</p><p>--H,</p><p>--C.sub.5 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.1 -C.sub.10 haloalkyl with 1-10 halogens, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, C.sub.5 -C.sub.10 cycloalkenyl, or C.sub.6 -C.sub.14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl,</p><p>-aryl, aryl(C.sub.1 -C.sub.4 alkyl), heteroaryl, heteroaryl(C.sub.1 -C.sub.4 alkyl), heterocyclyl or heterocyclyl(C.sub.1 -C.sub.4 alkyl),</p><p>alternatively, NR.sup.6 R.sup.7 and NR.sup.6a R.sup.7a are independently piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine, each optionally substituted with 1-3 C.sub.1 -C.sub.4 alkyl groups.</p><p>[33] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R.sup.6a and R.sup.7a are identical and are selected from:</p><p>--C.sub.1 -C.sub.4 alkyl or C.sub.3 -C.sub.6 cycloalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, --COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15,CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl, and -aryl or heteroaryl.</p><p>[34] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R.sup.6a and R.sup.7a are identical and are</p><p>--C.sub.1 -C.sub.4 alkyl, each such C.sub.1 -C.sub.4 alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, --COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl.</p><p>[35] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R.sup.6a is selected from:</p><p>--H,</p><p>--C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.1 -C.sub.10 haloalkyl with 1-10 halogens, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, C.sub.5 -C.sub.10 cycloalkenyl, or C.sub.6 -C.sub.14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 OR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl,</p><p>-aryl, aryl (C.sub.1 -C.sub.4 alkyl), heteroaryl, heteroaryl (C.sub.1 -C.sub.4 alkyl), heterocyclyl or heterocyclyl (C.sub.1 -C.sub.4 alkyl);</p><p>R.sup.7a is:</p><p>--C.sub.1 -C.sub.4 alkyl and each such C.sub.1 -C.sub.4 alkyl is substituted with 1-3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15,N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl.</p><p>[36] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein one of R.sup.6a and R.sup.7a is selected from:</p><p>--C.sub.3 -C.sub.6 cycloalkyl, each such C.sub.3 -C.sub.6 cycloalkyl optionally substituted with 1-3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O)nR.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl,</p><p>-aryl,</p><p>-heteroaryl or</p><p>-heterocyclyl,</p><p>and the other of R.sup.6a and R.sup.7a is unsubstituted C.sub.1 -C.sub.4 alkyl.</p><p>[37] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R.sup.6a and R.sup.7a are independently H or C.sub.1 -C.sub.10 alkyl, each such C.sub.1 -C.sub.10 alkyl optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.l3, COR.sup.15,CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, R.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl.</p><p>[38] Specifically preferred compounds of the above invention are compounds of Formula (50) ##STR19## and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof, selected from the group consisting of:</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(n-Pr).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(Et)(n-Bu), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --(n-Pr)(CH.sub.2 cPr), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(Et)(n-Bu), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(Et)(CH.sub.2 OMe), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(CH.sub.2 OEt).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(Me)(Ph), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(n-Pr).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(Et)(n-Pr), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is Me;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(Et)(CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --OEt, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(CH.sub.2 CN).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(Me)(CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --OCH(Et)(CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(n-Pr)(CH.sub.2 cPr), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(Me)(CH.sub.2 N(Me).sub.2), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(cPr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(n-Pr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(n-Bu)(CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(Et)(CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is Me;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is Me;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is Me;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(Et)(CH.sub.2 OMe), R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is Me;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(CH.sub.2 OEt).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is Me;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(CH.sub.2 CH.sub.2 OMe)(CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is Me;</p><p>a compound of Formula (50) wherein R.sup.3 is morpholino, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NH(c-Pr), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is CN, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(c-Pr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sub.4d is H and R.sup.4e is Me;</p><p>a compound of Formula (50) wherein R.sup.3 is --NCH(CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Br, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(CH.sub.2 OMe)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Br, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (50) wherein a compound of Formula (50) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(Et)(CH.sub.2 OMe), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(CH.sub.2 OMe)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(c-Pr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(c-Pr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is (S)--NHCH(CH.sub.2 OMe)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(CH.sub.2 OMe)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Br, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 oMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Br, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NH(CH.sub.2 OMe)(CH.sub.2 -iPr), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is H, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is NMe.sub.2, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(CH.sub.2 OMe)(n-Pr), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(CH.sub.2 OEt)(Et), R.sup.4a is Me, R.sup.4b is H, R.sup.4 C is Me, R.sup.4d is H and R.sup.4e H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(CH.sub.2 OMe)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is NMe.sub.2, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Br, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is NMe.sub.2, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is (S)--NHCH(CH.sub.2 oMe)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(CH.sub.2 OMe)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is (S)--NHCH(CH.sub.2 OMe)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(CH.sub.2 OMe)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(c-Pr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NH(Et)(CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R.sup.4b is Me, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe)(CH.sub.2 CH.sub.2 OH), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is Me, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Me, R.sup.4b is Me, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(CH.sub.2 c-Pr)(n-Pr), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(c-Pr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is Me, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(Et)(CH.sub.2 OMe), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is CN, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --N(c-Pr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (50) wherein R.sup.3 is --NHCH(CH.sub.2 OH).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H; and</p><p>a compound of Formula (50) wherein R.sup.3 is N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H.</p><p>[39] More specifically preferred is 4-(bis-(2-methoxyethyl)amino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-[1,5-a]-pyrazolo-1,3,5-triazine and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof.</p><p>[40] More specifically preferred is 4-(bis-(2-methoxyethyl)amino)-2,7-dimethyl-8-(2,5-dimethyl-4-methoxyphenyl)-[1,5-a]-pyrazolo-1,3,5-triazine and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof.</p><p>[41] More preferred are compounds of the above invention are compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein A is CR.</p><p>[42] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof.</p><p>[43] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R.sup.4 substituents.</p><p>[44] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R.sup.3 is NR.sup.6a R.sup.7a or OR.sup.7.</p><p>[45] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R.sup.4 substituents, and R.sup.3 is NR.sup.6a R.sup.7a or OR.sup.7.</p><p>[46] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Z is CR.sup.2.</p><p>[47] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R.sup.4 substituents.</p><p>[48] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R.sup.3 is NR.sup.6a R.sup.7a or OR.sup.7.</p><p>[49] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R.sup.4 substituents, and R.sup.3 is NR.sup.6a R.sup.7a or OR.sup.7.</p><p>[50] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R.sup.6a and R.sup.7a are independently H or C.sub.1 -C.sub.10 alkyl, and each such C.sub.1 -C.sub.10 alkyl is optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, R.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl.</p><p>[51] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein</p><p>--Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R.sup.4 substituents,</p><p>--R.sup.3 is NR.sup.6a R.sup.7a or OR.sup.7 and</p><p>--R.sup.1 and R.sup.2 are independently selected from H, C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl.</p><p>[52] More preferred compounds of the above invention also include compounds and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof wherein R.sup.6a and R.sup.7a are independently H or C.sub.1 -C.sub.10 alkyl, and each such C.sub.1 -C.sub.10 alkyl is optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, R.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl.</p><p>[53] Specifically preferred compounds of the above invention are compounds of Formula (51) ##STR20## and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof selected from the group consisting of:</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(n-Pr).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(c-Pr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(n-Pr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(n-Bu)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(n-Pr)(CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is (S)--NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Me, R .sup.4 b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NH(Et), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(n-Pr).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is (S)--NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(n-Pr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is (S)--NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4b is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(c-Pr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(c-Pr) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(n-Pr)(CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(n-Pr) (CH.sub.2 OMe), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is OMe and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is OMe and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is OMe and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(Pr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(Bu)(Et), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(Et)CH.sub.2 OMe, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is C.sub.1, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NEt.sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H; and</p><p>a compound of Formula (51) wherein R.sup.3 is --N(Pr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H.</p><p>[54] More specifically preferred is 7-(3-pentylamino)-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl)-[1,5-a]-pyrazolopyrimidine and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof.</p><p>[55] More specifically preferred is 7-(Diethylamino)-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl-[1,5-a]-pyrazolopyrimidine and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro- drug forms thereof.</p><p>[56] More specifically preferred is 7-(N-(3-cyanopropyl)--N-propylamino)-2,5-dimethyl-3-(2,4-dimethylphenyl)-[1,5-a]-pyrazolopyrimidine and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt or pro-drug forms thereof.</p><p>The present invention also provides pharmaceutical compositions comprising compounds of Formulae (1) and (2) and a pharmaceutically acceptable carrier.</p><p>[1] The present invention still further comprises a method of treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals comprising administering to the mammal a therapeutically effective amount of a compound of Formulae (1) or (2): ##STR21## and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof, wherein:</p><p>Z is N or CR.sup.2 ;</p><p>Ar is selected from phenyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, benzothienyl, benzofuranyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, indanyl, 1,2-benzopyranyl, 3,4-dihydro-1,2-benzopyranyl, tetralinyl, each Ar optionally substituted with 1 to 5 R.sup.4 groups and each Ar is attached to an unsaturated carbon atom;</p><p>R is independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.7 cycloalkylalkyl, halo, CN, C.sub.1 -C.sub.4 haloalkyl;</p><p>R.sup.1 is independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, halo, CN, C.sub.1 -C.sub.4 haloalkyl, C.sub.1 -C.sub.12 hydroxyalkyl, C.sub.2 -C.sub.12 alkoxyalkyl, C.sub.2 -C.sub.10 cyanoalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, NR.sup.9 R.sup.10, C.sub.1 -C.sub.4 alkyl-NR.sup.9 R.sup.10, NR.sup.9 COR.sup.10, OR.sup.11, SH or S(O).sub.n R.sup.12 ;</p><p>R.sup.2 is selected from H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, C.sub.1 -C.sub.4 hydroxyalkyl, halo, CN, --NR.sup.6 R.sup.7, NR.sup.9 COR.sup.10, --NR.sup.6 S(O).sub.n R.sup.7, S(O).sub.n NR.sup.6 R.sup.7, C.sub.1 -C.sub.4 haloalkyl, --OR.sup.7, SH or --S(O).sub.n R.sup.12 ;</p><p>R.sup.3 is selected from:</p><p>--H, OR.sup.7, SH, S(O).sub.n R.sup.13, COR.sup.7, CO.sub.2 R.sup.7, OC(O)R.sup.13, NR.sup.8 COR.sup.7, N(COR.sup.7).sub.2, NR.sup.8 CONR.sup.6 R.sup.7, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.6 R.sup.7, NR.sup.6a R.sup.7a, N(OR.sup.7)R.sup.6, CONR.sup.6 R.sup.7, aryl, heteroaryl and heterocyclyl, or</p><p>--C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.5 -C.sub.8 cycloalkenyl, C.sub.4 -C.sub.12 cycloalkylalkyl or C.sub.6 -C.sub.10 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl and heterocyclyl;</p><p>R.sup.4 is independently selected at each occurrence from:</p><p>C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, NO.sub.2, halo, CN, C.sub.1 -C.sub.4 haloalkyl, NR.sup.6 R.sup.7, NR.sup.8 COR.sup.7, NR.sup.8 CO.sub.2 R.sup.7, COR.sup.7, OR.sup.7, CONR.sup.6 R.sup.7, CO(NOR.sup.9)R.sup.7, CO.sub.2 R.sup.7, or S(O).sub.n R.sup.7, where each such C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.6 cycloalkyl and C.sub.4 -C.sub.12 cycloalkylalkyl are optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, NO.sub.2, halo, CN, NR.sup.6 R.sup.7, NR.sup.8 COR.sup.7, NR.sup.8 CO.sub.2 R.sup.7, COR.sup.7 OR.sup.7, CONR.sub.6 R.sup.7, CO.sub.2 R.sup.7, CO(NOR.sup.9)R.sup.7, or S(O).sub.n R.sup.7 ;</p><p>R.sup.6, R.sup.7, R.sup.6a and R.sup.7a are independently selected at each occurrence from:</p><p>--H,</p><p>--C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.1 -C.sub.10 haloalkyl with 1-10 halogens, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, C.sub.5 -C.sub.10 cycloalkenyl, or C.sub.6 -C.sub.14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl,</p><p>-aryl, aryl(C.sub.1 -.sub.4 alkyl), heteroaryl, heteroaryl(C.sub.1 -C.sub.4 alkyl), heterocyclyl or heterocyclyl(C.sub.1 -C.sub.4 alkyl);</p><p>alternatively, NR.sup.6 R.sup.7 and NR.sup.6a R.sup.7a are independently piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine, each optionally substituted with 1-3 C.sub.1 -C.sub.4 alkyl groups;</p><p>R.sup.8 is independently selected at each occurrence from H or C.sub.1 -C.sub.4 alkyl;</p><p>R.sup.9 and R.sup.10 are independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, or C.sub.3 -C.sub.6 cycloalkyl;</p><p>R.sup.11 is selected from H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, or C.sub.3 -C.sub.6 cycloalkyl;</p><p>R.sup.12 is C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 haloalkyl;</p><p>R.sup.13 is selected from C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, aryl, aryl(C.sub.1 -C.sub.4 alkyl)-, heteroaryl or heteroaryl(C.sub.1 -C.sub.4 alkyl)-;</p><p>R.sup.14 is selected from C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, or C.sub.4 -C.sub.12 cycloalkylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, and C.sub.1 -C.sub.6 alkylthio, C.sub.1 -C.sub.6 alkylsulfinyl and C.sub.1 -C.sub.6 alkylsulfonyl;</p><p>R.sup.15 and R.sup.16 are independently selected at each occurrence from H, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.10 cycloalkyl, C.sub.4 -C.sub.16 cycloalkylalkyl, except that for S(O).sub.n R.sup.15, R.sup.15 cannot be H;</p><p>aryl is phenyl or naphthyl, each optionally substituted with 1 to 5 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.16 R.sup.15, and CONR.sup.16 R.sup.15 ;</p><p>heteroaryl is pyridyl, pyrimidinyl, triazinyl, furanyl, pyranyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, isoxazolyl, pyrazolyl, 2,3-dihydrobenzothienyl or 2,3-dihydrobenzofuranyl, each being optionally substituted with 1 to 5 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, --COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.16 R.sup.15, and CONR.sup.16 R.sup.15 ;</p><p>heterocyclyl is saturated or partially saturated heteroaryl, optionally substituted with 1 to 5 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.15 R.sup.16, and CONR.sup.16 R.sup.15 ;</p><p>n is independently at each occurrence 0, 1 or 2.</p><p>[2] Further preferred methods of the present invention are methods of claim 1 wherein, in the compound of Formulae (1) or (2), Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, each optionally substituted with 1 to 4 R.sup.4 substituents.</p><p>[3] The present invention further comprises compounds of Formulae (1) or (2): ##STR22## and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein:</p><p>Z is N or CR.sup.2 ;</p><p>Ar is selected from phenyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, benzothienyl, benzofuranyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, indanyl, 1,2-benzopyranyl, 3,4-dihydro-1,2-benzopyranyl, tetralinyl, each Ar optionally substituted with 1 to 5 R.sup.4 groups and each Ar is attached to an unsaturated carbon atom;</p><p>R is independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.7 cycloalkylalkyl, halo, CN, C.sub.1 -C.sub.4 haloalkyl;</p><p>R.sup.1 is independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, halo, CN, C.sub.1 -C.sub.4 haloalkyl, C.sub.1 -C.sub.12 hydroxyalkyl, C.sub.2 -C.sub.12 alkoxyalkyl, C.sub.2 -C.sub.10 cyanoalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, NR.sup.9 R.sup.10, C.sub.1 -C.sub.4 alkyl-NR.sup.9 R.sup.10, NR.sup.9 COR.sup.10, OR.sup.11, SH or S(O).sub.n R.sup.12 ;</p><p>R.sup.2 is selected from H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, C.sub.1 -C.sub.4 hydroxyalkyl, halo, CN, --NR.sup.6 R.sup.7, NR.sup.9 COR.sup.10, --NR.sup.6 S(O).sub.n R.sup.7, S(O).sub.n NR.sup.6 R.sup.7, C.sub.1 -C.sub.4 haloalkyl, --OR.sup.7, SH or --S(O).sub.n R.sup.12 ;</p><p>R.sup.3 is selected from:</p><p>--H, OR.sup.7, SH, S(O).sub.n R.sup.13, COR.sup.7, CO.sub.2 R.sup.7, O(C)R.sup.13, NR.sup.8 COR.sup.7, N(COR.sup.7).sub.2, NR.sup.8 CONR.sup.6 R.sup.7, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.6 R.sup.7, NR.sup.6a R.sup.7a, N(OR.sup.7)R.sup.6, CONR.sup.6 R.sup.7, aryl, heteroaryl and heterocyclyl, or</p><p>--C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.5 -C.sub.8 cycloalkenyl, C.sub.4 -C.sub.12 cycloalkylalkyl or C.sub.6 -C.sub.10 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15 NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl and heterocyclyl;</p><p>R.sup.4 is independently selected at each occurrence from:</p><p>C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, NO.sub.2, halo, CN, C.sub.1 -C.sub.4 haloalkyl, NR.sup.6 R.sup.7, NR.sup.8 COR.sup.7, NR.sup.8 CO.sub.2 R.sup.7, COR.sup.7, OR.sup.7, CONR.sup.6 R.sup.7, CO(NOR.sup.9)R.sup.7, CO.sub.2 R.sup.7, or S(O).sub.n R.sup.7, where each such C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.6 cycloalkyl and C.sub.4 -C.sub.12 cycloalkylalkyl are optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, NO.sub.2, halo, CN, NR.sup.6 R.sup.7, NR.sup.8 COR.sup.7, NR.sup.8 CO.sub.2 R.sup.7, COR.sup.7 OR.sup.7, CONR.sup.6 R.sup.7, CO.sub.2 R.sup.7, CO(NOR.sup.9)R.sup.7, or S(O).sub.n R.sup.7 ;</p><p>R.sup.6, R.sup.7, R.sup.6a and R.sup.7a are independently selected at each occurrence from:</p><p>--H,</p><p>--C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.1 -C.sub.10 haloalkyl with 1-10 halogens, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, C.sub.5 -C.sub.10 cycloalkenyl, or C.sub.6 -C.sub.14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.l3, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl,</p><p>-aryl, aryl(C.sub.1 -C.sub.4 alkyl), heteroaryl, heteroaryl(C.sub.1 -C.sub.4 alkyl), heterocyclyl or heterocyclyl(C.sub.1 -C.sub.4 alkyl),</p><p>alternatively, NR.sup.6 R.sup.7 and NR.sup.6a R.sup.7a are independently piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine, each optionally substituted with 1-3 C.sub.1 -C.sub.4 alkyl groups;</p><p>R.sup.8 is independently selected at each occurrence from H or C.sub.1 -C.sub.4 alkyl;</p><p>R.sup.9 and R.sup.10 are independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, or C.sub.3 -C.sub.6 cycloalkyl;</p><p>R.sup.11 is selected from H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, or C.sub.3 -C.sub.6 cycloalkyl;</p><p>R.sup.12 is C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 haloalkyl;</p><p>R.sup.13 is selected from C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, aryl, aryl(C.sub.1 -C.sub.4 alkyl)-, heteroaryl or heteroaryl(C.sub.1 -C.sub.4 alkyl)-;</p><p>R.sup.14 is selected from C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, or C.sub.4 -C.sub.12 cycloalkylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, COR.sup.15, CO.sub.2 R.sup.15,OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2 NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, and C.sub.1 -C.sub.6 alkylthio, C.sub.1 -C.sub.6 alkylsulfinyl and C.sub.1 -C.sub.6 alkylsulfonyl;</p><p>R.sup.15 and R.sup.16 are independently selected at each occurrence from H, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.10 cycloalkyl, C.sub.4 -C.sub.16 cycloalkylalkyl, except that for S(O).sub.n R.sup.15, R.sup.15 cannot be H;</p><p>aryl is phenyl or naphthyl, each optionally substituted with 1 to 5 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.16 R.sup.15, and CONR.sup.16 R.sup.15 ;</p><p>heteroaryl is pyridyl, pyrimidinyl, triazinyl, furanyl, pyranyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, isoxazolyl, pyrazolyl, 2,3-dihydrobenzothienyl or 2,3-dihydrobenzofuranyl, each being optionally substituted with 1 to 5 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, --COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.16 R.sup.15, and CONR.sup.6 R.sup.16 R.sup.5 ;</p><p>heterocyclyl is saturated or partially saturated heteroaryl, optionally substituted with 1 to 5 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.15 R.sup.16, and CONR.sup.6 R.sup.16 R.sup.15 ;</p><p>n is independently at each occurrence 0, 1 or 2; with the provisos that:</p><p>(1) when Z is CR.sup.2, then R.sup.2 is not --NR.sup.6 SO.sub.2 R.sup.7 or --SO.sub.2 NR.sup.6 R.sup.7 ;</p><p>(2) when Z is CR.sup.2 and R.sup.2 is H, phenyl or alkyl and R.sup.3 is NR.sup.8 COR.sup.7 and Ar is phenyl or phenyl substituted with phenylthio, then R.sup.7 is not aryl, aryl(C.sub.1 -.sub.4 alkyl), heteroaryl, heteroaryl(C.sub.1 -C.sub.4 alkyl), heterocyclyl or heterocycly(C.sub.1 -C.sub.4 alkyl);</p><p>(3) when Z is CR.sup.2 and R.sup.2 is H or alkyl and Ar is phenyl and R.sup.3 is SR.sup.13 or NR.sup.6a R.sup.7a, then R.sup.13 is not aryl or heteroaryl and R.sup.6a and R.sup.7a are not H or aryl; or</p><p>(4) when Z is CR.sup.2 and R.sup.1 is OR.sup.11 and R.sup.2 is H and R.sup.3 is OR.sup.7 and R.sup.7 and R.sup.11 are both H, then Ar is not phenyl, p-Br-phenyl, p-Cl-phenyl, p--NHCOCH.sub.3 -phenyl, p-CH.sub.3 -phenyl, pyridyl or naphthyl;</p><p>(5) when Z is CR.sup.2 and R.sup.2 is H and Ar is unsubstituted phenyl and R.sup.3 is CH.sub.3, C.sub.2 H.sub.5, CF.sub.3 or C.sub.6 H.sub.4 F, then R.sub.1 is not CF.sub.3 or C.sub.2 F.sub.5 ;</p><p>(6) when R is H and Z is CR.sup.2 and R.sup.2 is OH and R.sup.1 and R.sup.3 are H, then Ar is not phenyl;</p><p>(7) when R is H and Z is CR.sup.2 and R.sup.2 is OH or NH.sub.2 and R.sup.1 and R.sup.3 are CH.sub.3, then Ar is not 4-phenyl-3-cyano-2-aminopyrid-2-yl; and</p><p>(7) when R is H and Z is CR.sup.2 and R.sup.1 and R.sup.2 are CH.sub.3 and Ar is 2-methyl-4-methoxyphenyl, then R.sup.3 is not 3-pentylamino.</p><p>[4] Further preferred compounds of the present invention include compounds of claim 3 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, each optionally substituted with 1 to 4 R.sup.4 substituents.</p><p>[5] The present invention further provides for a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 3.</p><p>[6] The present invention further provides for a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 4.</p><p>[7] Further preferred compounds of the present invention include compounds of Formula (2) of claim 3 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof.</p><p>[8] Further preferred compounds of the present invention include compounds of claim 7 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R.sup.4 substituents.</p><p>[9] Further preferred compounds of the present invention include compounds of claim 7 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein R.sup.3 is NR.sup.6a R.sup.7a or OR.sup.7.</p><p>[10] Further preferred compounds of the present invention include compounds of 7 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R.sup.4 substituents, and R.sup.3 is NR.sup.6a R.sup.7a or OR.sup.7.</p><p>[11] Further preferred compounds of the present invention include compounds of Formula (1) of claim 3 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein Z is CR.sup.2.</p><p>[12] Further preferred compounds of the present invention include compounds of claim 11 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R.sup.4 substituents.</p><p>[13] Further preferred compounds of the present invention include compounds of claim 11 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein R.sup.3 is NR.sup.6a R.sup.7a or OR.sup.7.</p><p>[14] Further preferred compounds of the present invention include compounds of claim 11 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R.sup.4 substituents, and R.sup.3 is NR.sup.6a R.sup.7a or OR.sup.7.</p><p>[15] Further preferred compounds of the present invention include compounds of claim 14 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein R.sup.6a and R.sup.7a are independently H or C.sub.1 -C.sub.10 alkyl, and each such C.sub.1 -C.sub.10 alkyl is optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, R.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl.</p><p>[16] Further preferred compounds of the present invention include compounds of claim 11 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein</p><p>--Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R.sup.4 substituents,</p><p>--R.sup.3 is NR.sup.6a R.sup.7a or OR.sup.7 and</p><p>--R.sup.1 and R.sup.2 are independently selected from H, C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl.</p><p>[17] Further preferred compounds of the present invention include compounds of claim 16 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein R.sup.6a and R.sup.7a are independently H or C.sub.1 -C.sub.10 alkyl, and each such C.sub.1 -C.sub.10 alkyl is optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, R.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl.</p><p>[18] Further preferred compounds of the present invention include compounds of Formula (51) ##STR23## and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof selected from the group consisting of:</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(n-Pr).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(c-Pr) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(n-Pr) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(n-Bu) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(n-Pr) (CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is (S)--NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NH(Et), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(n-Pr).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is (S)--NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(n-Pr) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is (S)--NH (CH.sub.2 CH.sub.2 OMe) CH.sub.2 OMe, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>compound of Formula (51) wherein R.sup.3 is --N(c-Pr) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(c-Pr) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH (n-Pr) (CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH (n-Pr) (CH.sub.2 OMe), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is OMe and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R .sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is OMe and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is OMe and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(Pr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --N(Bu)(Et), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(Et)CH.sub.2 OMe, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (51) wherein R.sup.3 is --NEt.sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H; and</p><p>a compound of Formula (51) wherein R.sup.3 is --N(Pr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H.</p><p>[19] Further preferred compounds of the present invention include compounds of Formula (70) ##STR24## and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof selected from the group consisting of:</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NHCH(n-Pr).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(c-Pr) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>compound of Formula (70) wherein R is Cl, R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(n-Pr) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(n-Bu) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NHCH(n-Pr)(CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is (S)--NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NH(Et), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NHCH(n-Pr).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is C.sub.1, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is (S)--NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(n-Pr) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4 C is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is (S)--NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(c-Pr) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(c-Pr) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NHCH (n-Pr)(CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NHCH (n-Pr)(CH.sub.2 OMe), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is OMe and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is OMe and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is OMe and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(Pr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(Bu)(Et), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NHCH(Et)CH.sub.2 OMe, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NEt.sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H; and</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(Pr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NHCH(n-Pr).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(c-Pr) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(n-Pr) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(n-Bu) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NHCH(n-Pr)(CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is (S)--NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NH(Et), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NHCH(n-Pr).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is (S)--NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(n-Pr) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is (S)--NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(c-Pr) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(c-Pr) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NHCH (n-Pr)(CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NHCH (n-Pr)(CH.sub.2 OMe), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is OMe and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of a compound of Formula (70) wherein R is Me, R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is OMe and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is OMe and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(Pr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(Bu)(Et), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NHCH(Et)CH.sub.2 OMe, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NEt.sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H; and</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(Pr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NHCH(n-Pr).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(c-Pr) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(n-Pr) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(n-Bu) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NHCH(n-Pr)(CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is (S)--NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NH(Et), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NHCH(n-Pr).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is (S)--NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(n-Pr) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is (S)--NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(c-Pr) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(c-Pr) (CH.sub.2 CH.sub.2 CN), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NHCH (n-Pr)(CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NHCH (n-Pr)(CH.sub.2 OMe), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is OMe and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Br, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is OMe and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is OMe and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(CH.sub.2 CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NHCH(CH.sub.2 OMe).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(Pr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(Bu)(Et), R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NHCH(Et)CH.sub.2 OMe, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Cl, R.sup.4b is H, R.sup.4c is Me, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NHCH(Et).sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is Cl, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NEt.sub.2, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H; and</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(Pr)(CH.sub.2 CH.sub.2 CN), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(Pr)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(Et)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(Me)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NMeEt, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NMePr, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NMeBu, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NH-2-butyl, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is cyclobutylamino, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(Pr)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(Et)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --N(Me)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NMeEt, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NMePr, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NMeBu, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is --NH-2-butyl, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Cl, R.sup.3 is cyclobutylamino, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is ME and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(Pr)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(Et)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(Me)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NMeEt, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NMePr, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NMeBu, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NH-2-butyl, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is cyclobutylamino, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(Pr)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(Et)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --N(Me)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NMeEt, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NMePr, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NMeBu, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is --NH-2-butyl, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is F, R.sup.3 is cyclobutylamino, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(Pr)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(Et)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(Me)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NMeEt, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NMePr, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NMeBu, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NH-2-butyl, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is cyclobutylamino, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is H and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(Pr)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(Et)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --N(Me)(CH.sub.2 CH.sub.2 OMe), R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NMeEt, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NMePr, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NMeBu, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H;</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is --NH-2-butyl, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H; and</p><p>a compound of Formula (70) wherein R is Me, R.sup.3 is cyclobutylamino, R.sup.4a is Me, R.sup.4b is H, R.sup.4c is OMe, R.sup.4d is Me and R.sup.4e is H.</p><p>[20] Further preferred compounds of the present invention include compounds of claim 18 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof, wherein said compound is selected from: 7-(diethylamino)-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl-[1,5-a]-pyrazolopyrimidine and 7-(N-(3-cyanopropyl)-N-propylamino)-2,5-dimethyl-3-(2,4-dimethylphenyl)-[1,5-a]-pyrazolopyrimidine.</p><p>[21] Further preferred compounds of the present invention include compounds of claims 3, 7 and 11 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein:</p><p>R.sup.1 is not H and R.sup.1 is independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, halo, CN, C.sub.1 -C.sub.4 haloalkyl, C.sub.1 -C.sub.12 hydroxyalkyl, C.sub.2 -C.sub.12 alkoxyalkyl, C.sub.2 -C.sub.10 cyanoalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, NR.sup.9 R.sup.10, C.sub.1 -C.sub.4 alkyl-NR.sup.9 R.sup.10, NR.sup.9 COR.sup.10, OR.sup.11, SH or S(O).sub.n R.sup.12.</p><p>[22] Further preferred compounds of the present invention include compounds of claims 3, 7 and 11 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein R.sup.1 is H.</p><p>[23] The present invention further provides for a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claims 7, 11, 18 and 19.</p><p>[24] The present invention further provides for a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 21.</p><p>[25] The present invention further provides for a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 22.</p><p>[26] The present invention further provides for a method of treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals comprising administering to the mammal a therapeutically effective amount of a compound of claim 3, 7, 11, 18, 19, 21 and 22.</p><p>Many compounds of this invention have one or more asymmetric centers or planes. Unless otherwise indicated, all chiral (enantiomeric and diastereomeric) and racemic forms are included in the present invention. Many geometric isomers of olefins, C═N double bonds, and the like can also be present in the compounds, and all such stable isomers are contemplated in the present invention. The compounds may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. All chiral, (enantiomeric and diastereomeric) and racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomer form is specifically indicated.</p><p>The term "alkyl" includes both branched and straight-chain alkyl having the specified number of carbon atoms. Commonly used abbreviations have the following meanings: Me is methyl, Et is ethyl, Pr is propyl, Bu is butyl. As is conventional, in a chemical structure drawing, a straight single bond attached to an atom at one end but with no atom designation at the other end indicates the presence of a methyl group at the unattached end of the bond. The prefix "n" means a straight chain alkyl. The prefix "c" means a cycloalkyl. The prefix "(S)" means the S enantiomer and the prefix "(R)" means the R enantiomer. Alkenyl" includes hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl, and the like. "Alkynyl" includes hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl, propynyl and the like. "Haloalkyl" is intended to include both branched and straight-chain alkyl having the specified number of carbon atoms, substituted with 1 or more halogen; "alkoxy" represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge; "cycloalkyl" is intended to include saturated ring groups, including mono-,bi- or poly-cyclic ring systems, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and so forth. "Halo" or "halogen" includes fluoro, chloro, bromo, and iodo.</p><p>The term "substituted", as used herein, means that one or more hydrogen on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substitent is keto (i.e., ═O), then 2 hydrogens on the atom are replaced.</p><p>Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By "stable compound" or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.</p><p>The term "appropriate amino acid protecting group" means any group known in the art of organic synthesis for the protection of amine or carboxylic acid groups. Such amine protecting groups include those listed in Greene and Wuts, "Protective Groups in Organic Synthesis" John Wiley &amp; Sons, New York (1991) and "The Peptides: Analysis, Synthesis, Biology, Vol. 3, Academic Press, New York (1981), the disclosure of which is hereby incorporated by reference. Any amine protecting group known in the art can be used. Examples of amine protecting groups include, but are not limited to, the following: 1) acyl types such as formyl, trifluoroacetyl, phthalyl, and p-toluenesulfonyl; 2) aromatic carbamate types such as benzyloxycarbonyl (Cbz) and substituted benzyloxycarbonyls, 1-(p-biphenyl)-1-methylethoxycarbonyl, and 9-fluorenylmethyloxycarbonyl (Fmoc); 3) aliphatic carbamate types such as tert-butyloxycarbonyl (Boc), ethoxycarbonyl, diisopropylmethoxycarbonyl, and allyloxycarbonyl; 4) cyclic alkyl carbamate types such as cyclopentyloxycarbonyl and adamantyloxycarbonyl; 5) alkyl types such as triphenylmethyl and benzyl; 6) trialkylsilane such as trimethylsilane; and 7) thiol containing types such as phenylthiocarbonyl and dithiasuccinoyl.</p><p>The term "pharmaceutically acceptable salts" includes acid or base salts of the compounds of Formulae (1) and (2). Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.</p><p>Pharmaceutically acceptable salts of the compounds of the invention can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418, the disclosure of which is hereby incorporated by reference.</p><p>"Prodrugs" are considered to be any covalently bonded carriers which release the active parent drug of formula (I) or (II) in vivo when such prodrug is administered to a mammalian subject. Prodrugs of the compounds of formula (I) and (II) are prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compounds. Prodrugs include compounds wherein hydroxy, amine, or sulfhydryl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino, or sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of formulas (I) and (II); and the like.</p><p>The term "therapeutically effective amount" of a compound of this invention means an amount effective to antagonize abnormal level of CRF or treat the symptoms of affective disorder, anxiety or depression in a host.</p><heading>Synthesis</heading><p>Some compounds of Formula (1) may be prepared from intermediate compounds of Formula (7), using the procedures outlined in Scheme 1: ##STR25## Compounds of Formula (7) (where Y is O) may be treated with a halogenating agent or sulfonylating agent in the presence or absence of a base in the presence or absence of an inert solvent at reaction temperatures ranging from -80 (where X is halogen, alkanesulfonyloxy, arylsulfonyloxy or haloalkane-sulfonyloxy). Halogenating agents include, but are not limited to, SOCl.sub.2, POCl.sub.3, PCl.sub.3, PCl.sub.5, POBr.sub.3, PBr.sub.3 or PBr.sub.5. Sulfonylating agents include, but are not limited to, alkanesulfonyl halides or anhydrides (such as methanesulfonyl chloride or methanesulfonic acid anhydride), arylsulfonyl halides or anhydrides (such as p-toluenesulfonyl chloride or anhydride) or haloalkylsulfonyl halides or anhydrides (preferably trifluoromethanesulfonic anhydride). Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine or triethylamine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamide (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane). Preferred reaction temperatures range from -20 C. to 100</p><p>Compounds of Formula (8) may be reacted with compounds of Formula R.sup.3 H (where R.sup.3 is defined as above except R.sup.3 is not SH, COR.sup.7, CO.sub.2 R.sup.7, aryl or heteroaryl) in the presence or absence of a base in the presence or absence of an inert solvent at reaction temperatures ranging from -80 to 250 Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal bicarbonates, alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane). Preferred reaction temperatures range from 0 to 140</p><p>Scheme 2 delineates the procedures for converting intermediate compounds of Formula (7) (where Y is S) to some compounds of Formula (1). ##STR26## Compounds of Formula (7) (where Y is S) may be treated with an alkylating agent R.sup.13 X (where R.sup.13 is defined as above, except R.sup.13 is not aryl or heteroaryl) in the presence or absence of a base in the presence or absence of an inert solvent at reaction temperatures ranging from -80 limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal hydroxides, alkali metal bis (trialkylsilyl) amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (preferably N,N-di-isopropyl--N-ethyl amine or triethyl amine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane). Preferred reaction temperatures range from -80 C. to 100</p><p>Compounds of Formula (12) (Formula (1) where R.sup.3 is SR.sup.13) may then be reacted with compounds of Formula R.sup.3 H to give compounds of Formula (1), using the same conditions and reagents as were used for the conversion of compounds of Formula (8) to compounds of Formula (1) as outlined for Scheme 1 above. Alternatively, compounds of Formula (12) (Formula (1) where R.sup.3 is SR.sup.13) may be oxidized to compounds of Formula (13) (Formula (1) where R.sup.3 is S(O).sub.n R.sup.l3, n is 1,2) by treatment with an oxidizing agent in the presence of an inert solvent at temperatures ranging from -80 agents include, but are not limited to, hydrogen peroxide, alkane or aryl peracids (preferably peracetic acid or m-chloro-perbenzoic acid), dioxirane, oxone, or sodium periodate. Inert solvents may include, but are not limited to, alkanones (3 to 10 carbons, preferably acetone), water, alkyl alcohols (1 to 6 carbons), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane) or combinations thereof. The choices of oxidant and solvent are known to those skilled in the art (cf. Uemura, S., Oxidation of Sulfur, Selenium and Tellurium, in Comprehensive Organic Synthesis, Trost, B. M. ed., (Elmsford, N.Y.: Pergamon Press, 1991), 7, 762-769). Preferred reaction temperatures range from -20 100 S(O).sub.n R.sup.13, n is 1,2) may then be reacted with compounds of Formula R.sup.3 H to give compounds of Formula (1), using the same conditions and reagents as were used for the conversion of compounds of Formula (8) to compounds of Formula (1) as outlined for Scheme (1) above.</p><p>Compounds of Formula (1), where R.sup.3 may be --NR.sup.8 COR.sup.7, --N(COR.sup.7).sub.2, --NR.sup.8 CONR.sup.6 R.sup.7, NR.sup.8 CO.sub.2 R.sup.13, --NR.sup.6 R.sup.7, --NR.sup.8 SO.sub.2 R.sup.7, may be prepared from compounds of Formula (7), where Y is NH, by the procedures depicted in Scheme 3. ##STR27## Reaction of compounds of Formula (7), where Y is NH, with alkylating agents, sulfonylating agents or acylating agents or sequential reactions with combinations thereof, in the presence or absence of a base in an inert solvent at reaction temperatures ranging from -80 250 --NR.sup.8 COR.sup.7, --N(COR.sup.7).sub.2, --NR.sup.8 CONR.sup.6 R.sup.7, --NR.sup.8 CO.sub.2 R.sup.13, --NR.sup.6 R.sup.7, --NR.sup.8 SO.sub.2 R.sup.7. Alkylating agents may include, but are not limited to, C.sub.1 -C.sub.10 alkyl -halides, -tosylates, -mesylates or -triflates; C.sub.1 -C.sub.10 haloalkyl (1-10 halogens)-halides, -tosylates, -mesylates or -triflates; C.sub.2 -C.sub.8 alkoxyalkyl-halides, -tosylates, -mesylates or -triflates; C.sub.3 -C.sub.6 cycloalkyl-halides, -tosylates, -mesylates or -triflates; C.sub.4 -C.sub.12 cycloalkylalkyl-halides, -tosylates, -mesylates or -triflates; aryl (C.sub.1 -C.sub.4 alkyl)-halides, -tosylates, -mesylates or -triflates; heteroaryl (C.sub.1 -C.sub.4 alkyl)-halides, -tosylates, -mesylates or -triflates; or heterocyclyl (C.sub.1 -C.sub.4 alkyl)-halides, -tosylates, -mesylates or -triflates. Acylating agents may include, but are not limited to, C.sub.1 -C.sub.10 alkanoyl halides or anhydrides, C.sub.1 -C.sub.10 haloalkanoyl halides or anhydrides with 1-10 halogens, C.sub.2 -C.sub.8 alkoxyalkanoyl halides or anhydrides, C.sub.3 -C.sub.6 cycloalkanoyl halides or anhydrides, C.sub.4 -C.sub.12 cycloalkylalkanoyl halides or anhydrides, aroyl halides or anhydrides, aryl (C.sub.1 -C.sub.4 ) alkanoyl halides or anhydrides, heteroaroyl halides or anhydrides, heteroaryl (C.sub.1 -C.sub.4 ) alkanoyl halides or anhydrides, heterocyclylcarboxylic acid halides or anhydrides or heterocyclyl (C.sub.1 -.sub.4) alkanoyl halides or anhydrides. Sulfonylating agents include, but are not limited to, C.sub.1 -C.sub.10 alkylsulfonyl halides or anhydrides, C.sub.1 -C.sub.10 haloalkylsulfonyl halides or anhydrides with 1-10 halogens, C.sub.2 -C.sub.8 alkoxyalkylsulfonyl halides or anhydrides, C.sub.3 -C.sub.6 cycloalkylsulfonyl halides or anhydrides, C.sub.4 -C.sub.12 cycloalkylalkylsulfonyl halides or anhydrides, arylsulfonyl halides or anhydrides, aryl (C.sub.1 -C.sub.4 alkyl)-, heteroarylsulfonyl halides or anhydrides, heteroaryl (C.sub.1 -C.sub.4 alkyl)sulfonyl halides or anhydrides, heterocyclylsulfonyl halides or anhydrides or heterocyclyl (C.sub.1 -C.sub.4 alkyl)sulfonyl halides or anhydrides. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (prefereably di-isopropylethyl amine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene). Preferred reaction temperatures range from 0 100</p><p>Scheme 4 delineates procedures, which may be employed to prepare intermediate compounds of Formula (7), where Y is 0, S and Z is CR.sup.2. ##STR28## Compounds of the formula ArCH.sub.2 CN are reacted with compounds of the formula R.sup.2 COR.sup.b, where R.sup.2 is defined above and R.sup.b is halogen, cyano, lower alkoxy (1 to 6 carbons) or lower alkanoyloxy (1 to 6 carbons), in the presence of a base in an inert solvent at reaction temperatures ranging from -78 compounds of Formula (3). Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal hydroxides, alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), water, dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene). Preferred reaction temperatures range from 0 100</p><p>Compounds of Formula (3) may be treated with hydrazine-hydrate in the presence of an inert solvent at temperatures ranging from 0 200 compounds of Formula (4). Inert solvents may include, but are not limited to, water, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene). Compounds of Formula (4) may be reacted with compounds of Formula (5) (where R.sup.c is alkyl (1-6 carbons)) in the presence or absence of an acid in the presence of an inert solvent at temperatures ranging from 0 Formula (6). Acids may include, but are not limited to alkanoic acids of 2 to 10 carbons (preferably acetic acid), haloalkanoic acids (2-10 carbons, 1-10 halogens, such as trifluoroacetic acid), arylsulfonic acids (preferably p-toluenesulfonic acid or benzenesulfonic acid), alkanesulfonic acids of 1 to 10 carbons (preferably methanesulfonic acid), hydrochloric acid, sulfuric acid or phosphoric acid. Stoichiometric or catalytic amounts of such acids may be used. Inert solvents may include, but are not limited to, water, alkanenitriles (1 to 6 carbons, preferably acetonitrile), halocarbons of 1 to 6 carbons and 1 to 6 halogens (preferably dichloromethane or chloroform), alkyl alcohols of 1 to 10 carbons (preferably ethanol), dialkyl ethers (4 to 12 carbons, preferably diethyl ether or di-isopropylether) or cyclic ethers such as dioxan or tetrahydrofuran. Preferred temperatures range from ambient temperature to 100</p><p>Compounds of Formula (6) may be converted to intermediate compounds of Formula (7) by treatment with compounds C═Y(R.sup.d).sub.2 (where Y is O or S and R.sup.d is halogen (preferably chlorine), alkoxy (1 to 4 carbons) or alkylthio (1 to 4 carbons)) in the presence or absence of a base in an inert solvent at reaction temperatures from -50 200 hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide or sodium ethoxide), alkali metal carbonates, alkali metal hydroxides, trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine or triethylamine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene). Preferred temperatures are 0 to 150</p><p>Intermediate compounds of Formula (7), where Z is N, may be synthesized according the methods outlined in Scheme 5. ##STR29## Compounds of ArCH.sub.2 CN are reacted with compounds of Formula R.sup.q CH.sub.2 N.sub.3 (where R.sup.q is a phenyl group optionally substituted by H, alkyl (1 to 6 carbons) or alkoxy (1 to 6 carbons) in the presence or absence of a base in an inert solvent at temperatures ranging from 0 may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide, sodium ethoxide or potassium t-butoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal hydroxides, alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (preferably N,N-di-isopropyl--N-ethyl amine or triethylamine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene). Preferred reaction temperatures range from ambient temperature to 100</p><p>Compounds of Formula (9) may be treated with a reducing agent in an inert solvent at -100 (10). Reducing agents include, but are not limited to, (a) hydrogen gas in combination with noble metal catalysts such as Pd-on-carbon, PtO.sub.2, Pt-on-carbon, Rh-on-alumina or Raney nickel, (b) alkali metals (preferably sodium) in combination with liquid ammonia or (c) ceric ammonium nitrate. Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), water, dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene). The preferred reaction temperatures are -50 60 Formula (7) (where Z is N) via intermediates of Formula (11) using the reagents and reaction conditions outlined in Scheme 4 for the conversion of compounds of Formula (4) to compounds of Formula (7) (where Z is CR.sup.2).</p><p>Compounds of Formula (1) may also be prepared from compounds of Formula (7) (where Y is O, S and Z is defined above) as outlined in Scheme 6: ##STR30## Compounds of Formula (7) may be reacted with compounds of Formula R.sup.3 H in the presence of a dehydrating agent in an inert solvent at reaction temperatures ranging from 0 agents include, but are not limited to, P.sub.2 O.sub.5, molecular sieves or inorganic or organic acids. Acids may include, but are not limited to alkanoic acids of 2 to 10 carbons (preferably acetic acid), arylsulfonic acids (preferably p-toluenesulfonic acid or benzenesulfonic acid), alkanesulfonic acids of 1 to 10 carbons (preferably methanesulfonic acid), hydrochloric acid, sulfuric acid or phosphoric acid. Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably glyme or diglyme), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or halocarbons of 1 to 10 carbons and 1 to 10 halogens (preferably chloroform). Preferred reaction temperatures range from ambient temperature to 150</p><p>Some compounds of Formula (1) (where A is N) may also be prepared by the methods shown in Scheme 7: ##STR31## Intermediate compounds of Formula (14), where Z is defined above, may be reacted with compounds of Formula R.sup.3 C(OR.sup.e)3, where R.sup.e may be alkyl (1 to 6 carbons) in the presence or absence of an acid in an inert solvent at temperatures ranging from 0 Acids may include, but are not limited to alkanoic acids of 2 to 10 carbons (preferably acetic acid), arylsulfonic acids (preferably p-toluenesulfonic acid or benzenesulfonic acid), alkanesulfonic acids of 1 to 10 carbons (preferably methanesulfonic acid), hydrochloric acid, sulfuric acid or phosphoric acid. Stoichiometric or catalytic amounts of such acids may be used. Inert solvents may include, but are not limited to, lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane). Preferred reaction temperatures range from 50</p><p>Intermediate compounds of Formula (7) may also be synthesized by the reactions displayed in Scheme 8. ##STR32## Compounds of Formula (15), (where Y is OH, SH, NR.sup.6 R.sup.7 ; Z is defined above, X is Br, Cl, I, O.sub.3 SCF.sub.3 or B(OR"").sub.2 and R"" is H or alkyl (1 to 6 carbons)) may be reacted with a compound of Formula ArM (where M is halogen, alkali metal, ZnCl, ZnBr, ZnI, MgBr, MgCl, MgI, CeCl.sub.2, CeBr.sub.2 or copper halides) in the presence or absence of an organometallic catalyst in the presence or absence of a base in an inert solvents at temperatures ranging from -100 Those skilled in the art will recognize that the reagents ArM may be generated in situ. Organometallic catalysts include, but are not limited to, palladium phosphine complexes (such as Pd(PPh.sub.3).sub.4), palladium halides or alkanoates (such as PdCl.sub.2 (PPh.sub.3).sub.2 or Pd(OAc).sub.2) or nickel complexes (such as NiCl.sub.2 (PPh.sub.3).sub.2). Bases may include, but are not limited to, alkali metal carbonates or trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine or triethylamine). Inert solvents may include, but are not limited to, dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or water. Preferred reaction temperatures range from -80</p><p>The choices of M and X are known to those skilled in the art (cf. Imamoto, T., Organocerium Reagents in Comprehensive Organic Synthesis, Trost, B. M. ed., (Elmsford, N.Y.: Pergamon Press, 1991), 1, 231-250; Knochel, P., Organozinc, Organocadmium and Organomercury Reagents in Comprehensive Organic Synthesis, Trost, B. M. ed., (Elmsford, N.Y.: Pergamon Press, 1991), 1, 211-230; Knight, D. W., Coupling Reactions between sp.sup.2 Carbon Centers, in Comprehensive Organic Synthesis, Trost, B. M. ed., (Elmsford, N.Y.: Pergamon Press, 1991), 3, 481-520).</p><p>Compounds of Formula (1) may also be prepared using the methods shown in Scheme 9. ##STR33## Compounds of Formula (16), where A, Z, R.sup.1 and R.sup.3 are defined above and X is Br, Cl, I, O.sub.3 SCF.sub.3 or B(OR"").sub.2 and R"" is H or alkyl (1 to 6 carbons)) may be reacted with a compound of Formula ArM (where M is halogen, alkali metal, ZnCl, ZnBr, ZnI, MgBr, MgCl, MgI, CeCl.sub.2, CeBr.sub.2 or copper halides) in the presence or absence of an organometallic catalyst in the presence or absence of a base in an inert solvents at temperatures ranging from -100 Those skilled in the art will recognize that the reagents ArM may be generated in situ (see the above references in Comprehensive Organic Synthesis). Organometallic catalysts include, but are not limited to, palladium phosphine complexes (such as Pd(PPh.sub.3).sub.4), palladium halides or alkanoates (such as PdCl.sub.2 (PPh.sub.3).sub.2 or Pd(OAc).sub.2) or nickel complexes (such as NiCl.sub.2 (PPh.sub.3).sub.2). Bases may include, but are not limited to, alkali metal carbonates or trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine or triethylamine). Inert solvents may include, but are not limited to, dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or water. Preferred reaction temperatures range from -80</p><p>Intermediate compounds of Formula (7)(where Y is O, S, NH, Z is CR.sup.2 and R.sup.1, R.sup.2 and Ar are defined as above) may be prepared as illustrated in Scheme 10. ##STR34## Compounds of Formula (3) may be reacted with compounds of Formula H.sub.2 NNH(C═Y)NH.sub.2, where Y is O, S or NH, in the presence or absence of a base or acid in an inert solvent at temperatures from 0 250 but are not limited to alkanoic acids of 2 to 10 carbons (preferably acetic acid), arylsulfonic acids (preferably p-toluenesulfonic acid or benzenesulfonic acid), alkanesulfonic acids of 1 to 10 carbons (preferably methanesulfonic acid), hydrochloric acid, sulfuric acid or phosphoric acid. Stoichiometric or catalytic amounts of such acids may be used. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine or triethylamine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 6 carbons), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane).</p><p>Preferred reaction temperatures range from 0 Compounds of Formula (17) may then be reacted with compounds of Formula R.sup.3 C(OR.sup.e)3, where R.sup.e may be alkyl (1 to 6 carbons) in the presence or absence of an acid in an inert solvent at temperatures ranging from 0 to alkanoic acids of 2 to 10 carbons (preferably acetic acid), arylsulfonic acids (preferably p-toluenesulfonic acid or benzenesulfonic acid), alkanesulfonic acids of 1 to 10 carbons (preferably methanesulfonic acid), hydrochloric acid, sulfuric acid or phosphoric acid. Stoichiometric or catalytic amounts of such acids may be used. Inert solvents may include, but are not limited to, lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane). Preferred reaction temperatures range from 50 to 150</p><p>In Scheme 11, the procedures which may be used to convert compounds of Formula (1), where R.sup.3 is COR.sup.7, CO.sub.2 R.sup.7, NR.sup.8 COR.sup.7 and CONR.sup.6 R.sup.7, to other compounds of Formula (1), where R.sup.3 is CH(OH)R.sup.7, CH.sub.2 OH, NR.sup.8 CH.sub.2 R.sup.7 and CH.sub.2 NR.sup.6 R.sup.7 by treatment with a reducing agent in an inert solvent at temperatures ranging from -80 ##STR35## Reducing agents include, but are not limited to, alkali metal or alkaline earth metal borohydrides (preferably lithium or sodium borohydride), borane, dialkylboranes (such as di-isoamylborane), alkali metal aluminum hydrides (preferably lithium aluminum hydride), alkali metal (trialkoxy)aluminum hydrides, or dialkyl aluminum hydrides (such as di-isobutylaluminum hydride). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 6 carbons), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), aromatic hydrocarbons (preferably benzene or toluene). Preferred reaction temperatures range from -80</p><p>In Scheme 12, the procedures are shown which may be used to convert compounds of Formula (1), where R.sup.3 is COR.sup.7 or C.sub.0.sub.2 R.sup.7, to other compounds of Formula (1), where R.sup.3 is C(OH)(R.sup.7).sub.2 by treatment with a reagent of Formula R.sup.7 M in an inert solvent at temperatures ranging from -80 250 ##STR36## M is halogen, alkali metal, ZnCl, ZnBr, ZnI, MgBr, MgCl, MgI, CeCl.sub.2, CeBr.sub.2 or copper halides. Inert solvents may include, but are not limited to, dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran) or aromatic hydrocarbons (preferably benzene or toluene). Preferred reaction temperatures range from -80 100</p><p>Compounds of Formula (1), where R.sup.3 may be --NR.sup.8 COR.sup.7, --N(COR.sup.7).sub.2, --NR.sup.8 CONR.sup.6 R.sup.7, --NR.sup.8 CO.sub.2 R.sup.13, --NR.sup.6 R.sup.7, --NR.sup.8 SO.sub.2 R.sup.7, may be synthesized as depicted in Scheme 13. ##STR37## Reaction of compounds of Formula (18), where R and R.sup.1 are defined above, with compounds of Formula (4) or (10) in the presence or absence of base in an inert solvent may produce compounds of Formula (19) at temperatures ranging from -50 include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (prefereably di-isopropylethyl amine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene). Preferred reaction temperatures range from 0 100</p><p>Compounds of Formula (19) may then be reacted with alkylating agents, sulfonylating agents or acylating agents or sequential reactions with combinations thereof, in the presence or absence of a base in an inert solvent at reaction temperatures ranging from -80 250 --NR.sup.8 COR.sup.7, --N(COR.sup.7).sub.2, --NR.sup.8 CONR.sup.6 R.sup.7, --NR.sup.8 CO.sub.2 R.sup.13, NR.sup.6 R.sup.7, --NR.sup.8 SO.sub.2 R.sup.7. Alkylating agents may include, but are not limited to, C.sub.1 -C.sub.10 alkyl -halides, -tosylates, -mesylates or -triflates; C.sub.1 -C.sub.10 haloalkyl (1-10 halogens)-halides, -tosylates, -mesylates or -triflates; C.sub.2 -C.sub.8 alkoxyalkyl-halides, -tosylates, -mesylates or -triflates; C.sub.3 -C.sub.6 cycloalkyl-halides, -tosylates, -mesylates or -triflates; C.sub.4 -C.sub.12 cycloalkylalkyl-halides, -tosylates, -mesylates or -triflates; aryl (C.sub.1 -C.sub.4 alkyl)-halides, -tosylates, -mesylates or -triflates; heteroaryl (C.sub.1 -C.sub.4 alkyl)-halides, -tosylates, -mesylates or -triflates; or heterocyclyl(C.sub.1 -C.sub.4 alkyl)-halides, -tosylates, -mesylates or -triflates. Acylating agents may include, but are not limited to, C.sub.1 -C.sub.10 alkanoyl halides or anhydrides, C.sub.1 -C.sub.10 haloalkanoyl halides or anhydrides with 1-10 halogens, C.sub.2 -C.sub.8 alkoxyalkanoyl halides or anhydrides, C.sub.3 -C.sub.6 cycloalkanoyl halides or anhydrides, C.sub.4 -C.sub.12 cycloalkylalkanoyl halides or anhydrides, aroyl halides or anhydrides, aryl (C.sub.1 -C.sub.4) alkanoyl halides or anhydrides, heteroaroyl halides or anhydrides, heteroaryl (C.sub.1 -C.sub.4 ) alkanoyl halides or anhydrides, heterocyclylcarboxylic acid halides or anhydrides or heterocyclyl (C.sub.1 -C.sub.4 ) alkanoyl halides or anhydrides. Sulfonylating agents include, but are not limited to, C.sub.1 -C.sub.10 alkylsulfonyl halides or anhydrides, C.sub.1 -C.sub.10 haloalkylsulfonyl halides or anhydrides with 1-10 halogens, C.sub.2 -C.sub.8 alkoxyalkylsulfonyl halides or anhydrides, C.sub.3 -C.sub.6 cycloalkylsulfonyl halides or anhydrides, C.sub.4 -C.sub.12 cycloalkylalkylsulfonyl halides or anhydrides, arylsulfonyl halides or anhydrides, aryl (C.sub.1 -C.sub.4 alkyl)-, heteroarylsulfonyl halides or anhydrides, heteroaryl (C.sub.1 -C.sub.4 alkyl)sulfonyl halides or anhydrides, heterocyclylsulfonyl halides or anhydrides or heterocyclyl (C.sub.1 -.sub.4 alkyl)sulfonyl halides or anhydrides. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (prefereably di-isopropylethyl amine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene). Preferred reaction temperatures range from 0 100</p><p>Compounds of Formula (1), where A is CR and R is defined above, may be synthesized by the methods depicted in Scheme 14. ##STR38## Compounds of Formula (4) or (10) may be treated with compounds of Formula (20), where R.sup.1 and R.sup.3 are defined above in the presence or absence of base in an inert solvent at temperatures ranging from 0 C. to 250 is defined above. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (preferably di-isopropylethyl amine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene). Preferred reaction temperatures range from 0 100 is defined above, may be synthesized through intermediates (22) and (23).</p><p>Compounds of Formula (4) or (10) may be treated with compounds of Formula (21), where R.sup.1 is defined above and R.sup.e is alkyl (1-6 carbons), in the presence or absence of base in an inert solvent at temperatures ranging from 0 (1), where A is CR and R is defined above. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (prefereably di-isopropylethyl amine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide) or aromatic hydrocarbons (preferably benzene or toluene). Preferred reaction temperatures range from 0 100 halogenating agent or sulfonylating agent in the presence or absence of a base in the presence or absence of an inert solvent at reaction temperatures ranging from -80 products of Formula (23) (where X is halogen, alkanesulfonyloxy, arylsulfonyloxy or haloalkane-sulfonyloxy). Halogenating agents include, but are not limited to, SOCl.sub.2, POCl.sub.3, PCl.sub.3, PCl.sub.5, POBr.sub.3, PBr.sub.3 or PBr.sub.5. Sulfonylating agents include, but are not limited to, alkanesulfonyl halides or anhydrides (such as methanesulfonyl chloride or methanesulfonic acid anhydride), arylsulfonyl halides or anhydrides (such as p-toluenesulfonyl chloride or anhydride) or haloalkylsulfonyl halides or anhydrides (preferably trifluoromethanesulfonic anhydride). Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine or triethylamine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane).</p><p>Preferred reaction temperatures range from -20</p><p>Compounds of Formula (23) may be reacted with compounds of Formula R.sup.3 H (where R.sup.3 is defined as above except R.sup.3 is not SH, COR.sup.7, CO.sub.2 R.sup.7, aryl or heteroaryl) in the presence or absence of a base in the presence or absence of an inert solvent at reaction temperatures ranging from -80 Formula (1). Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons) (preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal carbonates, alkali metal bicarbonates, alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, alkyl alcohols (1 to 8 carbons, preferably methanol or ethanol), lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane). Preferred reaction temperatures range from 0 to 140</p><p>Some compounds of Formula (1) may also be prepared using the methods shown in Scheme 15. ##STR39## A compound of Formula (24) (R.sub.c is a lower alkyl group and Ar is defined as above) may be reacted with hydrazine in the presence or absence of an inert solvent to afford an intermediate of Formula (25), where Ar is defined as above. The conditions employed are similar to those used for the preparation of intermediate of Formula (4) from compound of Formula (3) in Scheme 4. Compounds of Formula (25), where A is N, may be reacted with reagents of the formula R.sup.1 C(═NH)OR.sub.e, where R.sup.1 is defined above and R.sub.e is a lower alkyl group) in the presence or absence of an acid in an inert solvent, followed by reaction with a compound of formula YisC(R.sub.d)2 (where Y is O or S and R.sub.d is halogen (preferably chlorine), alkoxy (1 to 4 carbons) or alkylthio (1 to 4 carbons)) in the presence or absence of a base in an inert solvent to give compounds of Formula (27) (where A is N and Y is O, S). The conditions for these transformations are the same as those employed for the conversions of compound of Formula (4) to compound of Formula (7) in Scheme 4.</p><p>Alternatively, compounds of Formula (25), where A is CR, may be reacted with compounds of the formula R.sup.1 (C═O)CHR(C═Y)OR.sub.c (where R.sup.1 and R are defined as above and R.sub.c is a lower alkyl group) to give a compound of Formula (27) (where A is CR) using conditions similar to those employed for the conversion of compounds of Formula (21) to compounds of Formula (22) in Scheme 14. Intermediates of Formula (27) (where Y is O) may be treated with halogenating agents or sulfonylating agents in the presence or absence of a base in an inert solvent, followed by reaction with R.sup.3 H or R.sup.2 H in the presence or absence of a base in an inert solvent to give compounds of Formula (1) (where Z is CR.sup.2).</p><p>It will be recognized by those skilled in the art that various combinations of halogenating agents, sulfonylating agents, R.sup.3 H or R.sup.2 H may be used in different orders of reaction sequences in Scheme 15 to afford compounds of Formula (1). For example, in some cases, it may be desirable to react compounds with stoichiometric amounts of halogenating agents or sulfonylating agents, react with R.sup.2 H (or R.sup.3 H), then repeat the reaction with halogenating agents or sulfonylating agents and react with R.sup.3 H (or R.sup.2 H) to give compounds of Formula (1). The reaction conditions and reagents used for these conversions are similar to the ones employed for the conversion of intermediate compounds of Formulae (22) to (23) to (1) in Scheme 14 (for A is CR) or the conversion of intermediate compounds of Formulae (7) to (8) to (1) in Scheme 1 (where A is N).</p><p>Alternatively, compounds of Formula (27) (where Y is S) may be converted to compounds of Formula (1) in Scheme 15. Intermediate compounds of Formula (27) may be alkylated with a compound R.sup.f X (where R.sup.f is lower alkyl and X is halogen, alkanesulfonyloxy or haloalkanesulfonyloxy) in an inert solvent, (then optionally oxidized with an oxidizing agent in an inert solvent) and then reacted with R.sup.3 H in the presence or absence of a base in an inert solvent to give a compound of Formula (1). The conditions and reagents employed are similar to those used in the conversion of intermediate compounds of Formulae (7) to (12) (or to (13)) to compounds of Formula (1) in Scheme 2.</p><p>Compounds of Formula (1) may be prepared from compounds of Formula (24), using an alternate route as depicted in Scheme 15. Compounds of Formula (24) may be converted to compounds of Formula (27) via reaction with compounds of formula NH.sub.2 NH(C═NH)NH.sub.2 in the presence or absence of an acid in an inert solvent, followed by reaction with compounds R.sup.1 C(OR.sub.c).sub.3 (where R.sub.c is lower alkyl and R.sup.1 is defined as above), using the conditions employed for the conversion of compounds of Formulae (3) to (17) to (7) in Scheme 10.</p><p>Some compounds of Formula (2) may be prepared by the methods illustrated in Scheme 16. ##STR40## Compounds of Formula (27b) may be treated with various alkylating agents R.sup.14 X (where R.sup.14 is defined above and X is halogen, alkanesulfonyloxy or haloalkanesulfonyloxy) in the presence or absence of a base in an inert solvent to afford structures of Formula (28). Compounds of Formula (28) (Y is O) may then be converted to compounds of Formula (2) by treatment with halogenating agents or sulfonylating agents in the presence or absence of a base in an inert solvent, followed by reaction with R.sup.3 H in the presence or absence of a base in an inert solvent to give compounds of Formula (2). The reaction conditions used for these conversions are similar to the ones employed for the conversion of intermediate compounds (22) to (23) to (1) in Scheme 14 (for A is CR) or the conversion of intermediate compounds of Formulae (7) to (8) to (1) in Scheme 1 (where A is N). Alternatively, compounds of Formula (28) (Y is S) may be alkylated with a compound R.sup.f X (where R.sup.f is lower alkyl and X is halogen, alkanesulfonyloxy or haloalkanesulfonyloxy) in an inert solvent, (then optionally oxidized with an oxidizing agent in an inert solvent) and then reacted with R.sup.3 H in the presence or absence of a base in an inert solvent to give a compound of Formula (1). The conditions and reagents employed are similar to those used in the conversion of intermediate compounds of Formulae (7) to (12) (or to (13)) to compounds of Formula (1) in Scheme 2.</p><p>Compounds of Formula (1), where Z is COH, may be converted to compounds of Formula (2) as illustrated in Scheme 16. Treatment with various alkylating agents R.sup.14 X (where R.sup.14 is defined above and X is halogen, alkanesulfonyloxy or haloalkanesulfonyloxy) in the presence or absence of a base in an inert solvent to afford structures (2). It will be recognized by one skilled in the art that the methods used in Scheme 16 may also be used to prepare compounds of Formula (1) where Z is COR.sup.7.</p><p>For Scheme 16, the terms "base" and "inert solvent" may have the meanings given below. Bases may include, but are not limited to, alkali metal hydrides (preferably sodium hydride), alkali metal alkoxides (1 to 6 carbons)(preferably sodium methoxide or sodium ethoxide), alkaline earth metal hydrides, alkali metal dialkylamides (preferably lithium di-isopropylamide), alkali metal bis(trialkylsilyl)amides (preferably sodium bis(trimethylsilyl)amide), trialkyl amines (preferably N,N-di-isopropyl-N-ethyl amine or triethylamine) or aromatic amines (preferably pyridine). Inert solvents may include, but are not limited to, lower alkanenitriles (1 to 6 carbons, preferably acetonitrile), dialkyl ethers (preferably diethyl ether), cyclic ethers (preferably tetrahydrofuran or 1,4-dioxane), N,N-dialkylformamides (preferably dimethylformamide), N,N-dialkylacetamides (preferably dimethylacetamide), cyclic amides (preferably N-methylpyrrolidin-2-one), dialkylsulfoxides (preferably dimethylsulfoxide), aromatic hydrocarbons (preferably benzene or toluene) or haloalkanes of 1 to 10 carbons and 1 to 10 halogens (preferably dichloromethane). Preferred reaction temperatures range from -20</p><?description-type Detailed Description?><heading>EXAMPLES</heading><p>Analytical data were recorded for the compounds described below using the following general procedures. Proton NMR spectra were recorded on an IBM-Bruker FT-NMR (300 MHz); chemical shifts were recorded in ppm (δ) from an internal tetramethysilane standard in deuterochloroform or deuterodimethylsulfoxide as specified below. Mass spectra (MS) or high resolution mass spectra (HRMS) were recorded on a Finnegan MAT 8230 spectrometer (using chemi-ionization (CI) with NH.sub.3 as the carrier gas or gas chromatography (GC) as specified below) or a Hewlett Packard 5988A model spectrometer. Melting points were recorded on a Buchi Model 510 melting point apparatus and are uncorrected. Boiling points are uncorrected. All pH determinations during workup were made with indicator paper.</p><p>Reagents were purchased from commercial sources and, where necessary, purified prior to use according to 35 the general procedures outlined by D. Perrin and W. L. F. Armarego, Purification of Laboratory Chemicals, 3rd ed., (New York: Pergamon Press, 1988). Chromatography was performed on silica gel using the solvent systems indicated below. For mixed solvent systems, the volume ratios are given. Otherwise, parts and percentages are by weight.</p><p>The following examples are provided to describe the invention in further detail. These examples, which set forth the best mode presently contemplated for carrying out the invention, are intended to illustrate and not to limit the invention.</p><heading>Example 1</heading><heading>Preparation of 2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]-pyrazolo-[1,3,5]-triazin-4(3H)-one (Formula 7, where Y is O, R.sup.1 is CH.sub.3, Z is C--CH.sub.3, Ar is 2,4-dimethylphenyl)</heading><p>A. 1-Cyano-1-(2,4-dimethylphenyl)propan-2-one</p><p>Sodium pellets (9.8 g, 0.43 mol) were added portionwise to a solution of 2,4-dimethylphenylacetonitrile (48 g, 0.33 mol) in ethyl acetate (150 mL) at ambient temperature. The reaction mixture was heated to reflux temperature and stirred for 16 hours. The resulting suspension was cooled to room temperature and filtered. The collected precipitate was washed with copious amounts of ether and then air-dried. The solid was dissolved in water and a 1N HCl solution was added until the pH=5-6. The mixture was extracted with ethyl acetate (3 were dried over MgSO.sub.4 and filtered. Solvent was removed in vacuo to afford a white solid (45.7 g, 74% yield): NMR (CDCl.sub.3,300 MHz):; CI-MS: 188 (M+H).</p><p>B. 5-Amino-4-(2,4-dimethylphenyl)-3-methylpyrazole</p><p>A mixture of 1-cyano-1-(2,4-dimethylphenyl)propan-2-one (43.8 g, 0.23 mol), hydrazine-hydrate (22 mL, 0.46 mol), glacial acetic acid (45 mL, 0.78 mol) and toluene (500 mL) were stirred at reflux temperature for 18 hours in an apparatus fitted with a Dean-Stark trap. The reaction mixture was cooled to ambient temperature and solvent was removed in vacuo. The residue was dissolved in 6N HCl and the resulting solution was extracted with ether three times. A concentrated ammonium hydroxide solution was added to the aqueous layer until pH=11. The resulting semi-solution was extracted three times with ethyl acetate. The combined organic layers were dried over MgSO.sub.4 and filtered. Solvent was removed in vacuo to give a pale brown viscous oil (34.6 g, 75% yield): NMR (CDCl.sub.3, 300 MHz): 7.10 (s, 1H), 7.05 (d, 2H, J=1), 2.37 (s, 3H), 2.10 (s, 3H); CI-MS: 202 (M+H).</p><p>C. 5-Acetamidino-4-(2,4-dimethylphenyl)-3-methylpyrazole, acetic acid salt</p><p>Ethyl acetamidate hydrochloride (60 g, 0.48 mol) was added quickly to a rapidly stirred mixture of potassium carbonate (69.5 g, 0.50 mol), dichloromethane (120 mL) and water (350 mL). The layers were separated and the aqueous layer was extracted with dichloromethane (2 combined organic layers were dried over MgSO.sub.4 and filtered. Solvent was removed by simple distillation and the pot residue, a clear pale yellow liquid, (35.0 g) was used without further purification.</p><p>Glacial aetic acid (9.7 mL, 0.17 mol) was added to a stirred mixture of 5-amino-4-(2,4-dimethylphenyl)-3-methylpyrazole (34 g, 0.17 mol), ethyl acetamidate (22 g, 0.25 mol) and acetonitrile (500 mL). The resulting reaction mixture was stirred at room temperature for 3 days; at the end of which time, it was concentrated in vacuo to about one-third of its original volume. The resulting suspension was filtered and the collected solid was washed with copious amounts of ether. The white solid was dried in vacuo (31.4 g, 61% yield): NMR (DMSO-d.sub.6, 300 MHz): 7.00 (s, 1H), 6.90 (dd, 2H, J=7, 1), 2.28 (s, 3H), 2.08 (s, 3H), 2.00 (s, 3H), 1.90 (s, 3H), 1.81 (s, 3H); CI-MS: 243 (M+H).</p><p>D. 2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]-pyrazolo-[1,3,5]-triazin-4(3H)-one</p><p>Sodium pellets (23 g, 1 mol) were added portionwise to ethanol (500 mL) with vigorous stirring. After all the sodium reacted, 5-acetamidino-4-(2,4-dimethylphenyl)-3-methylpyrazole, acetic acid salt (31.2 g, 0.1 mol) and diethyl carbonate (97 mL, 0.8 mol) were added. The resulting reaction mixture was heated to reflux temperature and stirred for 18 hours. The mix was cooled to room temperature and solvent was removed in vacuo. The residue was dissolved in water and a 1N HCl solution was added slowly until pH=5-6. The aqueous layer was extracted with ethyl acetate three times; the combined organic layers were dried over MgSO.sub.4 and filtered. Solvent was removed in vacuo to give a pale tan solid (26 g, 98% yield): NMR (CDCl.sub.3, 300 MHz): 7.15(s, 1H), 7.09 (s, 2H), 2.45 (s, 3H), 2.39 (s, 3H), 2.30 (s, 3H); CI-MS: 269 (M+H).</p><heading>Example 2</heading><heading>Preparation of 5-methyl-3-(2,4,6-trimethylphenyl)[1,5-a]-[1,2,3]-triazolo-[1,3,5]-triazin-7(6H)-one (Formula 7, where Y is O, R.sub.1 is CH.sub.3, Z is N, Ar is 2,4,6-trimethylphenyl)</heading><p>A. 1-Phenylmethyl-4-(2,4,6-trimethylphenyl)-5-aminotriazole</p><p>A mixture of 2,4,6-trimethylbenzyl cyanide (1.0 g, 6.3 mmol), benzyl azide (0.92 g, 6.9 mmol) and potassium t-butoxide (0.78 g, 6.9 mmol) in tetrahydrofuran (10 mL) was stirred at ambient temperature for 2.5 days. The resulting suspension was diluted with water and extracted three times with ethyl acetate. The combined organic layers were dried over MgSO.sub.4 and filtered. Solvent was removed in vacuo to give a brown oil. Trituration with ether and filtration afforded a yellow solid (1.12 g, 61% yield): NMR (CDCl.sub.3, 300 MHz):7.60-7.30 (m, 5H), 7.30-7.20 (m, 2H), 5.50 (s, 2H), 3.18 (br s, 2H), 2.30 (s, 3H), 2.10 (s, 6H); CI-MS: 293 (M+H).</p><p>B. 4-(2,4,6-Trimethylphenyl)-5-aminotriazole</p><p>Sodium (500 mg, 22 mmol) was added with stirring to a mixture of liquid ammonia (30 mL) and 1-phenylmethyl-4-(2,4,6-trimethylphenyl)-5-aminotriazole (1.1 g, 3.8 mmol). The reaction mixture was stirred until a dark green color persisted. An ammonium chloride solution (mL) was added and the mixture was stirred while warming to ambient temperature over 16 hours. The residue was treated with a 1M HCl solution and filtered. The aqueous layer was basified with a concentrated ammonium hydroxide solution (pH=9) and then extracted with ethyl acetate three times. The combined organic layers were dried over MgSO.sub.4 and filtered. Solvent was removed in vacuo to give a yellow solid (520 mg), which was homogeneous by thin layer chromatography (ethyl acetate): NMR (CDCl.sub.3, 300 MHz): 6.97 (s, 2H), 3.68-3.50 (br.s, 2H), 2.32 (s, 3H), 2.10 (s, 6H); CI-MS: 203 (M+H).</p><p>C. 4-(2,4,6-Trimethylphenyl)-5-acetamidinotriazole, acetic acid salt</p><p>A mixture of 4-(2,4,6-trimethylphenyl)-5-aminotriazole (400 mg, 1.98 mmol), ethyl acetamidate 261 mg, 3 mmol) and glacial acetic acid (0.1 mL, 1.98 mmol) in acetonitrile (6 mL) was stirred at ambient temperature for 4 hours. The resulting suspension was filtered and the collected solid was washed with copious amounts of ether. Drying in vacuo afforded a white solid (490 mg, 82% yield): NMR (DMSO-d.sub.6, 300 MHz):7.90-7.70 (br s, 0.5H), 7.50-7.20 (br. s, 0.5H), 6.90 (s, 2H), 6.90 (s, 2H), 3.50-3.10 (br s, 3H), 2.30-2.20 (br s, 3H), 2.05 (d, 1H, J=7), 1.96 (s, 6H), 1.87 (s, 6H); CI-MS: 244 (M+H).</p><p>D. 5-methyl-3-(2,4,6-trimethylphenyl)[1,5-a]-[1,2,3]-triazolo-[1,3,5]-triazin-7(4H)-one</p><p>Sodium (368 mg, 16.2 mmol) was added with stirring to ethanol (10 mL) at room temperature. After the sodium had reacted, 4-(2,4,6-trimethylphenyl)-5-acetamidino-triazole, acetic acid salt (490 mg, 1.6 mmol) and diethyl carbonate (1.6 mL, 13 mmol) were added. The reaction mixture was stirred at reflux temperature for 5 hours, then cooled to room temperature. The reaction mixture was diluted with water; a 1N HCl solution was added until pH=5-6 and three extractions with ethyl acetate were performed. The combined organic layers were dried over MgSO.sub.4 and filtered. Solvent was removed in vacuo to give a yellow residue. Trituration with ether and filtration afforded a yellow solid (300 mg, 69% yield): NMR (CDCl.sub.3, 300 MHz): 6.98 (s, 2H), 2.55 (s, 3H), 2.35 (s, 3H), 2.10 (s, 6H); CI-MS: 270 (M+H).</p><heading>Example 3</heading><heading>Preparation of 4-(di(carbomethoxy)methyl)-2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]-pyrazolo-1,3,5-triazine</heading><p>(Formula 1, where R.sup.3 is CH(CHCO.sub.2 CH.sub.3).sub.2, R.sub.1 is CH.sub.3, Z is C--CH.sub.3, Ar is 2,4-dimethylphenyl)</p><p>A. 4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]-pyrazolotriazine</p><p>A mixture of 2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]-pyrazolo-1,3,5-triazin-4-one (Example 1, 1.38 g, 4.5 mmol), N,N-dimethylaniline (1 mL, 8 mmol) and phosphorus oxychloride (10 mL) was stirred at reflux temperature for 48 hours. The excess phosphorus oxychloride was removed in vacuo. The residue was poured onto ice-water, stirred briefly and extracted quickly with ethyl acetate three times. The combined organic layers were washed with ice water, then dried over MgSO.sub.4 and filtered. Solvent was removed in vacuo to give a brown oil. Flash column chromatography (ethyl acetate:hexanes::1:4) gave one fraction (Rf=0.5) Solvent was removed in vacuo to afford a yellow oil (1.0 g, 68% yield): NMR (CDCl.sub.3, 300 MHz): 7.55 (d, 1H, J=1), 7.38 (dd, 1H, J=7,1), 7.30 (d, 1H, J=7), 2.68 (s, 3H), 2.45 (s, 3H); CI-MS: 327 (M+H).</p><p>B. 4-(di(carbomethoxy)methyl)-2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]-pyrazolo-1,3,5-triazine</p><p>Sodium hydride (60% in oil, 80 mg, 2 mmol) was washed with hexanes twice, decanted after each washing and taken up in anhydrous tetrahydrofuran (THF, 1 mL). A solution of diethyl malonate (0.32 g, 2 mmol) in THF (2 mL) was added dropwise over 5 min, during which time vigorous gas evolution ensued. A solution of 4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]-pyrazolotriazine (0.5 g, 1.75 mmol) in THF (2 mL) was added and the reaction mixture was then stirred under a nitrogen atmosphere for 48 hours. The resulting suspension was poured onto water and extracted three times with ethyl acetate. The combined organic layers were washed once with brine, dried over MgSO.sub.4 and filtered. Solvent was removed in vacuo to give a brown oil. Column chromatography (ethyl acetate:hexanes::1:9) afforded, after removal of solvent in vacuo, a pale yellow solid (Rf=0.2, 250 mg, 35% yield): mp 50-52 (m, 3H), 4.40 (q, 2H, J=7), 4.30 (q, 2H, J=7), 2.4, 2.35, 2.3, 2.2, 2.1 (5 s, 12H), 1.4 (t, 3H, J=7), 1.35-1.25 (m, 3H); CI-HRMS: Calcd: 411.2032, Found: 411.2023.</p><heading>Example 6</heading><heading>Preparation of 4-(1,3-dimethoxy-2-propylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]-pyrazolo-1,3,5-triazine</heading><p>(Formula 1, where R.sup.3 is NHCH(CH.sub.2 OCH.sub.3).sub.2, R.sub.1 is CH.sub.3, Z is C--CH.sub.3, Ar is 2,4-dichlorophenyl)</p><p>A. 4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]-pyrazolotriazine</p><p>A mixture of 2,7-dimethyl-8-(2,4 dimethylphenyl) [1,5-a]-pyrazolo-1,3,5-triazin-4-one (Example 1, 1.38 g, 4.5 mmol), N,N-dimethylaniline (1 mL, 8 mmol) and phosphorus oxychloride (10 mL) was stirred at reflux temperature for 48 hours. The excess phosphorus oxychloride was removed in vacuo. The residue was poured onto ice-water, stirred briefly and extracted quickly with ethyl acetate three times. The combined organic layers were washed with ice water, then dried over MgSO.sub.4 and filtered. Solvent was removed in vacuo to give a brown oil. Flash column chromatography (ethyl acetate:hexanes::1:4) gave one fraction (Rf=0.5). Solvent was removed in vacuo to afford a yellow oil (1.0 g, 68% yield): NMR (CDCl.sub.3, 300 MHz): 7.55 (d, 1H, J=1), 7.38 (dd, 1H, J=7,1 ), 7.30 (d, 1H, J=7), 2.68 (s, 3H), 2.45 (s, 3H); CI-MS: 327 (M+H).</p><p>B. 4-(1,3-dimethoxy-2-propylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]-pyrazolo-1,3,5-triazine</p><p>A mixture of 4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]-pyrazolo-1,3,5-triazine (Part A, 570 mg, 1.74 mmol), 1,3-dimethoxypropyl-2-aminopropane (25 mg, 2.08 mmol) and ethanol (10 mL) was stirred at ambient temperature for 18 hours. The reaction mixture was poured onto water (25 mL) and extracted three times with ethyl acetate. The combined organic layers were dried over MgSO.sub.4 and filtered. Solvent was removed in vacuo. Column chromatography (CH.sub.2 Cl.sub.2 :CH.sub.3 OH: :50:1) afforded one fraction. Removal of solvent in vacuo gave a solid (250 mg, 35% yield): mp 118-120 J=8,1), 6.75 (d, 1H, J=8), 4.70-4.58 (m, 1H), 3.70-3.55 (m, 4H), 3.43 (s, 6H), 2.50 (s, 3H), 2.35 (s, 3H); CI-HRMS: Calcd: 409.1072, Found: 409.1085; Analysis Calcd. for C.sub.18 H.sub.21 Cl.sub.2 N.sub.5 O.sub.2 : C, 52.69, H, 5.17, N, 17.07, Cl, 17.28; Found: C, 52.82, H, 5.06, N, 16.77, Cl, 17.50.</p><p>Using the above procedures and modifications known to one skilled in the art of organic synthesis, the following additional examples of Tables 1-4 may be prepared.</p><p>The examples delineated in TABLE 1 may be prepared by the methods outlined in Examples 1, 2, 3 or 6. Commonly used abbreviations are: Ph is phenyl, Pr is propyl, Me is methyl, Et is ethyl, Bu is butyl, Ex is Example.</p><p><pre xml:space="preserve" listing-type="tabular"><!--Greenbook tabular data-->                                  TABLE 1__________________________________________________________________________  #STR41##   -Ex. Z   R.sub.3         Ar            mp (__________________________________________________________________________ 6.sup.a    C--Me   NHCH(CH.sub.2 OMe).sub.2                   2,4-Cl.sub.2 --Ph                                 118-120   7.sup.b C--Me NHCHPr.sub.2 2,4-Cl.sub.2 --Ph 114-116   8.sup.c C--Me NEtBu 2,4-Cl.sub.2 --Ph oil   9.sup.d C--Me NPr(CH.sub.2 -c-C.sub.3 H.sub.5) 2,4-Cl.sub.2 --Ph oil                                   10.sup.e C--Me N(CH.sub.2                                 CH.sub.2 OMe).sub.2 2,4-Cl.sub.2                                 --Ph oil   11.sup.f C--Me NH-3-heptyl 2,4-Cl.sub.2 --Ph 90-92   12.sup.g C--Me NHCH(Et)CH.sub.2 OMe 2,4-Cl.sub.2 --Ph 179-181   13.sup.h C--Me NEt.sub.2 2,4-Cl.sub.2 --Ph 133-134   14.sup.i C--Me NHCH(CH.sub.2 OEt).sub.2 2,4-Cl.sub.2 --Ph oil   15.sup.j C--Me NH-3-pentyl 2,4-Cl.sub.2 --Ph 139-140   16.sup.k C--Me NMePh 2,4-Cl.sub.2 --Ph 60-62   17.sup.l C--Me NPr.sub.2 2,4-Cl.sub.2 --Ph oil   18.sup.m C--Me NH-3-hexyl 2,4-Cl.sub.2 --Ph 130-132   19 C--Me morpholino 2,4-Cl.sub.2 --Ph   20 C--Me N(CH.sub.2 Ph)CH.sub.2 CH.sub.2 OMe 2,4-Cl.sub.2 --Ph                                   21 C--Me NHCH(CH.sub.2 Ph)CH.sub.2                                  OMe 2,4-Cl.sub.2 --Ph   22 C--Me NH-4-tetrahydropyranyl 2,4-Cl.sub.2 --Ph   23 C--Me NH-cyclopentyl 2,4-Cl.sub.2 --Ph   24 C--Me 1,2,3,4-tetrahydro- 2,4-Cl.sub.2 --Ph    isoquinolinyl   25 C--Me CH.sub.2 -(1,2,3,4-tetrahydro- 2,4-Cl.sub.2 --Ph    isoquinolinyl)   26.sup.n C--Me OEt 2,4-Cl.sub.2 --Ph 141-143   27 C--Me OCH(Et)CH.sub.2 OMe 2,4-Cl.sub.2 --Ph   28 C--Me OCH.sub.2 Ph 2,4-Cl.sub.2 --Ph   29 C--Me O-3-pentyl 2,4-Cl.sub.2 --Ph   30 C--Me SEt 2,4-Cl.sub.2 --Ph   31 C--Me S(O)Et 2,4-Cl.sub.2 --Ph   32 C--Me SO.sub.2 Et 2,4-Cl.sub.2 --Ph   33 C--Me CH(CO.sub.2 Et).sub.2 2,4-Cl.sub.2 --Ph   34 C--Me C(Et)(CO.sub.2 Et).sub.2 2,4-Cl.sub.2 --Ph   35 C--Me CH(Et)CH.sub.2 OH 2,4-Cl.sub.2 --Ph   36 C--Me CH(Et)CH.sub.2 OMe 2,4-Cl.sub.2 --Ph   37 C--Me CONMe.sub.2 2,4-Cl.sub.2 --Ph   38 C--Me COCH.sub.3 2,4-Cl.sub.2 --Ph   39 C--Me CH(OH)CH.sub.3 2,4-Cl.sub.2 --Ph   40 C--Me C(OH)Ph-3-pyridyl 2,4-Cl.sub.2 --Ph   41 C--Me Ph 2,4-Cl.sub.2 --Ph   42 C--Me 2-CF.sub.3 --Ph 2,4-Cl.sub.2 --Ph   43 C--Me 2-Ph--Ph 2,4-Cl.sub.2 --Ph   44 C--Me 3-pentyl 2,4-Cl.sub.2 --Ph   45 C--Me cyclobutyl 2,4-Cl.sub.2 --Ph   46 C--Me 3-pyrldyl 2,4-Cl.sub.2 --Ph   47 C--Me CH(Et)CH.sub.2 CONMe.sub.2 2,4-Cl.sub.2 --Ph   48 C--Me CH(Et)CH.sub.2 CH.sub.2 NMe.sub.2 2,4-Cl.sub.2 --Ph   49.sup.o C--Me NHCH(CH.sub.2 OMe).sub.2 2,4,6-Me.sub.3 --Ph 125-127                                   50 C--Me NHCHPr.sub.2 2,4,6-Me.sub                                 .3 --Ph   51 C--Me NEtBu 2,4,6-Me.sub.3 --Ph   52 C--Me NPr(CH.sub.2 -c-C.sub.3 H.sub.5) 2,4,6-Me.sub.3 --Ph   53.sup.ae C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4,6-Me.sub.3 --Ph                                 123-124   54 C--Me NH-3-heptyl 2,4,6-Me.sub.3 --Ph   55.sup.ac C--Me NHCH(Et)CH.sub.2 OMe 2,4,6-Me.sub.3 --Ph 145-146                                   56.sup.ah C--Me NEt.sub.2                                 2,4,6-Me.sub.3 --Ph 88-90   57.sup.ai C--Me NHCH(CH.sub.2 OEt).sub.2 2,4,6-Me.sub.3 --Ph 132-134                                   58.sup.ad C--Me NH-3-pentyl                                 2,4,6-Me.sub.3 --Ph 134-135                                   59 C--Me NMePh 2,4,6-Me.sub.3                                 --Ph   60 C--Me NPr.sub.2 2,4,6-Me.sub.3 --Ph   61 C--Me NH-3-hexyl 2,4,6-Me.sub.3 --Ph   62 C--Me morpholino 2,4,6-Me.sub.3 --Ph   63 C--Me N(CH.sub.2 Ph)CH.sub.2 CH.sub.2 OMe 2,4,6-Me.sub.3 --Ph                                   64 C--Me NHCH(CH.sub.2 Ph)CH.sub.2                                  OMe 2,4,6-Me.sub.3 --Ph   65 C--Me NH-4-tetrahydropyranyl 2,4,6-Me.sub.3 --Ph   66 C--Me NH-cyclopentyl 2,4,6-Me.sub.3 --Ph   67 C--Me 1,2,3,4-tetrahydro- 2,4,6-Me.sub.3 --Ph    isoquinolinyl   68 C--Me CH.sub.2 -(1,2,3,4-tetrahydro- 2,4,6-Me.sub.3 --Ph    isoquinolinyl)   69 C--Me OEt 2,4,6-Me.sub.3 --Ph   70 C--Me OCH(Et)CH.sub.2 OMe 2,4,6-Me.sub.3 --Ph   71 C--Me OCH.sub.2 Ph 2,4,6-Me.sub.3 --Ph   72 C--Me O-3-pentyl 2,4,6-Me.sub.3 --Ph   73 C--Me SEt 2,4,6-Me.sub.3 --Ph   74 C--Me S(O)Et 2,4,6-Me.sub.3 --Ph   75 C--Me SO.sub.2 Et 2,4,6-Me.sub.3 --Ph   76 C--Me CH(CO.sub.2 Et).sub.2 2,4,6-Me.sub.3 --Ph   77 C--Me C(Et)(CO.sub.2 Et).sub.2 2,4,6-Me.sub.3 --Ph   78 C--Me CH(Et)CH.sub.2 OH 2,4,6-Me.sub.3 --Ph   79 C--Me CH(Et)CH.sub.2 OMe 2,4,6-Me.sub.3 --Ph   80 C--Me CONMe.sub.2 2,4,6-Me.sub.3 --Ph   81 C--Me COCH.sub.3 2,4,6-Me.sub.3 --Ph   82 C--Me CH(OH)CH.sub.3 2,4,6-Me.sub.3 --Ph   83 C--Me C(OH)Ph-3-pyridyl 2,4,6-Me.sub.3 --Ph   84 C--Me Ph 2,4,6-Me.sub.3 --Ph   85 C--Me 2-CF.sub.3 --Ph 2,4,6-Me.sub.3 --Ph   86 C--Me 2-Ph--Ph 2,4,6-Me.sub.3 --Ph   87 C--Me 3-pentyl 2,4,6-Me.sub.3 --Ph   88 C--Me cyclobutyl 2,4,6-Me.sub.3 --Ph   89 C--Me 3-pyridyl 2,4,6-Me.sub.3 --Ph   90 C--Me CH(Et)CH.sub.2 CONMe.sub.2 2,4,6-Me.sub.3 --Ph   91 C--Me CH(Et)CH.sub.2 CH.sub.2 NMe.sub.2 2,4,6-Me.sub.3 --Ph                                   92.sup.p C--Me NHCH(CH.sub.2                                 OMe).sub.2 2,4-Me.sub.2 --Ph 44-45                                   93.sup.q C--Me N(CH.sub.2                                 CH.sub.2 OMe).sub.2 2,4-Me.sub.2                                 --Ph oil   94.sup.r C--Me NHCH(Et)CH.sub.2 OMe 2,4-Me.sub.2 --Ph 102-104   95.sup.s C--Me NH-3-pentyl 2,4-Me.sub.2 --Ph 102-104   96.sup.t C--Me NEt.sub.2 2,4-Me.sub.2 --Ph oil   97.sup.u C--Me N(CH.sub.2 CN).sub.2 2,4-Me.sub.2 --Ph 148-150   98.sup.v C--Me NHCH(Me)CH.sub.2 OMe 2,4-Me.sub.2 --Ph 102-104   99.sup.w C--Me OCH(Et)CH.sub.2 OMe 2,4-Me.sub.2 --Ph oil  100.sup.x C--Me NPr-c-C.sub.3 H.sub.5 2,4-Me.sub.2 --Ph oil  101.sup.y C--Me NHCH(Me)CH.sub.2 NMe.sub.2 2,4-Me.sub.2 --Ph 47-48                                  102.sup.z C--Me N(c-C.sub.3                                 H.sub.5)CH.sub.2 CH.sub.2 CN                                 2,4-Me.sub.2 --Ph 117-118  103.sup.aa C--Me N(Pr)CH.sub.2 CH.sub.2 CN 2,4-Me.sub.2 --Ph oil                                  104.sup.ab C--Me N(Bu)CH.sub.2                                 CH.sub.2 CN 2,4-Me.sub.2 --Ph oil                                  105 C--Me NHCHPr.sub.2 2,4-Me.sub.2                                  --Ph  106 C--Me NEtBu 2,4-Me.sub.2 --Ph  107 C--Me NPr(CH.sub.2 -c-C.sub.3 H.sub.5) 2,4-Me.sub.2 --Ph  108 C--Me NH-3-heptyl 2,4-Me.sub.2 --Ph  109 C--Me NEt.sub.2 2,4-Me.sub.2 --Ph  110 C--Me NHCH(CH.sub.2 OEt).sub.2 2,4-Me.sub.2 --Ph  111 C--Me NH-3-pentyl 2,4-Me.sub.2 --Ph  112 C--Me NMePh 2,4-Me.sub.2 --Ph  113 C--Me NPr.sub.2 2,4-Me.sub.2 --Ph  114 C--Me NH-3-hexyl 2,4-Me.sub.2 --Ph  115 C--Me morpholino 2,4-Me.sub.2 --Ph  116 C--Me N(CH.sub.2 Ph)CH.sub.2 CH.sub.2 OMe 2,4-Me.sub.2 --Ph                                  117 C--Me NHCH(CH.sub.2 Ph)CH.sub.2                                  OMe 2,4-Me.sub.2 --Ph  118 C--Me NH-4-tetrahydropyranyl 2,4-Me.sub.2 --Ph  119 C--Me NH-cyclopentyl 2,4-Me.sub.2 --Ph  120 C--Me 1,2,3,4-tetrahydro- 2,4-Me.sub.2 --Ph    isoquinolinyl  121 C--Me CH.sub.2 -(1,2,3,4-tetrahydro- 2,4-Me.sub.2 --Ph    isoquinolinyl)  122 C--Me OEt 2,4-Me.sub.2 --Ph  123 C--Me OCH(Et)CH.sub.2 OMe 2,4-Me.sub.2 --Ph  124 C--Me OCH.sub.2 Ph 2,4-Me.sub.2 --Ph  125 C--Me O-3-pentyl 2,4-Me.sub.2 --Ph  126 C--Me SEt 2,4-Me.sub.2 --Ph  127 C--Me S(O)Et 2,4-Me.sub.2 --Ph  128 C--Me SO.sub.2 Et 2,4-Me.sub.2 --Ph   3 C--Me CH(CO.sub.2 Et).sub.2 2,4-Me.sub.2 --Ph 50-52  129 C--Me C(Et)(CO.sub.2 Et).sub.2 2,4-Me.sub.2 --Ph  130 C--Me CH(Et)CH.sub.2 OH 2,4-Me.sub.2 --Ph  131 C--Me CH(Et)CH.sub.2 OMe 2,4-Me.sub.2 --Ph  132 C--Me CH(Et)CH.sub.2 OEt 2,4-Me.sub.2 --Ph  133 C--Me CONMe.sub.2 2,4-Me.sub.2 --Ph  134 C--Me COCH.sub.3 2,4-Me.sub.2 --Ph  135 C--Me CH(OH)CH.sub.3 2.4-Me.sub.2 --Ph  136 C--Me C(OH)Ph-3-pyridyl 2,4-Me.sub.2 --Ph  137 C--Me Ph 2,4-Me.sub.2 --Ph  138 C--Me 2-CF.sub.3 --Ph 2,4-Me.sub.2 --Ph  139 C--Me 2-Ph--Ph 2,4-Me.sub.2 --Ph  140 C--Me 3-pentyl 2,4-Me.sub.2 --Ph  141 C--Me cyclobutyl 2,4-Me.sub.2 --Ph  142 C--Me 3-pyridyl 2,4-Me.sub.2 --Ph  143 C--Me CH(Et)CH.sub.2 CONMe.sub.2 2,4-Me.sub.2 --Ph  144 C--Me CH(Et)CH.sub.2 CH.sub.2 NMe.sub.2 2,4-Me.sub.2 --Ph  145.sup.bc C--Me NHCH(CH.sub.2 OMe).sub.2 2-Me-4-MeO--Ph 45-46  146.sup.bd C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me-4-MeO--Ph oil                                  147.sup.be C--Me NHCH(Et)CH.sub.2                                 OMe 2-Me-4-MeO--Ph 86-88  148.sup.bf C--Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Me-4-MeO--Ph oil  149 C--Me OCH(Et)CH.sub.2 OMe 2-Me-4-MeO--Ph  150.sup.af C--Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4-MeO--Ph 88-90  151.sup.al C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4-MeO--Ph oil                                  152.sup.ag C--Me NHCH(Et)CH.sub.2                                 OMe 2-Br-4-MeO--Ph 95-97  153 C--Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Br-4-MeO--Ph  154 C--Me OCH(Et)CH.sub.2 OMe 2-Br-4-MeO--Ph  155 C--Me NHCH(CH.sub.2 OMe).sub.2 2-Me-4-NMe.sub.2 --Ph  156 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me-4-NMe.sub.2 --Ph oil                                  157 C--Me NHCH(Et)CH.sub.2 OMe                                 2-Me-4-NMe.sub.2 --Ph  158 C--Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Me-4-NMe.sub.2 --Ph  159 C--Me OCH(Et)CH.sub.2 OMe 2-Me-4-NMe.sub.2 --Ph  160 C--Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4-NMe.sub.2 --Ph  161 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4-NMe.sub.2 --Ph  162 C--Me NHCH(Et)CH.sub.2 OMe 2-Br-4-NMe.sub.2 --Ph  163 C--Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Br-4-NMe.sub.2 --Ph  164 C--Me OCH(Et)CH.sub.2 OMe 2-Br-4-NMe.sub.2 --Ph  165 C--Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4-i-Pr--Ph  166 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4-i-Pr--Ph  167 C--Me NHCH(Et)CH.sub.2 OMe 2-Br-4-i-Pr--Ph  168 C--Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Br-4-i-Pr--Ph  169 C--Me OCH(Et)CH.sub.2 OMe 2-Br-4-i-Pr--Ph  170 C--Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4-Me--Ph  171 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4-Me--Ph  172 C--Me NHCH(Et)CH.sub.2 OMe 2-Br-4-Me--Ph  173 C--Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Br-4-Me--Ph  174 C--Me OCH(Et)CH.sub.2 OMe 2-Br-4-Me--Ph  175.sup.ar C--Me NHCH(CH.sub.2 OMe).sub.2 2-Me-4-Br--Ph 108-109                                  176 C--Me N(CH.sub.2 CH.sub.2                                 OMe).sub.2 2-Me-4-Br--Ph  177 C--Me NHCH(Et)CH.sub.2 OMe 2-Me-4-Br--Ph  178 C--Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Me-4-Br--Ph  179 C--Me OCH(Et)CH.sub.2 OMe 2-Me-4-Br--Ph  180 C--Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4,6-Me.sub.2 --Ph  181 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4,6-Me.sub.2 --Ph                                  182 C--Me NHCH(CH.sub.2 OMe).sub.2                                 4-Br-2,6-(Me).sub.2 --Ph  183 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 4-Br-2,6-(Me).sub.2 --Ph                                  184 C--Me NHCH(CH.sub.2 OMe).sub.2                                 4-i-Pr-2-SMe--Ph  185 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 4-i-Pr-2-SMe--Ph  186 C--Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4-CF.sub.3 --Ph  187 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4-CF.sub.3 --Ph  188 C--Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4,6-(MeO).sub.2 --Ph  189 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4,6-(MeO).sub.2 --Ph                                  190 C--Me NHCH(CH.sub.2 OMe).sub.2                                 2-Cl-4,6-(MeO).sub.2 --Ph  191 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4,6-(MeO).sub.2 --Ph                                  192 C--Me NHCH(CH.sub.2 OMe).sub.2                                 2,6-(Me).sub.2 -4-SMe--Ph  193 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,6-(Me).sub.2 -4-SMe--Ph                                  194 C--Me NHCH(CH.sub.2 OMe).sub.2                                 4-(COMe)-2-Br--Ph  195 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 4-(COMe)-2-Br--Ph  196 C--Me NHCH(CH.sub.2 OMe).sub.2 2,4,6-Me.sub.3 -pyrid-3-yl  197 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4,6-Me.sub.3 -pyrid-3-yl                                  198 C--Me NHCH(CH.sub.2 OMe).sub.2                                 2,4-(Br).sub.2 --Ph  199 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4-(Br).sub.2 --Ph  200 C--Me NHCH(CH.sub.2 OMe).sub.2 4-i-Pr-2-SMe--Ph  201 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 4-i-Pr-2-SMe--Ph  202 C--Me NHCH(CH.sub.2 OMe).sub.2 4-i-Pr-2-SO.sub.2 Me--Ph  203 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 4-i-Pr-2-SO.sub.2 Me--Ph                                  204 C--Me NHCH(CH.sub.2 OMe).sub.2                                 2,6-(Me).sub.2 -4-SMe--Ph  205 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,6-(Me).sub.2 -4-SMe--Ph                                  206 C--Me NHCH(CH.sub.2 OMe).sub.2                                 2,6-(Me).sub.2 -4-SO.sub.2 Me--Ph                                  207 C--Me N(CH.sub.2 CH.sub.2                                 OMe).sub.2 2,6-(Me).sub.2 -4-SO.sub.                                 2 Me--Ph  208 C--Me NHCH(CH.sub.2 OMe).sub.2 2-I-4-i-Pr--Ph  209 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-I-4-i-Pr--Ph  210 C--Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4-N(Me).sub.2 -6-MeO--Ph                                  211 C--Me N(CH.sub.2 CH.sub.2                                 OMe).sub.2 2-Br-4-N(Me).sub.2                                 -6-MeO--Ph  212 C--Me NHCH(CH.sub.2 OMe).sub.2 2,4-[SMe]2-Ph  213 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4-[SMe]2-Ph  214 C--Me NHCH(CH.sub.2 OMe).sub.2 2,4-[SO.sub.2 Me]2-Ph  215 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4-[SO.sub.2 Me]2-Ph  216 C--Me NHCH(CH.sub.2 OMe).sub.2 4-i-Pr-2-SMe--Ph  217 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 4-i-Pr-2-SMe--Ph  218 C--Me NHCH(CH.sub.2 OMe).sub.2 4-i-Pr-2-SO.sub.2 Me--Ph  219 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 4-i-Pr-2-SO.sub.2 Me--Ph                                  220 C--Me NHCH(CH.sub.2 OMe).sub.2                                 2-N(Me).sub.2 -4-Me--Ph  221 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-N(Me).sub.2 -4-Me--Ph                                  222 C--Me NHCH(CH.sub.2 OMe).sub.2                                 2-MeS-4,6-(Me).sub.2 --Ph  223 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-MeS-4,6-(Me).sub.2 --Ph                                  224 C--Me NHCH(CH.sub.2 OMe).sub.2                                 2-(CH.sub.3 CO)-4,6-(Me).sub.2 --Ph  225 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-(CH.sub.3 CO)-4,6-(Me).sub.2                                 --Ph  226 H NHCH(CH.sub.2 OMe).sub.2 2,4-Me.sub.2 --Ph  227 H NHCH(CH.sub.2 OMe).sub.2 2,4-Me.sub.2 --Ph  228 CF.sub.3 N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4-Me.sub.2 --Ph  229 CF.sub.3 N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4-Me.sub.2 --Ph  230 N NHCH(CH.sub.2 OMe).sub.2 2,4,6-Me.sub.3 --Ph  231 N NHCHPr.sub.2 2,4,6-Me.sub.3 --Ph  232 N NEtBu 2,4,6-Me.sub.3 --Ph  233 N NPr(CH.sub.2 -c-C.sub.3 H.sub.5) 2,4,6-Me.sub.3 --Ph  234 N N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4,6-Me.sub.3 --Ph  235 N NH-3-heptyl 2,4,6-Me.sub.3 --Ph  236 N NHCH(Et)CH.sub.2 OMe 2,4,6-Me.sub.3 --Ph  237 N NEt.sub.2 2,4,6-Me.sub.3 --Ph  238 N NHCH(CH.sub.2 OEt).sub.2 2,4,6-Me.sub.3 --Ph  239 N NH-3-pentyl 2,4,6-Me.sub.3 --Ph  240 N NMePh 2,4,6-Me.sub.3 --Ph  241 N NPr.sub.2 2,4,6-Me.sub.3 --Ph  242 N NH-3-hexyl 2,4,6-Me.sub.3 --Ph  243 N morpholino 2,4,6-Me.sub.3 --Ph  244 N N(CH.sub.2 Ph)CH.sub.2 CH.sub.2 OMe 2,4,6-Me.sub.3 --Ph  245 N NHCH(CH.sub.2 Ph)CH.sub.2 OMe 2,4,6-Me.sub.3 --Ph  246 N NH-4-tetrahydropyranyl 2,4,6-Me.sub.3 --Ph  247 N NH-cyclopentyl 2,4,6-Me.sub.3 --Ph  248 N 1,2,3,4-tetrahydro- 2,4,6-Me.sub.3 --Ph    isoquinolinyl  249 N CH.sub.2 -(1,2,3,4-tetrahydro- 2,4,6-Me.sub.3 --Ph    isoquinolinyl)  250 N OEt 2,4,6-Me.sub.3 --Ph  251 N OCH(Et)CH.sub.2 OMe 2,4,6-Me.sub.3 --Ph  252 N OCH.sub.2 Ph 2,4,6-Me.sub.3 --Ph  253 N O-3-pentyl 2,4,6-Me.sub.3 --Ph  254 N SEt 2,4,6-Me.sub.3 --Ph  255 N S(O)Et 2,4,6-Me.sub.3 --Ph  256 N SO.sub.2 Et 2,4,6-Me.sub.3 --Ph  257 N CH(CO.sub.2 Et).sub.2 2,4,6-Me.sub.3 --Ph  258 N C(Et)(CO.sub.2 Et).sub.2 2,4,6-Me.sub.3 --Ph  259 N CH(Et)CH.sub.2 OH 2,4,6-Me.sub.3 --Ph  260 N CH(Et)CH.sub.2 OMe 2,4,6-Me.sub.3 --Ph  261 N CONMe.sub.2 2,4,6-Me.sub.3 --Ph  262 N COCH.sub.3 2,4,6-Me.sub.3 --Ph  263 N CH(OH)CH.sub.3 2,4,6-Me.sub.3 --Ph  264 N C(OH)Ph-3-pyridyl 2,4,6-Me.sub.3 --Ph  265 N Ph 2,4,6-Me.sub.3 --Ph  266 N 2-CF.sub.3 --Ph 2,4,6-Me.sub.3 --Ph  267 N 2-Ph--Ph 2,4,6-Me.sub.3 --Ph  268 N 3-pentyl 2,4,6-Me.sub.3 --Ph  269 N cyclobutyl 2,4,6-Me.sub.3 --Ph  270 N 3-pyridyl 2,4,6-Me.sub.3 --Ph  271 N CH(Et)CH.sub.2 CONMe.sub.2 2,4,6-Me.sub.3 --Ph  272 N CH(Et)CH.sub.2 CH.sub.2 NMe.sub.2 2,4,6-Me.sub.3 --Ph  273 N NHCH(CH.sub.2 OMe).sub.2 2,4-Me.sub.2 --Ph  274 N NHCHPr.sub.2 2,4-Me.sub.2 --Ph  275 N NEtBu 2,4-Me.sub.2 --Ph  276 N NPr(CH.sub.2 -c-C.sub.3 H.sub.5) 2,4-Me.sub.2 --Ph  277 N N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4-Me.sub.2 --Ph  278 N NH-3-heptyl 2,4-Me.sub.2 --Ph  279 N NHCH(Et)CH.sub.2 OMe 2,4-Me.sub.2 --Ph  280 N NEt.sub.2 2,4-Me.sub.2 --Ph  281 N NHCH(CH.sub.2 OEt).sub.2 2,4-Me.sub.2 --Ph  282 N NH-3-pentyl 2,4-Me.sub.2 --Ph  283 N NMePh 2,4-Me.sub.2 --Ph  284 N NPr.sub.2 2,4-Me.sub.2 --Ph  285 N NH-3-hexyl 2,4-Me.sub.2 --Ph  286 N morpholino 2,4-Me.sub.2 --Ph  287 N N(CH.sub.2 Ph)CH.sub.2 CH.sub.2 OMe 2,4-Me.sub.2 --Ph  288 N NHCH(CH.sub.2 Ph)CH.sub.2 OMe 2,4-Me.sub.2 --Ph  289 N NH-4-tetrahydropyranyl 2,4-Me.sub.2 --Ph  290 N NH-cyclopentyl 2,4-Me.sub.2 --Ph  291 N 1,2,3,4-tetrahydro- 2,4-Me.sub.2 --Ph    isoquinolinyl  292 N CH.sub.2 -(1,2,3,4-tetrahydro- 2,4-Me.sub.2 --Ph    isoquinolinyl)  293 N OEt 2,4-Me.sub.2 --Ph  294 N OCH(Et)CH.sub.2 OMe 2,4-Me.sub.2 --Ph  295 N OCH.sub.2 Ph 2,4-Me.sub.2 --Ph  296 N O-3-pentyl 2,4-Me.sub.2 --Ph  297 N SEt 2,4-Me.sub.2 --Ph  298 N S(O)Et 2,4-Me.sub.2 --Ph  299 N SO.sub.2 Et 2,4-Me.sub.2 --Ph  300 N CH(CO.sub.2 Et).sub.2 2,4-Me.sub.2 --Ph  301 N C(Et)(CO.sub.2 Et).sub.2 2,4-Me.sub.2 --Ph  302 N CH(Et)CH.sub.2 OH 2,4-Me.sub.2 --Ph  303 N CH(Et)CH.sub.2 OMe 2,4-Me.sub.2 --Ph  304 N CONMe.sub.2 2,4-Me.sub.2 --Ph  305 N COCH.sub.3 2,4-Me.sub.2 --Ph  306 N CH(OH)CH.sub.3 2,4-Me.sub.2 --Ph  307 N C(OH)Ph-3-pyridyl 2,4-Me.sub.2 --Ph  308 N Ph 2,4-Me.sub.2 --Ph  309 N 2-CF.sub.3 --Ph 2,4-Me.sub.2 --Ph  310 N 2-Ph--Ph 2,4-Me.sub.2 --Ph  311 N 3-pentyl 2,4-Me.sub.2 --Ph  312 N cyclobutyl 2,4-Me.sub.2 --Ph  313 N 3-pyridyl 2,4-Me.sub.2 --Ph  314 N CH(Et)CH.sub.2 CONMe.sub.2 2,4-Me.sub.2 --Ph  315 N CH(Et)CH.sub.2 CH.sub.2 NMe.sub.2 2,4-Me.sub.2 --Ph  316.sup.an C--Me NEt.sub.2 2-Br-4-MeO--Ph oil  317.sup.am C--Me NH-3-pentyl 2-Br-4-MeO--Ph oil  318.sup.aj C--Me NHCH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe 2,4,6-Me.sub.3                                 --Ph 101-103  319.sup.ao C--Me NH(c-C.sub.3 H.sub.5) 2,4-Me.sub.2 --Ph oil  320.sup.ak C--Me morpholino 2,4,6-Me.sub.3 --Ph 139-141  321.sup.ap C--Me NHCH(CH.sub.2 OMe).sub.2 2-CN-4-Me--Ph 152-153                                  322.sup.aq C--Me N(c-C.sub.3                                 H.sub.5)CH.sub.2 CH.sub.2 CN                                 2,4,6-Me.sub.3 --Ph 149-151                                  324.sup.as C--Me NHCH(CH.sub.2                                 CH.sub.2 OMe)CH.sub.2 OMe 2-Me-4-Br-                                 -Ph 115-117  325.sup.at C--Me NHCH(CH.sub.2 OMe).sub.2 2,5-Me.sub.2 -4-MeO--Ph 55-57  326.sup.au C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,5-Me.sub.2 -4-MeO--Ph                                 72  327.sup.av C--Me NH-3-pentyl 2,5-Me.sub.2 -4-MeO--Ph 45-47  328.sup.aw C--Me NEt.sub.2 2,5-Me.sub.2 -4-MeO--Ph oil  329.sup.ax C--Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4-MePh 80-81  330.sup.ay C--Me NCH(Et)CH.sub.2 OMe 2-Cl-4-MePh 77-79  331.sup.az C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4-MePh oil                                  332.sup.ba C--Me (S)-NHCH(CH.sub.2                                 CH.sub.2 OMe)CH.sub.2 OMe 2-Cl-4-MeP                                 h 139-140  333.sup.bb C--Me N(c-C.sub.3 H.sub.5)CH.sub.2 CH.sub.2 CN 2,5-Me.sub.2                                 -4-MeOPh 120-122  334.sup.bg C--Me NEt.sub.2 2-Me-4-MeOPh oil  335.sup.bh C--Me OEt 2-Me-4-MeOPh oil  336.sup.bi C--Me (S)-NHCH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe 2-Me-4-MeOP                                 h oil  337.sup.bj C--Me N(c-C.sub.3 H.sub.5)CH.sub.2 CH.sub.2 CN 2-Me-4-MeOPh                                 129  338.sup.bk C--Me NHCH(CH.sub.2 CH.sub.2 OEt).sub.2 2-Me-4-MeOPh amorph.  339 C--Me N(c-C.sub.3 H.sub.5)CH.sub.2 CH.sub.2 CN 2,4-Cl.sub.2 --Ph                                 109-110  340 C--Me (S)-NHCH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe 2,4-Cl.sub.2 --Ph                                 93-94  341 C--Me NH-3-pentyl 2-Me-4-BrPh 118-119  342 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me-4-BrPh oil  343 C--Me NHCH(CH.sub.2 -iPr)CH.sub.2 OMe 2,4-Me.sub.2 --Ph oil                                  344 C--Me NHCH(Pr)CH.sub.2 OMe                                 2,4-Me.sub.2 --Ph 94-95  345 C--Me NHCH(Et)CH.sub.2 OEt 2,4-Me.sub.2 --Ph 76-77  346 C--Me NHCH(CH.sub.2 OMe)CH.sub.2 CH.sub.2 OMe 2-Me-4-Me.sub.2 NPh                                 oil  347 C--Me NEt.sub.2 2-Me-4-ClPh oil  348 C--Me NH-3-pentyl 2-Me-4-ClPh 122-124  349 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me-4-ClPh oil  350 C--Me NHCH(CH.sub.2 OMe).sub.2 2-Me-4-ClPh 122-123  351 C--Me NEt.sub.2 2-Me-4-ClPh oil  352 C--Me NEt.sub.2 2-Cl-4-MePh oil  353 C--Me NH-3-pentyl 2-Cl-4-MePh 120-121  354 C--Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4-MeOPh  355.sup.bl C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4-MeOPh oi1                                  356.sup.bm C--Me NHCH(Et)CH.sub.2                                 OMe 2-Cl-4-MeOPh 108-110  357.sup.bn C--Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl-4-MeOPh 127-129                                  358.sup.bo C--Me NEt.sub.2                                 2-Cl-4-MeOPh oil  359.sup.bp C--Me NH-3-pentyl 2-Cl-4-MeOPh 77-79  360 C--Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Cl-4-MeOPh  361 C--Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Cl-4-MeOPh  362 C--Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Br-4-MeOPh  363 C--Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Br-4-MeOPh  364 C--Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  365 C--Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  366 C--Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4,5-(MeO).sub.2 Ph  367 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4,5-(MeO).sub.2 Ph                                  368 C--Me NHCH(Et)CH.sub.2 OMe                                 2-Cl-4,5-(MeO).sub.2 Ph  369 C--Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl-4,5-(MeO).sub.2 Ph  370 C--Me NEt.sub.2 2-Cl-4,5-(MeO).sub.2 Ph  371 C--Me NH-3-pentyl 2-Cl-4,5-(MeO).sub.2 Ph  372 C--Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Cl-4,5-(MeO).sub.2 Ph                                  373 C--Me NHCH(Me)CH.sub.2                                 CH.sub.2 OMe 2-Cl-4,5-(MeO).sub.2                                 Ph  374.sup.bq C--Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4,5-(MeO).sub.2 Ph                                 137-138  375 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4,5-(MeO).sub.2 Ph                                  376.sup.br C--Me NHCH(Et)CH.sub.2                                 OMe 2-Br-4,5-(MeO).sub.2 Ph 147-148  377 C--Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Br-4,5-(MeO).sub.2 Ph  378.sup.bs C--Me NEt.sub.2 2-Br-4,5-(MeO).sub.2 Ph 52-58  379 C--Me NH-3-pentyl 2-Br-4,5-(MeO).sub.2 Ph  380 C--Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Br-4,5-(MeO).sub.2 Ph                                  381 C--Me NHCH(Me)CH.sub.2                                 CH.sub.2 OMe 2-Br-4,5-(MeO).sub.2                                 Ph  382 C--Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4,6-(MeO).sub.2 Ph  383 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4,6-(MeO).sub.2 Ph                                  384 C--Me NHCH(Et)CH.sub.2 OMe                                 2-Cl-4,6-(MeO).sub.2 Ph  385 C--Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl-4,6-(MeO).sub.2 Ph  386 C--Me NEt.sub.2 2-Cl-4,6-(MeO).sub.2 Ph  387 C--Me NH-3-pentyl 2-Cl-4,6-(MeO).sub.2 Ph  388 C--Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Cl-4,6-(MeO).sub.2 Ph                                  389 C--Me NHCH(Me)CH.sub.2                                 CH.sub.2 OMe 2-Cl-4,6-(MeO).sub.2                                 Ph  390 C--Me NHCH(CH.sub.2 OMe).sub.2 2-Me-4,6-(MeO).sub.2 Ph  391 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me-4,6-(MeO).sub.2 Ph                                  392 C--Me NHCH(Et)CH.sub.2 OMe                                 2-Me-4,6-(MeO).sub.2 Ph  393 C--Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me-4,6-(MeO).sub.2 Ph  395 C--Me NEt.sub.2 2-Me-4,6-(MeO).sub.2 Ph  396 C--Me NH-3-pentyl 2-Me-4,6-(MeO).sub.2 Ph  397 C--Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me-4,6-(MeO).sub.2 Ph                                  398 C--Me NHCH(Me)CH.sub.2                                 CH.sub.2 OMe 2-Me-4,6-(MeO).sub.2                                 Ph  399 C--Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Br-4,6-(MeO).sub.2 Ph  400 C--Me NEt.sub.2 2-Br-4,6-(MeO).sub.2 Ph  401 C--Me NH-3-penty1 2-Br-4,6-(MeO).sub.2 Ph  402 C--Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Br-4,6-(MeO).sub.2 Ph                                  403 C--Me NHCH(Me)CH.sub.2                                 CH.sub.2 OMe 2-Br-4,6-(MeO).sub.2                                 Ph  404 C--Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  405 C--Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  406 C--Me NHCH(CH.sub.2 OMe).sub.2 2-MeO-4-MePh  407 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-MeO-4-MePh  408 C--Me NHCH(Et)CH.sub.2 OMe 2-MeO-4-MePh  409 C--Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-MeO-4-MePh  410 C--Me NEt.sub.2 2-MeO-4-MePh  411 C--Me NH-3-pentyl 2-MeO-4-MePh  412 C--Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-MeO-4-MePh  413 C--Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-MeO-4-MePh  414 C--Me NHCH(CH.sub.2 OMe).sub.2 2-MeO-4-MePh  415 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-MeO-4-MePh  416 C--Me NHCH(Et)CH.sub.2 OMe 2-MeO-4-MePh  417 C--Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-MeO-4-MePh  418 C--Me NEt.sub.2 2-MeO-4-MePh  419 C--Me NH-3-pentyl 2-MeO-4-MePh  420 C--Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-MeO-4-MePh  421 C--Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-MeO-4-MePh  423.sup.bt C--Me NHCH(CH.sub.2 OMe).sub.2 2-MeO-4-ClPh oil  424 C--Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-MeO-4-ClPh  425 C--Me NHCH(Et)CH.sub.2 OMe 2-MeO-4-ClPh  426 C--Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-MeO-4-ClPh  427 C--Me NEt.sub.2 2-MeO-4-ClPh  428 C--Me NH-3-pentyl 2-MeO-4-ClPh  429 C--Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-MeO-4-ClPh  430 C--Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-MeO-4-ClPh__________________________________________________________________________NOTES FOR TABLE 1:a) Analysis Calcd: C, 52.69, H, 5.17, N, 17.07, Cl,   17.28; Found: C, 52.82, H, 5.06, N, 16.77, Cl,   17.50.  b) CI-HRMS: Calcd: 406.1565, Found: 405.1573 (M+H);   Analysis Calcd: C: 59.11; H; 6.20; N: 17.23; Cl:   17.45; Found: C: 59.93; H: 6.34; N: 16.50; Cl:   16.95;   NMR (CDCl.sub.3, 300 MHz): 0.95 (t, J=8, 4H), 1.30-   1.40 (m, 4H), 1.50-1.75 (m, 4H), 2.35 (s, 3H), 2.48   (s, 3H) , 4.30-4.45 (m, 1H), 6.15 (d, J=8, 1H),   7.30 (s, 2H), 7.50 (s, 1H)  c) CI-HRMS: Calcd: 392.1409, Found: 392.1388 (M+H);   NMR (CDCl.sub.3, 300 MHz): 1.00 (t, J=8, 3H), 1.35 (t,   J=8, 3H), 1.41 (q, J=8, 2H), 1.65-1.85 (m, 2H)   2.30 (s, 3H), 2.40 (s, 3H), 3.85-4.20 (m, 4H), 7.30   (s, 2H), 7.50 (s, 1H).  d) CI-HRMS: Calcd: 404.1409, Found: 404.1408 (M+H);   NMR (CDCl.sub.3, 300 MHz): 0.35-0.45 (m, 2H), 0.52-0.62   (m, 2H), 0.98 (t, J=8, 3H), 1.70-1.90 (m, 2H),   2.30 (s, 3H), 2.40 (s, 3H), 3.85-4.02 (m, 2H),   4.02-4.20 (m, 2H), 7.30 (s, 2H), 7.50 (s, 1H).  e) CI-HRMS: Calcd: 424.1307, Found: 424.1307 (M+H):   NMR (CDCl.sub.3, 300 MHz): 2.28 (s, 3H), 2.40 (s, 3H),   3.40 (s, 6H), 3.75 (t, J=8, 4H), 4.20-4.45 (m,   4H), 7.30 (s, 2H), 7.50 (s, 1H).  f) CI-HRMS: Calcd: 406.1565, Found: 406.1578 (M+H);   NMR (CDCl.sub.3, 300 MHz): 0.90 (t, J=8, 3H), 1.00 (t,   J=8, 3H), 1.28-1.45 (m, 4H), 1.50-1.80 (m, 4H),   2.35 (s, 3H), 2.50 (s, 3H), 4.20-4.35 (m, 1H),   6.10-6.23 (m, 1H), 7.30 (s, 2H), 7.50 (s, 1H).  g) CI-HRMS: Calcd: 394.1201, Found: 394.1209 (M+H);   NMR (CDCl.sub.3, 300 MHz) 1.02 (t, J=8, 3H), 1.65-   1.90 (m, 2H), 2.35 (s, 3H), 2.48 (s, 3H), 3.40 (s,   3H), 3.50-3.60 (m, 2H), 4.35-4.45 (brs, 1H), 6.50-   6.60 (m, 1H), 7.30 (s, 2H), 7.50 (s, 1H).  h) CI-HRMS: Calcd: 364.1096, Found: 364.1093 (M+H);   Analysis: Calcd: C: 56.05; H: 5.27; N: 19.23; Cl:   19.46; Found: C: 55.96; H: 5.24; N: 18.93; Cl:   19.25;   NMR (CDCl.sub.3, 300 MHz): 1.35 (t, J=8, 6H), 2.30 (3,   3H), 2.40 (s, 3H), 3.95-4.15 (m, 4H), 7.30 (s, 2H),   7.50 (d, J=1, 1H).  i) CI-HRMS: Calcd: 438.1464, Found: 438.1454 (M+H);   NMR (CDCl.sub.3, 300 MHz): 1.22 (t, J=8, 6H), 2.35 (s,   3H), 2.47 (s, 3H), 3.39 (q, J=8, 4H), 3.65 (dd, J=   8, 1, 2H), 3.73 (dd, J=8, 1, 2H), 4.55-4.65 (m,   1H), 6.75 (d, J=8, 1H), 7.30 (d, J=1, 2H), 7.50   (s, 1H).  j) CI-HRMS: Calcd: 378.1252, Found: 378.1249 (M+H);   Analysis: Calcd: C: 57.15; H: 5.61; N: 18.51; Cl:   18.74; Found: C: 57.56; H: 5.65; N: 18.35; Cl:   18.45;   NMR (CDCl.sub.3, 300 MHz): 1.00 (t, J=8, 6H), 1.55-   1.70 (m, 2H), 1.70-1.85 (m, 2H), 2.35 (s, 3H), 2.50   (s, 3H), 4.15-4.25 (m, 1H), 6.18 (d, J=8, 1H),   7.30 (s, 2H), 7.50 (s, 1H).  k) CI-HRMS: Calcd: 398.0939, Found: 398.0922 (M+H);   Analysis: Calcd: C: 60.31; H: 4.30; N: 17.58; Cl:   17.80; Found: C: 60.29; H: 4.59; N: 17.09; Cl:   17.57;   NMR (CDCl.sub.3, 300 MHz): 2.05 (s, 3H), 2.50 (s, 3H),   3.78 (s, 3H), 7.20-7.45 (m, 7H), 7.50 (d, J=1,   1H).  l) CI-HRMS: Calcd: 392.1409, Found: 392.1391 (M+H);   NMR (CDCl.sub.3, 300 MHz): 0.98 (t, J=8, 6H), 1.70-   1.85 (m, 4H), 2.30 (s, 3H), 2.40 (s, 3H), 3.80-4.10   (m, 4H), 7.30 (s, 2H), 7.50 (d, J=1, 1H).  m) CI-HRMS: Calcd: 392.1409, Found: 392.1415 (M+H);   Analysis: Calcd: C: 58.17; H: 5.92; N: 17.85; Cl:   18.07; Found: C: 58.41; H: 5.85: N: 18.10; Cl:   17.75;   NMR (CDCl.sub.3, 300 MHz): 0.90-1.05 (m, 6H), 1.35-1.55   (m, 2H), 1.55-1.85 (m, 4H), 2.35 (s, 3H), 2.48 (s,   3H), 4.20-4.35 (m, 1H), 6.15 (d, J=8, 1H), 7.30   (s, 2H), 7.50 (d, J=1, 1H).  n) CI-HRMS: Calcd: 337.0623, Found: 337.0689 (M+H);   Analysis: Calcd: C: 53.43; H: 4.18; N: 16.62; Cl:   21.03, Found: C: 53.56; H: 4.33; N: 16.56; Cl:   20.75;   NMR (CDCl.sub.3, 300 MHz): 1.60 (t, J=8, 3H), 2.40 (s,   3H), 2.55 (s, 3H), 4.80 (q, J=8, 2H), 7.30 (d, J=   8, 1H), 7.35 (dd, J=8, 1, 1H), 7.55 (d, J=1,   1H)  o) CI-HRMS: Calcd: 383.2321, Found: 383.2309 (M+H);   NMR (CDCl.sub.3, 300 MHz): 2.00 (s, 6H), 2.20 (s, 3H),   2.30 (s, 3H), 2.45 (s, 3H), 3.45 (s, 6H), 3.61 (dd,   J=8, 8, 2H), 3.70 (dd, J=8, 8, 2H), 4.60-4.70   (m, 1H), 6.70 (d, J=8, 1H), 6.94 (s, 2H).  p) CI-HRMS: Calcd: 370.2243 Found: 370.2246 (M+H);   Analysis: Calcd: C: 65.02; H: 7.38; N: 18.96;   Found: C: 65.22; H: 7.39; N: 18.71;   NMR (CDCl.sub.3, 300 MHz): 2.18 (s, 3H), 2.30 (s, 3H),   2.45 (s, 3H), 3.45 (s, 6H), 3.60 (dd, J=8, 8,   2H), 3.69 (dd, J=8, 8, 2H), 4.60-4.70 (m, 1H),   6.70 (d, J=8, 1H), 7.05 (d, J=8, 1H), 7.07 (d,   J=8, 1H), 7.10 (s, 1H).  q) CI-HRMS: Calcd: 384.2400, Found: 384.2393 (M+H);   NMR (CDCl.sub.3, 300 MHz): 2.16 (s, 3H), 2.25 (s, 3H)   2.35 (s, 3H), 2.39 (s, 3H), 3.40 (s, 6H), 3.77 (t,   J=8, 4H), 4.20-4.45 (m, 4H), 7.02 (d, J=8, 1H)   7.05 (s, 1H), 7.10 (d, J=7, 1H)  r) CI-HRMS: Calcd: 354.2294, Found: 354.2271 (M+H);   Analysis: Calcd: C: 67.96; H: 7.71; N: 19.81;   Found: C: 67.56; H: 7.37; N: 19.60;   NMR (CDCl.sub.3, 300 MHz): 1.03 (t, J=8, 3H), 1.65-   1.88 (m, 2H), 2.17 (s, 3H), 2.30 (s, 3H), 2.35 (s,   3H), 2.45 (s, 3H), 3.40 (s, 3H), 3.50-3.62 (m, 2H),   4.30-4.45 (m, 1H), 6.51 (d, J=8, 1H), 7.04 (d, J=   8, 1H), 7.10 (d, J=8, 1H), 7.12 (s, 1H).  s) CI-HRMS: Calcd: 338.2345, Found: 338.2332 (M+H);   Analysis: Calcd: C: 71.18; H: 8.06; N: 20.75;   Found: C: 71.43; H: 7.80; N: 20.70;   NMR (CDCl.sub.3, 300 MHz): 1.00 (t, J=8, 6H), 1.55-   1.70 (m, 2H), 1.70-1.85 (m, 2H), 2.19 (s, 3H), 2.30   (s, 3H), 2.35 (s, 3H), 2.46 (s, 3H), 4.15-4.26 (m,   1H), 6.17 (d, J=8, 1H), 7.06 (d, J=8, 1H), 7.10   (d, J=1, 1H), 7.13 (s, 1H).  t) CI-HRMS: Calcd: 324.2188, Found: 324.2188 (M+H);   NMR (CDCl.sub.3, 300 MHz): 1.25 (t, J=8, 6H), 2.16 (s,   3H), 2.28 (s, 3H), 2.35 (s, 3H), 2.40 (s, 3H),   3.95-4.20 (m, 4H), 7.05 (dd, J=8, 1, 1H), 7.07   (s, 1H), 7.10 (d, J=1, 1H)  u) CI-HRMS: Calcd: 346.1780, Found: 346.1785 (M+H);   Analysis: Calcd: C: 66.07; H: 5.54; N: 28.39;   Found: C: 66.07; H: 5.60; N: 27.81;   NMR (CDCl.sub.3, 300 MHz): 2.15 (s, 3H), 2.32 (s, 3H)   2.17 (s, 3H), 2.52 (s, 3H), 5.25-5.35 (m, 4H), 7.08   (s, 2H), 7.15 (s, 1H).  v) CI-HRMS: Calcd: 340.2137, Found: 340.2137 (M+H);   Analysis: Calcd: C: 67.23; H: 7.42; N: 20.63;   Found: C: 67.11; H: 7.39; N: 20.26;   NMR (CDCl.sub.3, 300 MHz): 1.40 (d, J=8, 3H), 2.16 (s,   3H), 2.32 (s, 3H), 2.35 (s, 3H), 2.47 (s, 3H), 3.42   (s, 3H), 3.50-3.60 (m, 2H), 4.50-4.15 (m, 1H), 6.56   (d, J=8, 1H), 7.00-7.15 (m, 3H).  w) CI-HRMS: Calcd: 355.2134, Found: 355.2134 (M+H);   NMR (CDCl.sub.3, 300 MHz): 1.05 (t, J=8, 3H), 1.85-   2.00 (m, 2H), 2.17 (s, 3H), 2.36 (s, 6H), 2.50 (s,   3H), 3.41 (s, 3H), 3.45 (dd, J=8, 3, 1H), 3.82   (dd, J=8, 1, 1H), 5.70-5.80 (m, 1H), 7.00-7.20   (m, 3H).  x) CI-HRMS: Calcd: 364.2501, Found: 364.2501 (M+H);   NMR (CDCl.sub.3, 300 MHz): 0.35-0.43 (m, 2H), 0.50-0.60   (m, 2H), 0.98 (t, J=8, 3H), 1.20-1.30 (m, 1H),   1.72-1.90 (m, 2H), 2.18 (s, 3H) 2.28 (s, 3H), 2.35   (s, 3H), 2.40 (s, 3H), 3.88-4.03 (m, 2H), 4.03-4.20   (m, 2H), 7.00-7.15 (m, 3H).  y) CI-HRMS: Calcd: 353.2454, Found: 353.2454 (M+H);   Analysis: Calcd: C: 68.15; H: 8.02; N: 23.84;   Found: C: 67.43; H: 7.81; N: 23.45;   NMR (CDCl.sub.3, 300 MHz): 1.38 (d, J=8, 3H), 2.18 (s,   2.30-2.40 (m, 12H), 2.47 93, 3H), 2.60-2.75   (m, 2H), 4.30-4.50 (m, 1H), 6.60-6.70 (m, 1H),   7.00-7.15 (m, 3H).  z) CI-HRMS: Calcd: 361.2140, Found: 361.2128 (M+H);   NMR (CDCl.sub.3, 300 MHz): 0.75-0.83 (m, 2H), 1.00-1.10   (m, 2H), 2.17 (s, 3H), 2.30 (s, 3H), 2.36 (s, 3H),   2.47 (s, 3H), 2.85 (t, J=8, 2H), 3.30-3.40 (m,   1H), 4.40-4.55 (m, 2H), 7.00-7.18 (m, 3H).  aa) CI-HRMS: Calcd: 363.2297, Found: 363.2311 (M+H);   NMR (CDCl.sub.3, 300 MHz): 1.01 (t, 3H, J=8), 1.75-1.90   (m, 2H), 2.15 (s, 3H), 2.19 (s, 3H), 2.35 (s, 3H),   2.40 (s, 3H), 2.40 (s, 3H), 2.98 (t, 2H, J=8);   3.97-4.15 (m, 2H), 4.15-4.30 (m, 2H), 7.03 (d, 1H,   1H), 7.08 (d, 1H, J=8), 7.10 (s, 1H).  ab) CI-HRMS: Calcd: 363.2297, Found: 363.2295 (M+H);   NMR (CDCl.sub.3, 300 MHz): 1.01 (t, 3H, J=8), 1.35-   1.55 (m, 2H), 1.75-1.90 (m, 2H), 2.15 (s, 3H), 2.30   (s, 3H), 2.36 (s, 3H), 2.46 (s, 3H), 4.10-4.30 (m,   2H), 4.95-5.10 (br s, 2H), 7.05 (d, 1H, J=8),   7.10 (d, 1H, J=8), 7.15 (s, 1H).  ac) CI-HRMS: Calcd: 368.2450, Found: 368.2436;   Analysis: Calcd: C, 68.62; H, 7.95, N, 19.06;   Found: C, 68.73, H, 7.97, N, 19.09; NMR (CDCl.sub.3, 300   MHz): 1.05 (t, J=8, 3H), 1.70-1.90 (m, 2H), 2.01   (d, J=3, 6H), 2.20 (s, 3H), 2.30 (s, 3H), 2.46,   2.465 (s, s, 3H), 3.42, 3.48 (s, s, 3H), 3.53-3.63   (m, 2H), 4.35-4.45 (m, 1H), 6.73 (d, J=8, 1H),   6.97 (s, 2H).  (ad) CI-HRMS: Calcd: 352.2501; Found: 352.2500 (M+   H): Analysis: Calcd: C: 71.76; H: 8.33; N: 19.92,   Found: C: 71.55; H: 8.15; N: 19.28;   NMR (CDCl.sub.3, 300 MHz): 1.01 (t, J=8, 6H), 1.58-   1.70 (m, 2H), 1.70-1.85 (m, 2H), 2.02 (s, 6H), 2.19   (s, 3H), 2.45 (s, 3H), 4.12-4.28 (m, 1H), 6.18 (d,   J=8, 1H), 6.95 (s, 2H);  (ae) CI-HRMS: Calcd: 398.2556, Found: 398.2551 (M+   H); Analysis: Calcd: C: 66.47; H: 7.86; N: 17.62,   Found: C: 66.74; H: 7.79; N: 17.70;   NMR (CDCl.sub.3, 300 MHz): 2.00 (s, 6H), 2.12 (s, 3H),   2.30 (s, 3H), 2.37 (s, 3H), 3.40 (s, 6H), 3.78 (t,   J=8, 4H), 4.25-4.40 (m, 4H), 6.93 (s, 2H).  (af) CI-HRMS: Calcd: 450.1141, Found: 450.1133 (M+H);   Analysis: Calcd: C: 50.67; H: 5.37; N: 15.55; Br:   17.74; Found: C: 52.36; H: 5.84; N: 14.90; Br:   17.44;   NMR (CDCl.sub.3, 300 MHz): 2.32 (s, 3H), 2.57 (s, 3H),   3.42 (s, 6H), 3.60 (q, J=8, 2H), 3.69 (q, J=8,   2H), 3.82 (s, 3H), 4.60-4.70 (m, 1H), 6.73 (d, J=   8, 1H), 6.93 (dd, J=8, 1, 1H), 7.22 (d, J=8,   1H).  ag) CI-HRMS: Calcd: 434.1192, Found: 434.1169 (M+H);   Analysis: Calcd: C: 52.54; H: 5.58; N: 16.12; Br:   18.40; Found: C: 52.57; H: 5.60; N: 15.98; Br:   18.22;   NMR (CDCl.sub.3, 300 MHz): 1.00-1.07 (m, 3H), 1.65-1.85   (m, 2H), 2.35 (s, 3H), 2.46, 2.47 (s, s, 3H), 3.40,   3.45 (s, s, 3H), 3.83 (s, 3H), 4.35-4.45 (m, 1H),   6.55 (d, J=8, 1H), 6.92 (dd, J=8, 1, 1H), 7.20-   7.30 (m, 2H).  ah) CI-HRMS: Calcd: 337.2266, Found: 337.2251 (M+H);   Analysis: Calcd: C: 70.18; H: 8.06; N: 20.75;   Found: C: 70.69; H: 7.66; N: 20.34;   NMR (CDCl.sub.3, 300 MHz): 1.35 (t, J=8, 6H), 2.01 (s,   6H), 2.15 (s, 3H), 2.30 (s, 3H), 2.38 (s, 3H), 4.07   (q, J=8, 4H), 6.93 (s, 2H).  ai) CI-HRMS: Calcd: 412.2713, Found: 412.2687 (M+H);   Analysis: Calcd: C: 67.13; H: 8.08; N: 17.02;   Found: C: 67.22; H: 7.85; N: 17.13;   NMR (CDCl.sub.3, 300 MHz): 1.24 (t, J=8, 6H), 2.00 (s,   6H), 2.20 (s, 3H), 2.30 (s, 3H), 2.43 (s, 3H), 3.60   (g, J=8, 4H), 3.66 (dd, J=8, 3, 2H), 3.75 (dd,   J=8, 3, 2H), 4.55-4.65 (m, 1H), 6.75 (d, J=8,   1H), 6.95 (s, 2H).  aj) CI-HRMS: Calcd: 398.2556, Found: 398.2545 (M+H);   Analysis: Calcd: C: 66.47; H: 7.86; N: 17.62;   Found: C: 66.87; H: 7.62; N: 17.75;   NMR (CDCl.sub.3, 300 MHz): 1.95-2.10 (m, 8H), 2.20 (s,   3H), 2.32 (s, 3H), 2.44 (s, 3H), 3.38 (s, 3H), 3.42   (s, 3H), 3.50-3.70 (m, 4H), 4.58-4.70 (m, 1H), 6.87   (d, J=8, 1H), 6.95 (s, 2H).  ak) CI-HRMS: Calcd: 338.1981, Found: 338.1971 (M+H);   Analysis: Calcd: C: 67.63; H: 6.87; N: 20.06;   Found: C: 67.67; H: 6.82; N: 20.31;   NMR (CDCl.sub.3, 300 MHz): 2.15 (s, 3H), 2.29 (s, 3H),   2.35 (s, 3H), 2.43 (s, 3H), 3.90 (t, J=8, 4H),   4.35-4.45 (m, 4H), 7.00-7.15 (m, 3H).  al) CI-HRMS: Calcd: 464.1297, Found: 464.1297 (M+H);   NMR (CDCl.sub.3, 300 MHz): 2.28 (s, 3H), 2.40 (s, 3H),   3.40 (s, 6H), 3.75 (t, J=8, 4H), 3.83 (s, 3H),   4.20-4.50 (m, 4H), 6.93 (dd, J=8, 1, 1H), 7.20   (s, 1H), 7.24 (d, J=1, 1H).  am) CI-HRMS: Calcd: 418.1242, Found: 418.1223 (M+H);   NMR (CDCl.sub.3, 300 MHz): 1.00 (t, d, J=8, 1, 6H),   1.55-1.75 (m, 4H), 2.34 (s, 3H), 2.49 (s, 3H), 2.84   (s, 3H), 4.15-4.27 (m, 1H), 6.19 (d, J=8, 1H),   6.93 (dd, J=8, 1, 1H), 7.21-7.30 (m, 2H).  an) CI-HRMS: Calcd: 404.1086, Found: 404.1079 (M+H);   NMR (CDCl.sub.3, 300 MHz): 1.35 (t, J=8, 6H), 2.28 (s,   3H); 2.40 (s, 3H), 3.83 (s, 3H), 3.90-4.08 (m, 2H),   4.08-4.20 (m, 2H), 6.92 (dd, J=8, 1, 1H), 7.20-   7.25 (m, 2H).  ao) CI-HRMS: Calcd: 308.1875; Found: 308.1872 (M+H);   NMR (CDCl.sub.3, 300 MHz): 0.75-0.80 (m, 2H), 0.93-1.00   (m, 2H), 2.16 (s, 3H), 2.28 (s, 3H), 2.35 (s, 3H),   2.53 (s, 3H), 3.00-3.10 (m, 1H), 6.50-6.55 (m, 1H),   7.00-7.15 (m, 3H).  ap) CI-HRMS: Calcd: 397.1988, Found: 397.1984 (M+H);   NMR (CDCl.sub.3, 300 MHz): 2.43 (s, 3H); 2.50 (s, 3H),   3.43 (s, 3H), 3.61 (dd, J=8, 8, 2H), 3.69 (dd, J=   8, 8, 2H), 3.88 (s, 3H), 4.58-4.70 (m, 1H), 6.75   (d, J=8, 1H), 7.20 (dd, J=8, 1, 1H), 7.25 (d, J=   1, 1H), 7.40 (s, 1H).  aq) CI-HRMS: Calcd: 375.2297, Found: 375.2286 (M+H);   Analysis: Calcd: C: 70.56; H: 7.01; N: 22.44;   Found: C: 70.49; H: 6.99; N: 22.45;   NMR (CDCl.sub.3, 300 MHz): 0.79-0.85 (m, 2H), 1.00-1.05   (m, 1H), 2.00 (s, 6H), 2.19 (s, 3H), 2.32 (s, 3H),   2.44 (s, 3H), 2.84 (t, J=8, 2H), 3.30-3.40 (m,   1H), 4.50 (t, J=8, 2H), 6.95 (s, 2H).  ar) CI-HRMS: Calcd: 434.1192, Found: 434.1189 (M+H);   Analysis: Calcd: C: 52.54; H: 5.58; N: 16.12; Br:   18.40; Found: C: 52.75; H: 5.59; N: 16.09; Br:   18.67;   NMR (CDCl.sub.3, 300 MHz): 2.19 (s, 3H), 2.30 (s, 3H),   2.47 (s, 3H), 3.43 (s, 6H), 3.60 (dd, J=8, 8,   2H), 3.70 (dd, J=8, 8, 2H), 4.58-4.70 (m, 1H),   6.71 (d, J=8, 1H), 7.08 (d, J=8, 1H), 7.37 (dd,   J=8, 1, 1H), 7.45 (d, J=1, 1H).  as) CI-HRMS: Calcd: 448.1348, Found: 448.1332 (M+H);   Analysis: Calcd: C: 53.58; H: 5.85; N: 16.62; Br:   17.82; Found: C: 53.68; H: 5.74; N: 15.52; Br:   13.03;   NMR (CDCl.sub.3, 300 MHz): 1.95-2.10 (m, 2H), 2.20 (s,   3H), 2.30, (s, 3H), 2.47 (s, 3H), 3.38 (s, 3H), 3.41   (s, 3H), 3.50-3.67 (m, 4H), 4.55-4.70 (m, 1H), 6.89   (d, J=8, 1H), 7.05 (d, J=8, 1H), 7.35 (dd, J=   8, 1, 1H), 7.47 (d, J=1, 1H).  at) CI-HRMS: Calcd: 400.2349, Found: 400.2348 (M+H);   Analysis: Calcd: C: C: 63.14; H: 7.32; N: 17.53;   Found: C: 63.40; H: 7.08; N: 17.14;   NMR (CDCl.sub.3, 300 MHz): 2.16 (s, 3H), 2.20 (s, 3H),   2.30 (s, 3H), 2.46 (s, 3H), 3.42 (s, 6H), 3.60 (q,   J=8, 2H), 3.70 (q, J=8, 2H), 3.85 (s, 3H),   4.59-4.70 (m, 1H), 6.70 (d, J=8, 1H), 6.76 (s,   1H), 6.96 (s, 1H).  au) CI-HRMS: Calcd: 414.2505, Found: 414.2493 (M+H);   NMR (CDCl.sub.3, 300 MHz): 2.15 (s, 3H), 2.19 (s, 3H),   2.25 (s, 3H), 2.40 (s, 3H), 3.40 (s, 6H); 3.76 (t,   J=8, 4H), 3,84 (s, 3H), 4.20-4.45 (m, 4H), 6.77   (s, 1H), 6.93 (s, 1H).  av) CI-HRMS: Calcd: 368.2450, Found: 368.2447 (M+H);   NMR (CDCl.sub.3, 300 MHz): 1.00 (t, J=8, 6H), 1.55-   1.85 (m, 4H), 2.19 (s, 3H), 2.20 (s, 3H), 2.30 (s,   3H), 2.47 (s, 3H), 3.88 (s, 3H), 4.10-4.30 (m, 1H),   6.15 (d, J=8, 1H), 6.78 (s, 1H), 6.98 (s, 1H).  aw) CI-HRMS: Calcd: 353.2216, Found: 353.2197 (M+H);   NMR (CDCl.sub.3, 300 MHz): 1.35 (t, J=8, 6H), 2.17 (s,   3H), 2.19 (s, 3H), 2.28 (s, 3H), 2.40 (s, 3H), 3.85   (s, 3H), 3.90-4.20 (m, 4H), 6.78 (s, 1H), 6.95 (s,   1H).  ax) CI-HRMS: Calcd: 390.1697, Found: 390.1688 (M+H);   Analysis: Calcd: C: 58.53; H: 6.20; N: 17.96; Cl:   9.09; Found: C: 58.95; H: 6.28; N: 17.73; Cl: 9.15;   NMR (CDCl.sub.3, 300 MHz): 2.35 (s, 3H), 2.37 (s, 3H),   2.48 (s, 3H), 3.42 (s, 6H), 3.60 (dd, J=8, 8, 2H)   3.68 (dd, J=8, 8, 2H), 4.59-4.72 (m, 1H), 6.72   (d, J=8, 1H), 7.12 (d, J=8, 1H), 7.23 (d, J=   8, 1H), 7.32 (s, 1H).  ay) CI-HRMS: Calcd: 374.1748, Found: 374.1735 (M+H);   Analysis: Calcd: C: 61.04; H: 6.47; N: 18.73; Cl:   9.48; Found: C: 61.47; H: 6.54; N: 18.23; Cl: 9.61;   NMR (CDCl.sub.3, 300 MHz): 1.01 (t, J=8, 3H), 1.62-   1.88 (m, 4H); 2.35, (s, 3H), 2.37 (s, 3H), 2.48 (d,   J=1, 3H), 3.40, 3.45 (s, s, 3H), 3.50-3.64 (m,   2H), 4.38-4.47 (m, 1H), 6.53 (d, J=8, 1H), 7.12   (d, J=8, 1H), 7.07 (d, J=8, 1H), 7.12 (s, 1H).  az) CI-HRMS: Calcd: 404.1853, Found: 404.1839 (M+H);   NMR (CDCl.sub.3, 300 MHz): 2.29 (s, 3H), 2.38 (s, 3H),   2.40 (s, 3H), 3.40 (s, 6H), 3.76 (t, J=8, 4H),   4.20-4.45 (m, 4H), 7.11 (d, J=8, 1H), 7.22 (d, J=   8, 1H), 7.31 (s, 1H).  ba) CI-HRMS: Calcd: 404.1853, Found: 404.1859 (M+H);   Analysis: C: 59.47; H: 6.50; N: 17.34; Cl: 8.79;   Found: C: 59.73; H: 6.46; N: 17.10; Cl: 8.73;   NMR (CDCl.sub.3, 300 MHz): 1.95-2.08 (m, 2H), 2.35 (s,   3H), 2.38 (s, 3H), 2.46 (s, 3H), 3.38 (s, 3H), 3.41   (s, 3H), 3.50-3.65 (m, 4H), 4.56-4.70 (m, 1H), 6.85   (d, J=8, 1H), 7.12 (d, J=8, 1H), 7.45 (d, J=   8, 1H), 7.32 (s, 1H).  bb) CI-HRMS: Calcd: 391.2246, Found: 391.2258, (M+H);   Analysis: C: 67.67; H: 6.71; N: 21.52; Found: C:   67.93; H: 6.70; N: 21.48;   NMR (CDCl.sub.3, 300 MHz): 0.76-0.84 (m, 2H), 0.84-0.91   (m, 2H), 1.00-1.08 (m, 2H), 2.15 (s, 3H), 2.20 (s,   3H), 2.29 (s, 3H), 2.45 (s, 3H), 2.85 (t, J=8,   2H), 3.28-3.30 (m, 1H), 3.85 (s, 3H), 6.78 (s, 1H),   6.95 (s, 1H).  bc) CI-HRMS: Calcd: 386.2192, Found: 386.2181 (M+H);   Analysis: C: 62.32; H: 7.06; N: 18.17; Found: C:   62.48; H: 6.83; N: 18.15;   NMR (CDCl.sub.3, 300 MHz): 7.1 (d, 1H, J=8), 6.9 (d,   1H, J=1); 6.8 (dd, 1H, J=8, 1), 6.7 (br.d, 1H,   J=8), 4.7-4.6 (m, 1H), 3.85 (s, 3H), 3.70-3.55   (m, 4H), 3.45 (s, 6H), 2.5 (s, 3H), 2.3 (s, 3H),   2.15 (s, 3H).  bd) CI-HRMS: Calcd: 400.2349, Found: 400.2336 (M+H);   NMR (CDCl.sub.3, 300 MHz): 7.1 (d, 1H, J=7), 6.85 (d,   1H, J=1), 6.75 (dd, 1H, J=7, 1), 4.45-4.25   (br.s, 4H), 3.75 (t, 4H, J=7), 3.4 (s, 6H), 2.4   (s, 3H), 2.25 (s, 3H), 2.15 (s, 3H).  be) CI-HRMS: Calcd: 370.2243, Found: 370.2247 (M+H);   Analysis: C: 65.02; H: 7.38; N: 18.96; Found: C:   65.28; H: 7.27; N: 18.71;   NMR (CDCl.sub.3, 300 MHz): 7.1 (d, 1H, J=8), 6.85 (d,   1H, J=1), 6.8 (dd, 1H, J=8, 1), 6.5 (br. d, 1H,   J=1), 4.5-4.3 (m, 1H), 3.85 (s, 3H), 3.65-3.5 (m,   2H), 3.4 (s, 2H), 2.5 (s, 3H), 2.3 (s, 3H), 2.2 (s,   3H), 1.9-1.7 (m, 2H), 1.05 (t, 3H, J=7).  bf) CI-HRMS: Calcd: 379.2246, Found: 379.2248 (M+H);   NRM (CDCl.sub.3, 300 MHz): 7.1 (d, 1H, J=8), 6.85 (d,   1H, J=1), 6.8 (dd, 1H, J=8, 1), 4.3-4.0 (m, 4H),   3.85 (s, 3H), 3.0 (t, 2H, J=7), 2.45 (s, 3H), 2.3   (s, 3H), 2.2 (s, 3H), 1.9-1.8 (m, 2H), 1.0 (t, 3H,   J=7).  bg) CI-HRMS: Calcd: 340.2137, Found: 340.2122 (M+H);   NMR (CDCl.sub.3, 300 MHz): 7.1 (d, 1H, J=8), 6.85 (d,   1H, J=1), 6.75 (dd, 1H, J=8, 1), 4.2-4.0 (br.m,   4H), 3.85 (s, 3H, 2.4 (s, 3H), 2.3 (s, 3H), 2.2   (s, 3H), 1.35 (t, 6H, J=7).  bh) CI-HRMS: Calcd: 313.1665, Found: 313.6664 (M+H).  bi) CI-HRMS: Calcd: 400.2349, Found: 400.2346 (M+H);   NMR (CDCl.sub.3, 300 MHz): 7.1 (d, 1H, J=7), 6.9-6.75   (m, 3H), 4.7-4.55 (m, 1H), 3.8 (s, 3H), 3, 7-3.5 (m,   4H), 3.45 (s, 3H), 3.35 (s, 3H), 2.5 (s, 3H), 2.3   (s, 3H), 2.2 (s, 3H), 2.1-1.95 (m, 2H).  bj) CI-HRMS: Calcd: 377.2090, Found: 377.2092 (M+H),   Analysis: C: 67.00; H: 6.44; N: 22.32; Found: C:   67.35; H: 6.44; N: 22.23;   NMR (CDCl.sub.3, 300 MHz): 7.1 (d, 1H, J=8), 6.9 (d,   1H, J=1), 6.8 (dd, 1H, J=8, 1), 4.55-4.4 (m,   2H), 3.85 (s, 3H), 3.4-3.3 (m, 1H), 2.85 (t, 2H, J=   7), 2.5 (s, 3H), 2.3 (s, 3H), 2.2 (s, 3H), 1.1-   1.0 (m, 2H), 0.85-0.75 (m, 2H).  bk) CI-HRMS: Calcd: 413.2427, Found: 413.2416 (M+H);   NMR (CDCl.sub.3, 300 Hz): 7.1 (d, 1H, J=8), 6.85 (d,   1H, J=1), 6.75 (dd, 1H, J=8, 1), 4.6 (m, 1H),   3.85 (s, 3H), 3.75-3.6 (m, 4H), 3.6 (q, 4H, J=7),   2.5 (s, 3H), 2.3 s, 3H), 2.2 (s, 3H), 1.25 (t, 6H,   J=7).  bl) CI-HRMS: Calcd: 420.1802, Found: 420.1825 (M+H);  bm) CI-HRMS: Calcd: 390.1697, Found: 390.1707 (M+H);  bn) CI-HRMS: Calcd: 397.1465, Found: 397.1462 (M+H);  bo) CI-HRMS: Calcd: 360.1513, Found: 360.1514 (M+H);  bp) CI-HRMS: Calcd: 374.1748, Found: 374.1737 (M+H);  bq) CI-HRMS: Calcd: 479.1155, Found: 479.1154 (M+H);  br) CI-HRMS: Calcd: 463.1219, Found: 463.1211 (M+H);   Analysis Calcd: C: 51.96, H: 5.23, N, 15.15, Br:   17.28; Found: C: 52.29, H: 5.62, N: 14.79, Br:   17.47  bs) CI-HRMS: Calcd: 433.1113, Found: 433.1114 (M, .sup.79 Br);  bt) NH.sub.3 -CI MS: Calcd: 406, Found: 406 (M+H)+;   NMR (CDCl.sub.3, 300 MHz): δ 7.28 (d, J=10 Hz, 1H), 7.03(d, J=8 Hz, 1H), 6.96 (s, 1H), 6.7 (d, J=9, 1H),   4.63 (m, 1H), 3.79 (s, 3H), 3.6 (m, 4H), 3.42 (s,   6H), 2.47 (s, 3H), 2.32 (s, 3H).</pre></p><heading>Example 431</heading><heading>Preparation of 2,4,7-dimethyl-8-(4-methoxy-2-methylphenyl)[1,5-a]-pyrazolo-1,3,5-triazine (Formula 1, where R.sup.3 is CH.sub.3, R.sub.1 is CH.sub.3, Z is C--CH.sub.3, Ar is 2,4-dimethylphenyl)</heading><p>5-Acetamidino-4-(4-methoxy-2-methylphenyl)-3-methylpyrazole, acetic acid salt (602 mg, 2 mmol) was mixed with a saturated NaHCO.sub.3 solution (10 mL). The aqueous mixture was extracted with EtOAc three times. The combined organic layers were dried over MgSO.sub.4, filtered and concentrated in vacuo. The residue was taken up in toluene (10 mL) and trimethyl orthoacetate 0.36 g, 3 mmol) was added to the suspension. The reaction mixture was heated to reflux temperature under a nitrogen atmosphere and stirred for 16 hours. After being cooled to ambient temperature, the reaction mixture was concentrated in vacuo to give an oily solid. Column chromatography (CHCl.sub.3: MeOH::9:1) afforded, after removal of solvent in vacuo, a yellow viscous oil (Rf=0.6, 210 mg, 37% yield): NMR (CDCl.sub.3, 300 MHz): 7.15 (d, 1H, J=8), 6.9 (d, 1H, J=1), 6.85 (dd, 1H, J=8,1), 3.85 (s, 3H), 2.95 (s, 3H), 2.65 (s, 3H), 2.4 (s, 3H), 2.15 (s, 3H); CI-HRMS: Calcd: 283.1559, Found: 283.1554 (M+H).</p><heading>Example 432</heading><heading>7-hydroxy-5-methyl-3-(2-chloro-4-methylphenyl)pyrazolo[1,5-a]pyrimidine (Formula 1 where A is CH, R1 is Me, R3 is OH, Z is C-Me, Ar is 2-chloro-4-methylphenyl)</heading><p>5-Amino-4-(2-chloro-4-methylphenyl)-3-methylpyrazole (1.86 g, 8.4 mmol) was dissolved in glacial acetic acid (30 mL) with stirring. Ethyl acetoacetate (1.18 mL, 9.2 mmol) was then added dropwise to the resulting solution. The reaction mixture was then heated to reflux temperature and stirred for 16 hours, then cooled to room temperature. Ether (100 mL) was added and the resulting precipitate was collected by filtration. Drying in vacuo afforded a white solid 1.0 g, 42% yield): NMR (CDCl.sub.3, 300 Hz): 8.70 (br.s 1H), 7.29 (s, 1H), 7.21-7.09 (m, 2H), 5.62 (s, 1H), 2.35 (s, 6H), 2.29 (s, 3H); CI-MS: 288 (M+H).</p><heading>Example 433</heading><heading>7-chloro-5-methyl-3-(2-chloro-4-methylphenyl)pyrazolo[1,5-a]pyrimidine (Formula 1 where A is CH, R1 is Me, R3 is Cl, Z is C-Me, Ar is 2-chloro-4-methylphenyl)</heading><p>A mixture of 7-hydroxy-5-methyl-3-(2-chloro-4-methylphenyl)-pyrazolo[1,5-a]-pyrimidine (1.0 g, 3.5 mmol), phosphorus oxychloride (2.7 g, 1.64 mL, 17.4 mmol), N,N-diethylaniline (0.63 g, 0.7 mL, 4.2 mmol) and toluene (20 mL) was stirred at reflux temperature for 3 hours, then it was cooled to ambient temperature. The volatiles were removed in vacuo. Flash chromatography (EtOAc:hexane::1:2) on the residue gave 7-chloro-5-methyl-3-(2-chloro-4-methylphenyl)-pyrazolo[1,5-a]pyrimidine (900 mg, 84% yield) as a yellow oil: NMR (CDCl.sub.3, 300Hz): 7.35 (s, 1H), 7.28-7.26 (m, 1H), 71.6 (d, 1H, J=7), 6.80 (s, 1H), 2.55 (s, 3H), 2.45 (s, 3H), 2.40 (s, 3H); CI-MS: 306 (M+H).</p><heading>Example 434</heading><heading>7-(pentyl-3-amino)-5-methyl-3-(2-chloro-4-methylphenyl)pyrazolo[1,5-a]pyrimidine (Formula 1 where A is CH, R1 is Me, R3 is pentyl-3-amino, Z is C-Me, Ar is 2-chloro-4-methylphenyl)</heading><p>A solution of 3-pentylamine (394 mg, 6.5 mmol) and 7-chloro-5-methyl-3-(2-chloro-4-methylphenyl)pyrazolo[1,5-a]pyrimidine (200 mg, 0.65 mmol) in dimethylsulfoxide (DMSO, 10 mL) was stirred at 150 reaction mixture was then poured onto water (100 mL) and mixed. Three extractions with dichloromethane, washing the combined organic layers with brine, drying over MgSO.sub.4, filtration and removal of solvent in vacuo produced a yellow solid. Flash chromatography (EtOAc:hexanes::1:4) afforded a white solid (140 mg, 60% yield): mp 139-141 (CDCl.sub.3, 300 Hz):7.32 (s, 1H), 7.27 (d, 1H, J=8), 7.12 (d, 1H, J=7), 6.02 (d, 1H, J=9), 5.78 (s, 1H), 3.50-3.39 (m, 1H), 2.45 (s, 3H), 2.36 (s, 6H), 1.82-1.60 (m, 4H), 1.01 (t, 6H, J=8); Analysis Calcd for C.sub.2 OH.sub.25 ClN.sub.4 : C, 67.31, H, 7.06, N, 15.70, Cl: 9.93; Found: C, 67.32, H, 6.95, N, 15.50, Cl, 9.93.</p><p>The examples delineated in TABLE 2 may be prepared by the methods outlined in Examples 1A, 1B, 432, 433, 434. Commonly used abbreviations are: Ph is phenyl, Pr is propyl, Me is methyl, Et is ethyl, Bu is butyl, Ex is Example, EtOAc is ethyl acetate.</p><p><pre xml:space="preserve" listing-type="tabular"><!--Greenbook tabular data-->                                  TABLE 2__________________________________________________________________________  #STR42##   -Ex. Z  R.sub.3           Ar         mp (__________________________________________________________________________435.sup.b    C-Me  N(CH.sub.2 CH.sub.2 OMe).sub.2                    2,4-Cl.sub.2 -Ph                               71-73  436.sup.c C-Me N(Bu)Et 2,4-Cl.sub.2 -Ph 86-87  437.sup.d C-Me NHCH(Et)CH.sub.2 OMe 2,4-Cl.sub.2 -Ph 110-111  438.sup.e C-Me N(Pr)CH.sub.2 CH.sub.2 CN 2,4-Cl.sub.2 -Ph 83-85                                439.sup.f C-Me NH-3-pentyl 2,4-Cl.sub                               .2 -Ph 175-176  440.sup.g C-Me NHCH(CH.sub.2 OMe).sub.2 2,4-Cl.sub.2 -Ph 107  441.sup.h C-Me NHCH(Et).sub.2 2,4-Me.sub.2 -Ph oil  442.sup.i C-Me NHCH(CH.sub.2 OMe).sub.2 2,4-Me.sub.2 -Ph 103-105                                443.sup.j C-Me N(CH.sub.2 CH.sub.2                               OMe).sub.2 2,4-Me.sub.2 -Ph 87-89                                444.sup.k C-Me N(c-Pr)CH.sub.2                               CH.sub.2 CN 2,4-Me.sub.2 -Ph 133                               (dec)  445.sup.l C-Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl,4-MePh 77-78                                446.sup.m C-Me NHCH(CH.sub.2                               OMe).sub.2 2-Cl,4-MePh 131-133                                447.sup.n C-Me NHCH(Et).sub.2                               2-Cl,4-MePh 139-141  448.sup.o C-Me NEt.sub.2 2,4-Me.sub.2 -Ph 92-94  449.sup.p C-Me N(Pr)CH.sub.2 CH.sub.2 CN 2,4-Me.sub.2 -Ph 143-144                                450.sup.q C-Me N(Bu)CH.sub.2                               CH.sub.2 CN 2,4-Me.sub.2 -Ph 115-117                                451.sup.r C-Me NHCH(Et)CH.sub.2 OMe                               2,4-Me.sub.2 -Ph oil  452.sup.s C-Me NHCH(Et).sub.2 2-Me,4-MeOPh 104-106  453.sup.t C-Me NHCH(CH.sub.2 OMe).sub.2 2-Me,4-MeOPh 115-116  454.sup.u C-Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me,4-MeOPh oil  455.sup.v C-Me (S)-NHCH(CH.sub.2 CH.sub.2 OMe)-(CH.sub.2 OMe) 2-Me,4-MeO                               Ph oil  456.sup.w C-Me (S)-NHCH(CH.sub.2 CH.sub.2 OMe)-(CH.sub.2 OMe) 2,4-Me.sub                               .2 -Ph oil  457.sup.x C-Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me,4-ClPh oil  458.sup.y C-Me NHEt 2,4-Me.sub.2 -Ph oil  459.sup.z C-Me NHCH(Et).sub.2 2-Me,4-ClPh 94-96  460.sup.aa C-Me NHCH(CH.sub.2 OMe).sub.2 2-Me,4-ClPh 113-114  461.sup.ab C-Me N(Ac)Et 2,4-Me.sub.2 -Ph oil  462.sup.ac C-Me (S)-NHCH(CH.sub.2 CH.sub.2 OMe)--(CH.sub.2 OMe)                               2-Me,4-ClPh oil  463.sup.ad C-Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Me,4-MeOPh 118-119  464.sup.ae C-Me NEt.sub.2 2-Me,4-MeOPh 97-99  465.sup.af C-Me (S)-NHCH(CH.sub.2 CH.sub.2 OMe)--(CH.sub.2 OMe)                               2-Cl,4-MePh 101-103  466.sup.ag C-Me NEt.sub.2 2-Cl,4-MePh 129-130  467.sup.ah C-Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me,4-MeOPh 177-178                                468.sup.ai C-Me N(c-Pr)CH.sub.2                               CH.sub.2 CN 2-Cl,4-MePh 162-163                                469.sup.aj C-Me NHCH(Et)CH.sub.2 OMe                               2-Me,4-MeOPh oil  470.sup.ak C-Me NHCH(Et)CH.sub.2 OMe 2-Cl,4-MePh 111-113  471 C-Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4-MeOPh  472 C-Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4-MeOPh  473 C-Me NHCH(Et)CH.sub.2 OMe 2-Cl-4-MeOPh  474 C-Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl-4-MeOPh  475 C-Me NEt.sub.2 2-Cl-4-MeOPh  476 C-Me NH-3-pentyl 2-Cl-4-MeOPh  477 C-Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Cl-4-MeOPh  478 C-Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Cl-4-MeOPh  479 C-Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Br-4-MeOPh  480 C-Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Br-4-MeOPh  481 C-Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  482 C-Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  483 C-Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4,5-(MeO).sub.2 Ph  484 C-Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-415-(MeO).sub.2 Ph                                485 C-Me NHCH(Et)CH.sub.2 OMe                               2-Cl-4,5-(MeO).sub.2 Ph  486 C-Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl-4,5-(MeO).sub.2 Ph  487 C-Me NEt.sub.2 2-Cl-4,5-(MeO).sub.2 Ph  99-101  488 C-Me NH-3-pentyl 2-Cl-4,5-(MeO).sub.2 Ph 169-170  489 C-Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Cl-4,5-(MeO).sub.2 Ph  490 C-Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Cl-4,5-(MeO).sub.2 Ph  491 C-Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4,5-(MeO).sub.2 Ph 90-93                                492 C-Me N(CH.sub.2 CH.sub.2                               OMe).sub.2 2-Br-4,5-(MeO).sub.2 Ph                               110  493 C-Me NHCH(Et)CH.sub.2 OMe 2-Br-4,5-(MeO).sub.2 Ph  494 C-Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Br-4,5-(MeO).sub.2 Ph  495 C-Me NEt.sub.2 2-Br-4,5-(MeO).sub.2 Ph  496 C-Me NH-3-pentyl 2-Br-4,5-(MeO).sub.2 Ph  497 C-Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Br-4,5-(MeO).sub.2 Ph  498 C-Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Br-4,5-(MeO).sub.2 Ph  499 C-Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4,6-(MeO).sub.2 Ph  500 C-Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4,6-(MeO).sub.2 Ph                                501 C-Me NHCH(Et)CH.sub.2 OMe                               2-Cl-4,6-(MeO).sub.2 Ph  502 C-Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl-4,6-(MeO).sub.2 Ph  503 C-Me NEt.sub.2 2-Cl-4,6-(MeO).sub.2 Ph  504 C-Me NH-3-pentyl 2-Cl-4,6-(MeO).sub.2 Ph  505 C-Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Cl-4,6-(MeO).sub.2 Ph  506 C-Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Cl-4,6-(MeO).sub.2 Ph  507 C-Me NHCH(CH.sub.2 OMe).sub.2 2-Me-4,6-(MeO).sub.2 Ph  508 C-Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me-4,6-(MeO).sub.2 Ph                                509 C-Me NHCH(Et)CH.sub.2 OMe                               2-Me-4,6-(MeO).sub.2 Ph  510 C-Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me-4,6-(MeO).sub.2 Ph  511 C-Me NEt.sub.2 2-Me-4,6-(MeO).sub.2 Ph  512 C-Me NH-3-pentyl 2-Me-4,6-(MeO).sub.2 Ph  513 C-Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me-4,6-(MeO).sub.2 Ph  514 C-Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me-4,6-(MeO).sub.2 Ph  515 C-Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Br-4,6-(MeO).sub.2 Ph  516 C-Me NEt.sub.2 2-Br-4,6-(MeO).sub.2 Ph  517 C-Me NH-3-pentyl 2-Br-4,6-(MeO).sub.2 Ph  518 C-Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Br-4,6-(MeO).sub.2 Ph  519 C-Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Br-4,6-(MeO).sub.2 Ph  520 C-Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  521 C-Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  522 C-Me NHCH(CH.sub.2 OMe).sub.2 2-Me0-4-MePh  523 C-Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me0-4-MePh  524 C-Me NHCH(Et)CH.sub.2 OMe 2-Me0-4-MePh  525 C-Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me0-4-MePh  526 C-Me NEt.sub.2 2-Me0-4-MePh  527 C-Me NH-3-pentyl 2-Me0-4-MePh  528 C-Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me0-4-MePh  529 C-Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me0-4-MePh  530 C-Me NHCH(CH.sub.2 OMe).sub.2 2-Me0-4-MePh  531 C-Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me0-4-MePh  532 C-Me NHCH(Et)CH.sub.2 OMe 2-Me0-4-MePh  533 C-Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me0-4-MePh  534 C-Me NEt.sub.2 2-Me0-4-MePh  535 C-Me NH-3-pentyl 2-Me0-4-MePh  536 C-Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me0-4-MePh  537 C-Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me0-4-MePh  538 C-Me NHCH(CH.sub.2 OMe).sub.2 2-Me0-4-dlPh  539 C-Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me0-4-ClPh  540 C-Me NHCH(Et)CH.sub.2 OMe 2-Me0-4-ClPh  541 C-Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me0-4-ClPh  542 C-Me NEt.sub.2 2-Me0-4-ClPh  543 C-Me NH-3-pentyl 2-Me0-4-ClPh  544 C-Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me0-4-ClPh  545 C-Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me0-4-ClPh__________________________________________________________________________NOTES FOR TABLE 2:b) CI-HRMS: Calcd: 423.1355; Found: 423.1337 (M + H).  c) Analysis: Calcd: C, 61.38, H, 6.18, N, 14.32:   Found: C, 61.54, H, 6.12, N, 14.37.  d) Analysis: Calcd: C: 58.02, H, 5.65, N, 14.24;   Found: C, 58.11, H, 5.52, N, 14.26.  e) Analysis: Calcd: C, 59.71, H, 5.26, N, 14.85,   Found: C, 59.94, H, 5.09, N, 17.23.  f) Analysis: Calcd: C, 60.48, H, 5.89, N, 14.85,   Found: C, 60.62, H; 5.88, N, 14.82.  h) CI-HRMS: Caicd: 337.2388; Found: 337.2392 (M + H).  i) Analysis: Calcd: C, 68.45, H, 7.669, N, 15.21,   Found: C, 68.35, H, 7.49 N, 14.91.  j) Analysis: Calcd: C, 69.08, H, 7.915, N, 14.65,   Found: C, 68.85, H, 7.83, N, 14.54.  k) Analysis: Calcd: C, 73.51, H, 7.01, N, 19.48,   Found: C, 71.57, H, 7.15, N, 19.12.  l) CI-HRMS: Calcd: 403.1899; Found: 403.1901 (M + H).  m) Analysis: Calcd: C, 61.77, H, 6.49, N, 14.41, Cl.   9.13; Found: C, 61.90, H, 6.66, N, 13.62, Cl, 9.25.  n) Analysis: Calcd: C, 67.31, H, 7.06, N, 15.70, Cl.   9.93; Found: C, 67.32, H, 6.95, N, 15.50, Cl, 9.93.  o) Analysis: Calcd: C, 74.50, H, 8.14, N, 17.38,   Found: C, 74.43, H, 7.59, N, 17.16.  p) Analysis: Calcd: C, 73.10, H, 7.54, N, 19.37,   Found: C, 73.18, H, 7.59, N, 18.81.  q) Analysis: Calcd: C, 73.57, H, 7.78, N, 18.65,   Found: C, 73.55, H, 7.79, N, 18.64.  r) CI-HRMS: Calcd: 353.2333; Found: 353.2341 (M + H).  s) Analysis: Calcd: C, 71.56, H, 8.02, N, 15.90,   Found: C, 71.45, H, 7.99, N, 15.88.  t) Analysis: Calcd: C, 65.60, H, 7.34, N, 14.57,   Found: C, 65.42, H, 7.24, N, 14.37.  u) CI-HRMS: Calcd: 399.2398; Found: 399.2396 (M + H).  v) CI-HRMS: Calcd: 399.2398; Found: 399.2396 (M + H).  w) CI-HRMS: Calcd: 383.2450; Found: 383.2447 (M + H).  x) CI-HRMS: Calcd: 403.1887; Found: 403.1901 (M + H).  y) CI-HRMS: Calcd: 295.1919; Found: 295.1923 (M + H).  z) Analysis: Calcd: C, 67.31, H, 7.06, N, 15.70,   Found: C, 67.12, H, 6.86, N, 15.53.  aa) Analysis: Calcd: C, 61.77, H, 6.49, N, 14.41, Cl,   9.13; Found: C, 62.06, H, 6.37, N, 14.25, Cl, 9.12.  ab) CI-HRMS: Calcd: 337.2017; Found: 337.2028 (M + H).  ac) CI-HRMS: Calcd: 403.1893; Found: 403.1901 (M + H).  ad) Analysis: Calcd: C, 70.00, H, 7.22, N, 18.55,   Found: C, 70.05, H, 7.22, N, 18.36.  ae) Analysis: Calcd: C, 70.98, H, 7.74, N, 16.55,   Found: C, 71.15, H, 7.46, N, 16.56.  ag) Analysis: Calcd: C, 66.59, H, 6.76, N, 16.34,   Found: C, 66.69, H, 6.82, N, 16.20.  ah) Analysis: Calcd: C, 70.38, H, 6.71, N, 18.65,   Found: C, 70.35, H, 6.82, N, 18.83.  ai) Analysis: Calcd: C, 66.39, H, 5.85, N, 18.44, Cl,   9.33;   Found: C, 66.29, H, 5.51, N, 18.36, Cl, 9.31.  aj) CI-HRMS: Calcd: 369.2278; Found: 369.2291 (M + H).  ak) Analysis: Calcd: C, 64.42, H, 6.77, N, 15.02,   Found: C, 64.59, H, 6.51, N, 14.81.</pre></p><p>The examples delineated in TABLE 3 may be prepared by the methods outlined in Examples 1, 2, 3 or 6. Commonly used abbreviations are: Ph is phenyl, Pr is propyl, Me is methyl, Et is ethyl, Bu is butyl, Ex is Example.</p><p><pre xml:space="preserve" listing-type="tabular"><!--Greenbook tabular data-->                                  TABLE 3__________________________________________________________________________  #STR43##   -Ex. Z    R.sub.3         Ar       mp (__________________________________________________________________________546.sup.a    C-Me NHCH(Et).sub.2  2-Me-4-Me.sub.2 N-Ph                             164-166  547.sup.b C-Me S-NHCH(CH.sub.2 CH.sub.2 OMe)-CH.sub.2 OMe 2,4-Me.sub.2                             -Ph oil  548.sup.c C-Me S-NHCH(CH.sub.2 CH.sub.2 OMe)-CH.sub.2 OMe 2-Me-4-Cl-Ph                             oil  549.sup.d C-Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me-4-Cl-Ph 115-116                              550.sup.e C-Me NHCH(Et)CH.sub.2 CN                             2-Me-4-Cl-Ph 131-132  551.sup.f C-Me N(Et).sub.2 2,3-Me.sub.2 -4-OMe-Ph oil  552.sup.g C-Me N(CH.sub.2 CH.sub.2 OMe)CH.sub.2 CH.sub.2 OH 2,4-Cl.sub.2                              -Ph oil  553.sup.h C-Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,3-Me.sub.2 -4-OMe-Ph                             oil  554.sup.i C-Me NHCH(Et).sub.2 2,3-Me.sub.2 -4-OMePh 123-124  555.sup.j C-Me N(CH.sub.2 -c-Pr)Pr 2-Me-4-Cl-Ph oil  556.sup.k C-Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2,3-Me.sub.2 -4-OMePh                             158-160  557 C-Me N(c-Pr)Et 2-Cl-4-OMePh  558 C-Me N(c-Pr)Me 2-Cl-4-OMePh  559 C-Me N(c-Pr)Pr 2-Cl-4-OMePh  560 C-Me N(c-Pr)Bu 2-Cl-4-OMePh  561.sup.l C-Me N(Et).sub.2 2-Cl-4-CN-Ph 115-117  562 C-Me N(c-Pr).sub.2 2-Cl-4-OMe 127-129  563.sup.m C-Me NHCH(CH.sub.2 OH).sub.2 2,4-Cl.sub.2 -Ph 128-129                              564 C-Me N(c-Pr)Et 2-Br-4,5-(MeO)2Ph                              565 C-Me N(c-Pr)Me 2-Br-4,5-(MeO)2Ph                              566 C-Me NH-c-Pr 2-Me-4-MeOPh 126-128                              567 C-Me NHCH(Et)CH.sub.2 OH 2-Me-4-MeO                             Ph 60-62  568 C-Me NMe2 2-Br-4,5-(MeO)2Ph  569 C-Me NHCH(Et).sub.2 2-Me-4-MeOPh 103-105  570 C-Me N(c-Pr)Et 2-Me-4-MeOPh 173-174  571 C-Me NH-2-pentyl 2,4-Cl.sub.2 -Ph 118-120  572 C-Me NHCH(Et)CH.sub.2 CN 2,4-Cl.sub.2 -Ph 141-142  573 C-Me NHCH(Pr)CH.sub.2 OMe 2,4-Cl.sub.2 -Ph 87-88  574 C-Me NHCH(CH.sub.2 -iPr)CH.sub.2 OMe 2,4-Cl.sub.2 -Ph amorphous                              575 C-Me NH-2-butyl 2,4-Me.sub.2 -Ph                             oil  576 C-Me NH-2-pentyl 2,4-Me.sub.2 -Ph oil  577 C-Me NH-2-hexyl 2,4-Me.sub.2 -Ph oil  578 C-Me NHCH(i-Pr)Me 2,4-Me.sub.2 -Ph oil  579 C-Me NHCH(Me)CH.sub.2 -iPr 2,4-Me.sub.2 -Ph oil  580 C-Me NHCH(Me)-c-C.sub.6 H.sub.11 2,4-Me.sub.2 -Ph oil  581 C-Me NH-2-indanyl 2,4-Me.sub.2 -Ph oil  582 C-Me NH-1-indanyl 2,4-Me.sub.2 -Ph oil  583 C-Me NHCH(Me)Ph 2,4-Me.sub.2 -Ph oil  584 C-Me NHCH(Me)CH.sub.2 -(4-ClPh) 2,4-Me.sub.2 -Ph oil  585 C-Me NHCH(Me)CH.sub.2 COCH.sub.3 2,4-Me.sub.2 -Ph oil  586 C-Me NHCH(Ph)CH.sub.2 Ph 2,4-Me.sub.2 -Ph oil  587 C-Me NHCH(Me)(CH.sub.2).sub.3 NEt.sub.2 2,4-Me.sub.2 -Ph oil                              588 C-Me NH-(2-Ph-c-C.sub.3 H.sub.4)                             2,4-Me.sub.2 -Ph oil  589 C-Me NHCH(Et)CH.sub.2 CN 2,4-Me.sub.2 -Ph 119-120  590 C-Me NH-3-hexyl 2,4-Me.sub.2 -Ph oil  591.sup.n C-Me NEt.sub.2 2-MeO-4-ClPh oil  592.sup.o C-Me NHCH(Et).sub.2 2-MeO-4-ClPh oil  593.sup.p C-Me NHCH(Et)CH.sub.2 OMe 2-MeO-4-ClPh oil  594 C-Me NMe.sub.2 2-MeO-4-ClPh oil  595.sup.q C-Me NHCH(Et).sub.2 2-OMe-4-MePh oil  596.sup.r C-Me NEt.sub.2 2-OMe-4-MePh oil  597.sup.s C-c-Pr NHCH(CH.sub.2 OMe).sub.2 2,4-Cl.sub.2 -Ph oil  598 C-Me N(c-Pr)Et 2,4-Me.sub.2 -Ph  599 C-Me N(c-Pr)Et 2,4-Cl.sub.2 -Ph  600 C-Me N(c-Pr)Et 2,4,6-Me.sub.3 -Ph  601 C-Me N(c-Pr)Et 2-Me-4-Cl-Ph  602 C-Me N(c-Pr)Et 2-Cl-4-Me-Ph  603 C-Me NHCH(c-Pr).sub.2 2,4-Cl.sub.2 -Ph  604 C-Me NHCH(c-Pr).sub.2 2,4-Me.sub.2 -Ph  605 C-Me NHCH(c-Pr).sub.2 2-Me-4-Cl-Ph  606 C-Me NHCH(c-Pr).sub.2 2-Cl-4-Me-Ph  607 C-Me NHCH(c-Pr).sub.2 2-Me-4-OMe-Ph  608 C-Me NHCH(c-Pr).sub.2 2-Cl-4-OMe-Ph  609 C-Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-5-F--OMePh  610 C-Me NEt.sub.2 2-Cl-5-F--OMePh  611 C-Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl-5-F--OMePh  612 C-Me NHCH(Et).sub.2 2-Cl-5-F--OMePh  613 C-Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-5-F--OMePh  614 C-Me NEt.sub.2 2,6-Me.sub.2 -Pyrid-3-yl  615 C-Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2,6-Me.sub.2 -pyrid-3-yl  616 C-Me NHCH(Et).sub.2 2,6-Me.sub.2 -pyrid-3-yl  617 C-Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,6-Me.sub.2 -pyrid-3-yl                              618 C--OH NHCH(CH.sub.2 OMe).sub.2                             2,4-Me.sub.2 -Ph  619 C--OH NEt.sub.2 2,4-Me.sub.2 -Ph  620 C--OH N(c-Pr)CH.sub.2 CH.sub.2 CN 2,4-Me.sub.2 -Ph  621 C--OH NHCH(Et).sub.2 2,4-Me.sub.2 -Ph  623 C--OH N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4-Me.sub.2 -Ph  624 C--NEt.sub.2 NHCH(CH.sub.2 OMe).sub.2 2,4-Me.sub.2 -Ph  625 C--NEt.sub.2 NEt.sub.2 2,4-Me.sub.2 -Ph  626 C--NEt.sub.2 N(c-Pr)CH.sub.2 CH.sub.2 CN 2,4-Me.sub.2 -Ph  627 C--NEt.sub.2 NHCH(Et).sub.2 2,4-Me.sub.2 -Ph  628 C--NEt.sub.2 N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4-Me.sub.2 -Ph                              629 C-Me NHCH(Et).sub.2 2-Me-4-CN-Ph                              630 C-Me N(CH.sub.2 CH.sub.2 OMe).sub.2                              2-Me-4-CN-Ph__________________________________________________________________________Notes for Table 3:a) CI-HRMS: Calcd: 367.2610, Found: 367.2607 (M + H).  b) CI-HRMS: Calcd: 384.2400, Found: 384.2393 (M + H);  c) CI-HRMS: Calcd: 404.1853, Found: 404.1844 (M + H);  d) CI-HRMS: Calcd: 381.1594, Found: 381.1596 (M + H);   Analysis: Calcd: C: 63.07, H, 5.57, N, 22.07, Cl, 9.32;   Found: C: 63.40, H, 5.55, N, 21.96, Cl: 9.15  e) CI-HRMS: Calcd: 369.1594, Found: 369.1576 (M + H);  f) CI-HRMS: Calcd: 354.2216, Found: 354.2211 (M + H);  g) CI-HRMS: Calcd: 410.1072, Found: 410.1075 (M + H);  h) CI-HRMS: Calcd: 414.2427, Found: 414.2427 (M + H);  i) CI-HRMS: Calcd: 368.2372, Found: 368.2372 (M + H);  j) CI-HRMS: Calcd: 384.1955, Found: 384.1947 (M + H);  k) CI-HRMS: Calcd: 391.2168, Found: 391.2160 (M + H);  l) CI-HRMS: Calcd: 335.1984, Found: 335.1961 (M + H);  m) CI-HRMS: Calcd: 382.0759, Found: 382.0765 (M + H);  n) NH.sub.3 -CI MS: Calcd: 360, Found: 360 (M + H) +  o) NH.sub.3 -CI MS: Calcd: 374, Found: 374 (M + H) +;   NMR (CDCl.sub.3, 300 MHz): δ 7.29(d, J = 8.4Hz, 1H), 7.04(dd, J   = 1.8, 8Hz, 1H),   6.96(d, J = 1.8Hz, 1H), 6.15(d, J = 10, 1H); 4.19(m, 1H), 3.81(s, 3H),   2.47(s, 3H),   2.32(s, 3H), 1.65(m, 4H), 0.99(t, J = 7.32Hz, 6H)  p) NH.sub.3 -CI MS: Calcd: 390, Found: 390 (M + H) +;   NMR (CDCl.sub.3, 300 MHz): δ 7.28(d, J = 8Hz, 1H), 7.03(d, J =   8Hz, 1H), 6.96(s, 1H),   6.52(d, J = 9Hz, 1H), 4.36(m, 1H), 3.8(s, 3H), 3.55(m, 2H), 3.39(s,   3H), 2.47(s, 3H),   2.32(s, 3H), 1.76(m, 2H), 1.01(t, J = 7.32Hz, 3H).  q) CI-HRMS: Calcd: 354.2294, Found: 354.2279 (M + H)+  r) CI-HRMS: Calcd: 340.2137, Found: 340.2138 (M + H)+  s) CI-HRMS: Calcd: 436.1307, Found: 436.1296 (M + H)+</pre></p><p>The examples delineated in TABLE 4 may be prepared by the methods outlined in Examples 1A, 1B, 432, 433, 434. Commonly used abbreviations are: Ph is phenyl, Pr is propyl, Me is methyl, Et is ethyl, Bu is butyl, Ex is Example, EtOAc is ethyl acetate.</p><p><pre xml:space="preserve" listing-type="tabular"><!--Greenbook tabular data-->              TABLE 4______________________________________  #STR44##  Ex.    Z        R.sub.3    Ar         mp (______________________________________631  C-Me     NHCH(Et).sub.2                      2-Br-4,5-(MeO).sub.2 Ph                                 160-161  632 C-Me NHCH(Et).sub.2 2-Br-4-MeOPh 110-111  633 C-Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4-MeOPh 74-76  634 C-Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4-MeOPh 128-130  635 C-Me N(Et).sub.2 2-Me-4-ClPh 113-114  636 C-Me N(c-Pr)Et 2,4-Cl.sub.2 Ph  637 C-Me N(c-Pr)Et 2,4-Me.sub.2 Ph  638 C-Me N(c-Pr)Et 2,4,6-Me.sub.3 Ph  639 C-Me N(c-Pr)Et 2-Me-4-MeOPh  640 C-Me N(c-Pr)Et 2-Cl-4-MeOPh  641 C-Me N(c-Pr)Et 2-Cl-4-MePh  642 C-Me N(c-Pr)Et 2-Me-4-ClPh  643 C-Me NHCH(c-Pr).sub.2 2,4-Cl.sub.2 -Ph  644 C-Me NHCH(c-Pr).sub.2 2,4-Me.sub.2 -Ph  645 C-Me NHCH(c-Pr).sub.2 2-Me-4-Cl-Ph  646 C-Me NHCH(c-Pr).sub.2 2-Cl-4-Me-Ph  647 C-Me NHCH(c-Pr).sub.2 2-Me-4-OMe-Ph  648 C-Me NHCH(c-Pr).sub.2 2-Cl-4-OMe-Ph  649 C-Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-5-F--OMePh  650 C-Me NEt.sub.2 2-Cl-5-F--OMePh  651 C-Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl-5-F--OMePh  652 C-Me NHCH(Et).sub.2 2-Cl-5-F--OMePh  653 C-Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-5-F--OMePh  654 C-Me NEt.sub.2 2,6-Me.sub.2 -pyrid-3-yl  655 C-Me N(C-Pr)CH.sub.2 CH.sub.2 CN 2,6-Me.sub.2 -pyrid-3-yi  656 C-Me NHCH(Et).sub.2 2,6-Me.sub.2 -pyrid-3-yl  657 C-Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,6-Me.sub.2 -pyrid-3-yl                                  658 C--OH NHCH(CH.sub.2 OMe).sub.2                                 2,4-Me.sub.2 -Ph  659 C--OH NEt.sub.2 2,4-Me.sub.2 -Ph  660 C--OH N(c-Pr)CH.sub.2 CH.sub.2 CN 2,4-Me.sub.2 -Ph  661 C--OH NHCH(Et).sub.2 2,4-Me.sub.2 -Ph  662 C--OH N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4-Me.sub.2 -Ph  663 C-NEt.sub.2 NHCH(CH.sub.2 OMe).sub.2 2,4-Me.sub.2 -Ph  664 C-NEt.sub.2 NEt.sub.2 2,4-Me.sub.2 -Ph  665 C-NEt.sub.2 N(c-Pr)CH.sub.2 CH.sub.2 CN 2,4-Me.sub.2 -Ph  666 C-NEt.sub.2 NHCH(Et).sub.2 2,4-Me.sub.2 -Ph  667 C-NEt.sub.2 N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4-Me.sub.2 -Ph                                  668 C-Me NHCH(Et).sub.2 2-Me-4-CN-P                                 h  669 C-Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me-4-CN-Ph______________________________________</pre></p><p>The examples in Tables 5 or 6 may be prepared by the methods illustrated in Examples 1A, 1B, 2, 3, 6, 431, 432, 433, 434 or by appropriate combinations thereof. Commonly used abbreviations are: Ph is phenyl, Pr is propyl, Me is methyl, Et is ethyl, Bu is butyl, Ex is Example.</p><p><pre xml:space="preserve" listing-type="tabular"><!--Greenbook tabular data-->                                  TABLE 5__________________________________________________________________________  #STR45##   -Ex.   R.sub.14   R.sub.3         Ar__________________________________________________________________________670   Me   NHCH(CH.sub.2 OMe).sub.2                   2,4-Cl.sub.2 -Ph  671 Me NHCHPr.sub.2 2,4-Cl.sub.2 -Ph  672 Me NEtBu 2,4-Cl.sub.2 -Ph  673 Me NPr(CH.sub.2 -c-C.sub.3 H.sub.5) 2,4-Cl.sub.2 -Ph  674 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4-Cl.sub.2 -Ph  675 Me NH-3-heptyl 2,4-Cl.sub.2 -Ph  676 Me NHCH(Et)CH.sub.2 OMe 2,4-Cl.sub.2 -Ph  677 Me NEt.sub.2 2,4-Cl.sub.2 -Ph  678 Me NHCH(CH.sub.2 OEt).sub.2 2,4-Cl.sub.2 -Ph  679 Me NH-3-pentyl 2,4-Cl.sub.2 -Ph  680 Me NMePh 2,4-Cl.sub.2 -Ph  681 Me NPr.sub.2 2,4-Cl.sub.2 -Ph  682 Me NH-3-hexyl 2,4-Cl.sub.2 -Ph  683 Me morpholino 2,4-Cl.sub.2 -Ph  684 Me N(CH.sub.2 Ph)CH.sub.2 CH.sub.2 OMe 2,4-Cl.sub.2 -Ph  685 Me NHCH(CH.sub.2 Ph)CH.sub.2 OMe 2,4-Cl.sub.2 -Ph  686 Me NH-4-tetrahydropyranyl 2,4-Cl.sub.2 -Ph  687 Me NH-cyclopentyl 2,4-Cl.sub.2 -Ph  688 Me OEt 2,4-Cl.sub.2 -Ph  689 Me OCH(Et)CH.sub.2 OMe 2,4-Cl.sub.2 -Ph  690 Me OCH.sub.2 Ph 2,4-Cl.sub.2 -Ph  691 Me O-3-pentyl 2,4-Cl.sub.2 -Ph  692 Me SEt 2,4-Cl.sub.2 -Ph  693 Me S(O)Et 2,4-Cl.sub.2 -Ph  694 Me SO.sub.2 Et 2,4-Cl.sub.2 -Ph  695 Me Ph 2,4-Cl.sub.2 -Ph  696 Me 2-CF.sub.3 -Ph 2,4-Cl.sub.2 -Ph  697 Me 2-Ph-Ph 2,4-Cl.sub.2 -Ph  698 Me 3-pentyl 2,4-Cl.sub.2 -Ph  699 Me cyclobutyl 2,4-Cl.sub.2 -Ph  700 Me 3-pyridyl 2,4-Cl.sub.2 -Ph  701 Me CH(Et)CH.sub.2 CONMe.sub.2 2,4-Cl.sub.2 -Ph  702 Me CH(Et)CH.sub.2 CH.sub.2 NMe.sub.2 2,4-Cl.sub.2 -Ph  703 Me NHCH(CH.sub.2 OMe).sub.2 2,4,6-Me.sub.3 -Ph  704 Me NHCHPr.sub.2 2,4,6-Me.sub.3 -Ph  705 Me NEtBu 2,4,6-Me.sub.3 -Ph  706 Me NPr(CH.sub.2 -c-C.sub.3 H.sub.5) 2,4,6-Me.sub.3 -Ph  707 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4,6-Me.sub.3 -Ph  708 Me NH-3-heptyl 2,4,6-Me.sub.3 -Ph  709 Me NHCH(Et)CH.sub.2 OMe 2,4,6-Me.sub.3 -Ph  710 Me NEt.sub.2 2,4,6-Me.sub.3 -Ph  711 Me NHCH(CH.sub.2 OEt).sub.2 2,4,6-Me.sub.3 -Ph  712 Me NH-3-pentyl 2,4,6-Me.sub.3 -Ph  713 Me NMePh 2,4,6-Me.sub.3 -Ph  714 Me NPr.sub.2 2,4,6-Me.sub.3 -Ph  715 Me NH-3-hexyl 2,4,6-Me.sub.3 -Ph  716 Me morpholino 2,4,6-Me.sub.3 -Ph  717 Me N(CH.sub.2 Ph)CH.sub.2 CH.sub.2 OMe 2,4,6-Me.sub.3 -Ph  718 Me NHCH(CH.sub.2 Ph)CH.sub.2 OMe 2,4,6-Me.sub.3 -Ph  719 Me NH-4-tetrahydropyranyl 2,4,6-Me.sub.3 -Ph  720 Me NH-cyclopentyl 2,4,6-Me.sub.3 -Ph  721 Me OEt 2,4,6-Me.sub.3 -Ph  722 Me OCH(Et)CH.sub.2 OMe 2,4,6-Me.sub.3 -Ph  723 Me OCH.sub.2 Ph 2,4,6-Me.sub.3 -Ph  724 Me O-3-pentyl 2,4,6-Me.sub.3 -Ph  725 Me SEt 2,4,6-Me.sub.3 -Ph  726 Me S(O)Et 2,4,6-Me.sub.3 -Ph  727 Me SO.sub.2 Et 2,4,6-Me.sub.3 -Ph  728 Me CH(CO.sub.2 Et).sub.2 2,4,6-Me.sub.3 -Ph  729 Me C(Et)(CO.sub.2 Et).sub.2 2,4,6-Me.sub.3 -Ph  730 Me CH(Et)CH.sub.2 OH 2,4,6-Me.sub.3 -Ph  731 Me CH(Et)CH.sub.2 OMe 2,4,6-Me.sub.3 -Ph  732 Me CONMe.sub.2 2,4,6-Me.sub.3 -Ph  733 Me COCH.sub.3 2,4,6-Me.sub.3 -Ph  734 Me CH(OH)CH.sub.3 2,4,6-Me.sub.3 -Ph  735 Me C(OH)Ph-3-pyridyl 2,4,6-Me.sub.3 -Ph  736 Me Ph 2,4,6-Me.sub.3 -Ph  737 Me 2-Ph-Ph 2,4,6-Me.sub.3 -Ph  738 Me 3-pentyl 2,4,6-Me.sub.3 -Ph  739 Me cyclobutyl 2,4,6-Me.sub.3 -Ph  740 Me 3-pyridyl 2,4,6-Me.sub.3 -Ph  741 Me CH(Et)CH.sub.2 CONMe.sub.2 2,4,6-Me.sub.3 -Ph  742 Me CH(Et)CH.sub.2 CH.sub.2 NMe.sub.2 2,4,6-Me.sub.3 -Ph  743 Me NHCH(CH.sub.2 OMe).sub.2 2,4-Me.sub.2 -Ph  744 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4-Me.sub.2 -Ph  745 Me NHCH(Et)CH.sub.2 OMe 2,4-Me.sub.2 -Ph  746 Me NH-3-pentyl 2,4-Me.sub.2 -Ph  747 Me NEt.sub.2 2,4-Me.sub.2 -Ph  748 Me N(CH.sub.2 CN).sub.2 2,4-Me.sub.2 -Ph  749 Me NHCH(Me)CH.sub.2 OMe 2,4-Me.sub.2 -Ph  750 Me OCH(Et)CH.sub.2 OMe 2,4-Me.sub.2 -Ph  751 Me NPr-c-C.sub.3 H.sub.5 2,4-Me.sub.2 -Ph  752 Me NHCH(Me)CH.sub.2 NMe.sub.2 2,4-Me.sub.2 -Ph  753 Me N(c-C.sub.3 H.sub.5)CH.sub.2 CH.sub.2 CN 2,4-Me.sub.2 -Ph                    754 Me N(Pr)CH.sub.2 CH.sub.2 CN 2,4-Me.sub.2                   -Ph  755 Me N(Bu)CH.sub.2 CH.sub.2 CN 2,4-Me.sub.2 -Ph  756 Me NHCHPr.sub.2 2,4-Me.sub.2 -Ph  757 Me NEtBu 2,4-Me.sub.2 -Ph  758 Me NPr(CH.sub.2 -c-C.sub.3 H.sub.5) 2,4-Me.sub.2 -Ph  759 Me NH-3-heptyl 2,4-Me.sub.2 -Ph  760 Me NEt.sub.2 2,4-Me.sub.2 -Ph  761 Me NHCH(CH.sub.2 OEt).sub.2 2,4-Me.sub.2 -Ph  762 Me NH-3-pentyl 2,4-Me.sub.2 -Ph  763 Me NMePh 2,4-Me.sub.2 -Ph  764 Me NPr.sub.2 2,4-Me.sub.2 -Ph  765 Me NH-3-hexyl 2,4-Me.sub.2 -Ph  766 Me morpholino 2,4-Me.sub.2 -Ph  767 Me N(CH.sub.2 Ph)CH.sub.2 CH.sub.2 OMe 2,4-Me.sub.2 -Ph  768 Me NHCH(CH.sub.2 Ph)CH.sub.2 OMe 2,4-Me.sub.2 -Ph  769 Me NH-4-tetrahydropyranyl 2,4-Me.sub.2 -Ph  770 Me NH-cyclopentyl 2,4-Me.sub.2 -Ph  771 Me NHCH(CH.sub.2 OMe).sub.2 2-Me-4-MeO-Ph  772 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me-4-MeO-Ph  773 Me NHCH(Et)CH.sub.2 OMe 2-Me-4-MeO-Ph  774 Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Me-4-MeO-Ph  775 Me OCH(Et)CH.sub.2 OMe 2-Me-4-MeO-Ph  776 Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4-MeO-Ph  777 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4-MeO-Ph  778 Me NHCH(Et)CH.sub.2 OMe 2-Br-4-MeO-Ph  779 Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Br-4-MeO-Ph  780 Me OCH(Et)CH.sub.2 OMe 2-Br-4-MeO-Ph  781 Me NHCH(CH.sub.2 OMe).sub.2 2-Me-4-NMe.sub.2 -Ph  782 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me-4-NMe.sub.2 -Ph  783 Me NHCH(Et)CH.sub.2 OMe 2-Me-4-NMe.sub.2 -Ph  784 Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Me-4-NMe.sub.2 -Ph  785 Me OCH(Et)CH.sub.2 OMe 2-Me-4-NMe.sub.2 -Ph  786 Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4-NMe.sub.2 -Ph  787 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4-NMe.sub.2 -Ph  788 Me NHCH(Et)CH.sub.2 OMe 2-Br-4-NMe.sub.2 -Ph  789 Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Br-4-NMe.sub.2 -Ph  790 Me OCH(Et)CH.sub.2 OMe 2-Br-4-NMe.sub.2 -Ph  791 Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4-i-Pr-Ph  792 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4-i-Pr-Ph  793 Me NHCH(Et)CH.sub.2 OMe 2-Br-4-i-Pr-Ph  794 Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Br-4-i-Pr-Ph  795 Me OCH(Et)CH.sub.2 OMe 2-Br-4-i-Pr-Ph  796 Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4-Me-Ph  797 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4-Me-Ph  798 Me NHCH(Et)CH.sub.2 OMe 2-Br-4-Me-Ph  799 Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Br-4-Me-Ph  800 Me OCH(Et)CH.sub.2 OMe 2-Br-4-Me-Ph  801 Me NHCH(CH.sub.2 OMe).sub.2 2-Me-4-Br-Ph  802 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me-4-Br-Ph  803 Me NHCH(Et)CH.sub.2 OMe 2-Me-4-Br-Ph  804 Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Me-4-Br-Ph  805 Me OCH(Et)CH.sub.2 OMe 2-Me-4-Br-Ph  806 Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4,6-Me.sub.2 -Ph  807 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4,6-Me.sub.2 -Ph  808 Me NHCH(CH.sub.2 OMe).sub.2 4-Br-2,6-(Me).sub.2 -Ph  809 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 4-Br-2,6-(Me).sub.2 -Ph  810 Me NHCH(CH.sub.2 OMe).sub.2 4-i-Pr-2-SMe-Ph  811 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 4-i-Pr-2-SMe-Ph  812 Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4-CF.sub.3 -Ph  813 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4-CF.sub.3 -Ph  814 Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4,6-(MeO).sub.2 -Ph  815 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4,6-(MeO).sub.2 -Ph  816 Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4,6-(MeO).sub.2 -Ph  817 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4,6-(MeO).sub.2 -Ph  818 Me NHCH(CH.sub.2 OMe).sub.2 2,6-(Me).sub.2 -4-SMe-Ph  819 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,6-(Me).sub.2 -4-SMe-Ph  820 Me NHCH(CH.sub.2 OMe).sub.2 4-(COMe)-2-Br-Ph  821 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 4-(COMe)-2-Br-Ph  822 Me NHCH(CH.sub.2 OMe).sub.2 2,4,6-Me.sub.3 -pyrid-3-yl  823 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4,6-Me.sub.3 -pyrid-3-yl                    824 Me NHCH(CH.sub.2 OMe).sub.2 2,4-(Br).sub.2                   -Ph  825 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4-(Br).sub.2 -Ph  826 Me NHCH(CH.sub.2 OMe).sub.2 4-i-Pr-2-SMe-Ph  827 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 4-i-Pr-2-SMe-Ph  828 Me NHCH(CH.sub.2 OMe).sub.2 4-i-Pr-2-SO.sub.2 Me-Ph  829 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 4-i-Pr-2-SO.sub.2 Me-Ph  830 Me NHCH(CH.sub.2 OMe).sub.2 2,6-(Me).sub.2 -4-SMe-Ph  831 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,6-(Me).sub.2 -4-SMe-Ph  832 Me NHCH(CH.sub.2 OMe).sub.2 2,6-(Me).sub.2 -4-SO.sub.2 Me-Ph                    833 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,6-(Me).su                   b.2 -4-SO.sub.2 Me-Ph  834 Me NHCH(CH.sub.2 OMe).sub.2 2-I-4-i-Pr-Ph  835 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-I-4-i-Pr-Ph  836 Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4-N(Me).sub.2 -6-MeO-Ph  837 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4-N(Me).sub.2 -6-MeO-Ph                    838 Me NEt.sub.2 2-Br-4-MeO-Ph  839 Me NH-3-pentyl 2-Br-4-MeO-Ph  840 Me NHCH(CH.sub.2 OMe).sub.2 2-CN-4-Me-Ph  841 Me N(c-C.sub.3 H.sub.5)CH.sub.2 CH.sub.2 CN 2,4,6-Me.sub.3 -Ph                    842 Me NHCH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe                   2-Me-4-Br-Ph  843 Me NHCH(CH.sub.2 OMe).sub.2 2,5-Me.sub.2 -4-MeO-Ph  844 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,5-Me.sub.2 -4-MeO-Ph  845 Me NH-3-pentyl 2,5-Me.sub.2 -4-MeO-Ph  846 Me NEt.sub.2 2,5-Me.sub.2 -4-MeO-Ph  847 Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4-MePh  848 Me NCH(Et)CH.sub.2 OMe 2-Cl-4-MePh  849 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4-MePh  850 Me (S)-NHCH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe 2-Cl-4-MePh  851 Me N(c-C.sub.3 H.sub.5)CH.sub.2 CH.sub.2 CN 2,5-Me.sub.2 -4-MeOPh                    852 Me NEt.sub.2 2-Me-4-MeOPh  853 Me OEt 2-Me-4-MeOPh  854 Me (S)-NHCH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe 2-Me-4-MeOPh                    855 Me N(c-C.sub.3 H.sub.5)CH.sub.2 CH.sub.2 CN                   2-Me-4-MeOPh  856 Me NHCH(CH.sub.2 CH.sub.2 OEt).sub.2 2-Me-4-MeOPh  857 Me N(c-C.sub.3 H.sub.5)CH.sub.2 CH.sub.2 CN 2,4-Cl.sub.2 -Ph                    858 Me NEt.sub.2 2-Me-4-ClPh  859 Me NH-3-pentyl 2-Me-4-ClPh  860 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me-4-ClPh  861 Me NHCH(CH.sub.2 OMe).sub.2 2-Me-4-ClPh  862 Me NEt.sub.2 2-Me-4-ClPh  863 Me NEt.sub.2 2-Cl-4-MePh  864 Me NH-3-pentyl 2-Cl-4-MePh  865 Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4-MeOPh  866 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4-MeOPh  867 Me NHCH(Et)CH.sub.2 OMe 2-Cl-4-MeOPh  868 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl-4-MeOPh  869 Me NEt.sub.2 2-Cl-4-MeOPh  870 Me NH-3-pentyl 2-Cl-4-MeOPh  871 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Cl-4-MeOPh  872 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Cl-4-MeOPh  873 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Br-4-MeOPh  874 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Br-4-MeOPh  875 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  876 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  877 Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4,5-(MeO).sub.2 Ph  878 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4,5-(MeO).sub.2 Ph  879 Me NHCH(Et)CH.sub.2 OMe 2-Cl-4,5-(MeO).sub.2 Ph  880 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl-4,5-(MeO).sub.2 Ph  881 Me NEt.sub.2 2-Cl-4,5-(MeO).sub.2 Ph  882 Me NH-3-pentyl 2-Cl-4,5-(MeO).sub.2 Ph  883 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Cl-4,5-(MeO).sub.2 Ph  884 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Cl-4,5-(MeO).sub.2 Ph  885 Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4,5-(MeO).sub.2 Ph  886 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4,5-(MeO).sub.2 Ph  887 Me NHCH(Et)CH.sub.2 OMe 2-Br-4,5-(MeO).sub.2 Ph  888 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Br-4,5-(MeO).sub.2 Ph  889 Me NEt.sub.2 2-Br-4,5-(MeO).sub.2 Ph  890 Me NH-3-pentyl 2-Br-4,5-(MeO).sub.2 Ph  891 Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4,6-(MeO).sub.2 Ph  892 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4,6-(MeO).sub.2 Ph  893 Me NEt.sub.2 2-Cl-4,6-(MeO).sub.2 Ph  894 Me NH-3-pentyl 2-Cl-4,6-(MeO).sub.2 Ph  895 Me NHCH(CH.sub.2 OMe).sub.2 2-Me-4,6-(MeO).sub.2 Ph  896 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me-4,6-(MeO).sub.2 Ph  897 Me NHCH(Et)CH.sub.2 OMe 2-Me-4,6-(MeO).sub.2 Ph  898 Me NEt.sub.2 2-Me-4,6-(MeO).sub.2 Ph  899 Me NH-3-pentyl 2-Me-4,6-(MeO).sub.2 Ph  900 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  901 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  902 Me NHCH(CH.sub.2 OMe).sub.2 2-Me0-4-MePh  903 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me0-4-MePh  904 Me NHCH(Et)CH.sub.2 OMe 2-Me0-4-MePh  905 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me0-4-MePh  906 Me NEt.sub.2 2-Me0-4-MePh  907 Me NH-3-pentyl 2-Me0-4-MePh  908 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me0-4-MePh  909 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me0-4-MePh  910 Me NHCH(CH.sub.2 OMe).sub.2 2-Me0-4-MePh  911 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me0-4-MePh  912 Me NHCH(Et)CH.sub.2 OMe 2-Me0-4-MePh  913 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me0-4-MePh  914 Me NEt.sub.2 2-Me0-4-MePh  915 Me NH-3-pentyl 2-Me0-4-MePh  916 Me NHCH(CH.sub.2 OMe).sub.2 2-Me0-4-ClPh  917 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me0-4-ClPh  918 Me NHCH(Et)CH.sub.2 OMe 2-Me0-4-ClPh  919 Me NEt.sub.2 2-Me0-4-ClPh  920 Me NH-3-pentyl 2-Me0-4-ClPh__________________________________________________________________________</pre></p><p><pre xml:space="preserve" listing-type="tabular"><!--Greenbook tabular data-->                                  TABLE 6__________________________________________________________________________  #STR46##   -Ex.   R.sub.14  R.sub.3         Ar__________________________________________________________________________ 921   Me  NHCH(CH.sub.2 OMe).sub.2                  2,4-Cl.sub.2 -Ph   922 Me NHCHPr.sub.2 2,4-Cl.sub.2 -Ph   923 Me NEtBu 2,4-Cl.sub.2 -Ph   924 Me NPr(CH.sub.2 -c-C.sub.3 H.sub.5) 2,4-Cl.sub.2 -Ph   925 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4-Cl.sub.2 -Ph   926 Me NH-3-heptyl 2,4-Cl.sub.2 -Ph   927 Me NHCH(Et)CH.sub.2 OMe 2,4-Cl.sub.2 -Ph   928 Me NEt.sub.2 2,4-Cl.sub.2 -Ph   929 Me NHCH(CH.sub.2 OEt).sub.2 2,4-Cl.sub.2 -Ph   930 Me NH-3-pentyl 2,4-Cl.sub.2 -Ph   931 Me NMePh 2,4-Cl.sub.2 -Ph   932 Me NPr.sub.2 2,4-Cl.sub.2 -Ph   933 Me NH-3-hexyl 2,4-Cl.sub.2 -Ph   934 Me morpholino 2,4-Cl.sub.2 -Ph   935 Me N(CH.sub.2 Ph)CH.sub.2 CH.sub.2 OMe 2,4-Cl.sub.2 -Ph   936 Me NHCH(CH.sub.2 Ph)CH.sub.2 OMe 2,4-Cl.sub.2 -Ph   937 Me NH-4-tetrahydropyranyl 2,4-Cl.sub.2 -Ph   938 Me NH-cyclopentyl 2,4-Cl.sub.2 -Ph   939 Me OEt 2,4-Cl.sub.2 -Ph   940 Me OCH(Et)CH.sub.2 OMe 2,4-Cl.sub.2 -Ph   941 Me OCH.sub.2 Ph 2,4-Cl.sub.2 -Ph   942 Me O-3-pentyl 2,4-Cl.sub.2 -Ph   943 Me SEt 2,4-Cl.sub.2 -Ph   944 Me S(O)Et 2,4-Cl.sub.2 -Ph   945 Me SO.sub.2 Et 2,4-Cl.sub.2 -Ph   946 Me Ph 2,4-Cl.sub.2 -Ph   947 Me 2-CF.sub.3 -Ph 2,4-Cl.sub.2 -Ph   948 Me 2-Ph-Ph 2,4-Cl.sub.2 -Ph   949 Me 3-pentyl 2,4-Cl.sub.2 -Ph   950 Me cyclobutyl 2,4-Cl.sub.2 -Ph   951 Me 3-pyridyl 2,4-Cl.sub.2 -Ph   952 Me CH(Et)CH.sub.2 CONMe.sub.2 2,4-Cl.sub.2 -Ph   953 Me CH(Et)CH.sub.2 CH.sub.2 NMe.sub.2 2,4-Cl.sub.2 -Ph   954 Me NHCH(CH.sub.2 OMe).sub.2 2,4,6-Me.sub.3 -Ph   955 Me NHCHPr.sub.2 2,4,6-Me.sub.3 -Ph   956 Me NEtBu 2,4,6-Me.sub.3 -Ph   957 Me NPr(CH.sub.2 -c-C.sub.3 H.sub.5) 2,4,6-Me.sub.3 -Ph   958 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4,6-Me.sub.3 -Ph   959 Me NH-3-heptyl 2,4,6-Me.sub.3 -Ph   960 Me NHCH(Et)CH.sub.2 OMe 2,4,6-Me.sub.3 -Ph   961 Me NEt.sub.2 2,4,6-Me.sub.3 -Ph   962 Me NHCH(CH.sub.2 OEt).sub.2 2,4,6-Me.sub.3 -Ph   963 Me NH-3-pentyl 2,4,6-Me.sub.3 -Ph   964 Me NMePh 2,4,6-Me.sub.3 -Ph   965 Me NPr.sub.2 2,4,6-Me.sub.3 -Ph   966 Me NH-3-hexyl 2,4,6-Me.sub.3 -Ph   967 Me morpholino 2,4,6-Me.sub.3 -Ph   968 Me N(CH.sub.2 Ph)CH.sub.2 CH.sub.2 OMe 2,4,6-Me.sub.3 -Ph   969 Me NHCH(CH.sub.2 Ph)CH.sub.2 OMe 2,4,6-Me.sub.3 -Ph   970 Me NH-4-tetrahydropyranyl 2,4,6-Me.sub.3 -Ph   971 Me NH-cyclopentyl 2,4,6-Me.sub.3 -Ph   972 Me OEt 2,4,6-Me.sub.3 -Ph   973 Me OCH(Et)CH.sub.2 OMe 2,4,6-Me.sub.3 -Ph   974 Me OCH.sub.2 Ph 2,4,6-Me.sub.3 -Ph   975 Me O-3-pentyl 2,4,6-Me.sub.3 -Ph   976 Me SEt 2,4,6-Me.sub.3 -Ph   977 Me S(O)Et 2,4,6-Me.sub.3 -Ph   978 Me SO.sub.2 Et 2,4,6-Me.sub.3 -Ph   979 Me CH(CO.sub.2 Et).sub.2 2,4,6-Me.sub.3 -Ph   980 Me C(Et)(CO.sub.2 Et).sub.2 2,4,6-Me.sub.3 -Ph   981 Me CH(Et)CH.sub.2 OH 2,4,6-Me.sub.3 -Ph   982 Me CH(Et)CH.sub.2 OMe 2,4,6-Me.sub.3 -Ph   983 Me CONMe.sub.2 2,4,6-Me.sub.3 -Ph   984 Me COCH.sub.3 2,4,6-Me.sub.3 -Ph   985 Me CH(OH)CH.sub.3 2,4,6-Me.sub.3 -Ph   986 Me C(OH)Ph-3-pyridyl 2,4,6-Me.sub.3 -Ph   987 Me Ph 2,4,6-Me.sub.3 -Ph   988 Me 2-Ph-Ph 2,4,6-Me.sub.3 -Ph   989 Me 3-pentyl 2,4,6-Me.sub.3 -Ph   990 Me cyclobutyl 2,4,6-Me.sub.3 -Ph   991 Me 3-pyridyl 2,4,6-Me.sub.3 -Ph   992 Me CH(Et)CH.sub.2 CONMe.sub.2 2,4,6-Me.sub.3 -Ph   993 Me CH(Et)CH.sub.2 CH.sub.2 NMe.sub.2 2,4,6-Me.sub.3 -Ph   994 Me NHCH(CH.sub.2 OMe).sub.2 2,4-Me.sub.2 -Ph   995 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4-Me.sub.2 -Ph   996 Me NHCH(Et)CH.sub.2 OMe 2,4-Me.sub.2 -Ph   997 Me NH-3-pentyl 2,4-Me.sub.2 -Ph   998 Me NEt.sub.2 2,4-Me.sub.2 -Ph   999 Me N(CH.sub.2 CN).sub.2 2,4-Me.sub.2 -Ph  1000 Me NHCH(Me)CH.sub.2 OMe 2,4-Me.sub.2 -Ph  1001 Me OCH(Et)CH.sub.2 OMe 2,4-Me.sub.2 -Ph  1002 Me NPr-c-C.sub.3 H.sub.5 2,4-Me.sub.2 -Ph  1003 Me NHCH(Me)CH.sub.2 NMe.sub.2 2,4-Me.sub.2 -Ph  1004 Me N(c-C.sub.3 H.sub.5)CH.sub.2 CH.sub.2 CN 2,4-Me.sub.2 -Ph                   1005 Me N(Pr)CH.sub.2 CH.sub.2 CN 2,4-Me.sub.2                  -Ph  1006 Me N(Bu)CH.sub.2 CH.sub.2 CN 2,4-Me.sub.2 -Ph  1007 Me NHCHPr.sub.2 2,4-Me.sub.2 -Ph  1008 Me NEtBu 2,4-Me.sub.2 -Ph  1009 Me NPr(CH.sub.2 -c-C.sub.3 H.sub.5) 2,4-Me.sub.2 -Ph  1010 Me NH-3-heptyl 2,4-Me.sub.2 -Ph  1011 Me NEt.sub.2 2,4-Me.sub.2 -Ph  1012 Me NHCH(CH.sub.2 OEt).sub.2 2,4-Me.sub.2 -Ph  1013 Me NH-3-pentyl 2,4-Me.sub.2 -Ph  1014 Me NMePh 2,4-Me.sub.2 -Ph  1015 Me NPr.sub.2 2,4-Me.sub.2 -Ph  1016 Me NH-3-hexyl 2,4-Me.sub.2 -Ph  1017 Me morpholino 2,4-Me.sub.2 -Ph  1018 Me N(CH.sub.2 Ph)CH.sub.2 CH.sub.2 OMe 2,4-Me.sub.2 -Ph  1019 Me NHCH(CH.sub.2 Ph)CH.sub.2 OMe 2,4-Me.sub.2 -Ph  1020 Me NH-4-tetrahydropyranyl 2,4-Me.sub.2 -Ph  1021 Me NH-cyclopentyl 2,4-Me.sub.2 -Ph  1022 Me NHCH(CH.sub.2 OMe).sub.2 2-Me-4-MeO-Ph  1023 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me-4-MeO-Ph  1024 Me NHCH(Et)CH.sub.2 OMe 2-Me-4-MeO-Ph  1025 Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Me-4-MeO-Ph  1026 Me OCH(Et)CH.sub.2 OMe 2-Me-4-MeO-Ph  1027 Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4-MeO-Ph  1028 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4-MeO-Ph  1029 Me NHCH(Et)CH.sub.2 OMe 2-Br-4-MeO-Ph  1030 Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Br-4-MeO-Ph  1031 Me OCH(Et)CH.sub.2 OMe 2-Br-4-MeO-Ph  1032 Me NHCH(CH.sub.2 OMe).sub.2 2-Me-4-NMe.sub.2 -Ph  1033 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me-4-NMe.sub.2 -Ph  1034 Me NHCH(Et)CH.sub.2 OMe 2-Me-4-NMe.sub.2 -Ph -  1035 Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Me-4-NMe.sub.2 -Ph  1036 Me OCH(Et)CH.sub.2 OMe 2-Me-4-NMe.sub.2 -Ph  1037 Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4-NMe.sub.2 -Ph  1038 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4-NMe.sub.2 -Ph  1039 Me NHCH(Et)CH.sub.2 OMe 2-Br-4-NMe.sub.2 -Ph  1040 Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Br-4-NMe.sub.2 -Ph  1041 Me OCH(Et)CH.sub.2 OMe 2-Br-4-NMe.sub.2 -Ph  1042 Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4-i-Pr-Ph  1043 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4-i-Pr-Ph  1044 Me NHCH(Et)CH.sub.2 OMe 2-Br-4-i-Pr-Ph  1045 Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Br-4-i-Pr-Ph  1046 Me OCH(Et)CH.sub.2 OMe 2-Br-4-i-Pr-Ph  1047 Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4-Me-Ph  1048 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4-Me-Ph  1049 Me NHCH(Et)CH.sub.2 OMe 2-Br-4-Me-Ph  1050 Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Br-4-Me-Ph  1051 Me OCH(Et)CH.sub.2 OMe 2-Br-4-Me-Ph  1052 Me NHCH(CH.sub.2 OMe).sub.2 2-Me-4-Br-Ph  1053 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me-4-Br-Ph  1054 Me NHCH(Et)CH.sub.2 OMe 2-Me-4-Br-Ph  1055 Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Me-4-Br-Ph  1056 Me OCH(Et)CH.sub.2 OMe 2-Me-4-Br-Ph  1057 Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4,6-Me.sub.2 -Ph  1058 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4,6-Me.sub.2 -Ph  1059 Me NHCH(CH.sub.2 OMe).sub.2 4-Br-2,6-(Me).sub.2 -Ph  1060 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 4-Br-2,6-(Me).sub.2 -Ph  1061 Me NHCH(CH.sub.2 OMe).sub.2 4-i-Pr-2-SMe-Ph  1062 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 4-i-Pr-2-SMe-Ph  1063 Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4-CF.sub.3 -Ph  1064 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4-CF.sub.3 -Ph  1065 Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4,6-(MeO).sub.2 -Ph  1066 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4,6-(MeO).sub.2 -Ph                   1067 Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4,6-(MeO).su                  b.2 -Ph  1068 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4,6-(MeO).sub.2 -Ph                   1069 Me NHCH(CH.sub.2 OMe).sub.2 2,6-(Me).sub.2                  -4-SMe-Ph  1070 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,6-(Me).sub.2 -4-SMe-Ph                   1071 Me NHCH(CH.sub.2 OMe).sub.2 4-(COMe)-2-Br-Ph  1072 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 4-(COMe)-2-Br-Ph  1073 Me NHCH(CH.sub.2 OMe).sub.2 2,4,6-Me.sub.3 -pyrid-3-yl  1074 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4,6-Me.sub.3 -pyrid-3-yl                   1075 Me NHCH(CH.sub.2 OMe).sub.2 2,4-(Br).sub.2                  -Ph  1076 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4-(Br).sub.2 -Ph  1077 Me NHCH(CH.sub.2 OMe).sub.2 4-i-Pr-2-SMe-Ph  1078 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 4-i-Pr-2-SMe-Ph  1079 Me NHCH(CH.sub.2 OMe).sub.2 4-i-Pr-2-SO.sub.2 Me-Ph  1080 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 4-i-Pr-2-SO.sub.2 Me-Ph  1081 Me NHCH(CH.sub.2 OMe).sub.2 2,6-(Me).sub.2 -4-SMe-Ph  1082 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,6-(Me).sub.2 -4-SMe-Ph                   1083 Me NHCH(CH.sub.2 OMe).sub.2 2,6-(Me).sub.2                  -4-SO.sub.2 Me-Ph  1084 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,6-(Me).sub.2 -4-SO.sub.2 Me-Ph  1085 Me NHCH(CH.sub.2 OMe).sub.2 2-I-4-i-Pr-Ph  1086 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-I-4-i-Pr-Ph  1087 Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4-N(Me).sub.2 -6-MeO-Ph  1088 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4-N(Me).sub.2 -6-MeO-Ph                   1089 Me NEt.sub.2 2-Br-4-MeO-Ph  1090 Me NH-3-pentyl 2-Br-4-MeO-Ph  1091 Me NHCH(CH.sub.2 OMe).sub.2 2-CN-4-Me-Ph  1092 Me N(c-C.sub.3 H.sub.5)CH.sub.2 CH.sub.2 CN 2,4,6-Me.sub.3 -Ph                   1093 Me NHCH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe                  2-Me-4-Br-Ph  1094 Me NHCH(CH.sub.2 OMe).sub.2 2,5-Me.sub.2 -4-MeO-Ph  1095 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,5-Me.sub.2 -4-MeO-Ph  1096 Me NH-3-pentyl 2,5-Me.sub.2 -4-MeO-Ph  1097 Me NEt.sub.2 2,5-Me.sub.2 -4-MeO-Ph  1098 Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4-MePh  1099 Me NCH(Et)CH.sub.2 OMe 2-Cl-4-MePh  1100 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4-MePh  1101 Me (S)-NHCH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe 2-Cl-4-MePh                   1102 Me N(c-C.sub.3 H.sub.5)CH.sub.2 CH.sub.2 CN                  2,5-Me.sub.2 -4-MeOPh  1103 Me NEt.sub.2 2-Me-4-MeOPh  1104 Me OEt 2-Me-4-MeOPh  1105 Me (S)-NHCH(CH.sub.2 CH.sub.2 OMe)CH.sub.2 OMe 2-Me-4-MeOPh                   1106 Me N(c-C.sub.3 H.sub.5)CH.sub.2 CH.sub.2 CN                  2-Me-4-MeOPh  1107 Me NHCH(CH.sub.2 CH.sub.2 OEt).sub.2 2-Me-4-MeOPh  1108 Me N(c-C.sub.3 H.sub.5)CH.sub.2 CH.sub.2 CN 2,4-Cl.sub.2 -Ph                   1109 Me NEt.sub.2 2-Me-4-ClPh  1110 Me NH-3-pentyl 2-Me-4-ClPh  1111 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me-4-ClPh  1112 Me NHCH(CH.sub.2 OMe).sub.2 2-Me-4-ClPh  1113 Me NEt.sub.2 2-Me-4-ClPh  1114 Me NEt.sub.2 2-Cl-4-MePh  1115 Me NH-3-pentyl 2-Cl-4-MePh  1116 Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4-MeOPh  1117 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4-MeOPh  1118 Me NHCH(Et)CH.sub.2 OMe 2-Cl-4-MeOPh  1119 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl-4-MeOPh  1120 Me NEt.sub.2 2-Cl-4-MeOPh  1121 Me NH-3-pentyl 2-Cl-4-MeOPh  1123 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Cl-4-MeOPh  1124 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Cl-4-MeOPh  1125 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Br-4-MeOPh  1126 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Br-4-MeOPh  1127 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  1128 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  1129 Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4,5-(MeO).sub.2 Ph  1130 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4,5-(MeO).sub.2 Ph  1131 Me NHCH(Et)CH.sub.2 OMe 2-Cl-4,5-(MeO).sub.2 Ph  1132 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl-4,5-(MeO).sub.2 Ph  1133 Me NEt.sub.2 2-Cl-4,5-(MeO).sub.2 Ph  1134 Me NH-3-pentyl 2-Cl-4,5-(MeO).sub.2 Ph  1135 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Cl-4,5-(MeO).sub.2 Ph  1136 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Cl-4,5-(MeO).sub.2 Ph  1137 Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4,5-(MeO).sub.2 Ph  1138 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4,5-(MeO).sub.2 Ph  1139 Me NHCH(Et)CH.sub.2 OMe 2-Br-4,5-(MeO).sub.2 Ph  1140 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Br-4,5-(MeO).sub.2 Ph  1141 Me NEt.sub.2 2-Br-4,5-(MeO).sub.2 Ph  1142 Me NH-3-pentyl 2-Br-4,5-(MeO).sub.2 Ph  1143 Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4,6-(MeO).sub.2 Ph  1144 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4,6-(MeO).sub.2 Ph  1145 Me NEt.sub.2 2-Cl-4,6-(MeO).sub.2 Ph  1146 Me NH-3-pentyl 2-Cl-4,6-(MeO).sub.2 Ph  1147 Me NHCH(CH.sub.2 OMe).sub.2 2-Me-4,6-(MeO).sub.2 Ph  1148 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me-4,6-(MeO).sub.2 Ph  1149 Me NHCH(Et)CH.sub.2 OMe 2-Me-4,6-(MeO).sub.2 Ph  1150 Me NEt.sub.2 2-Me-4,6-(MeO).sub.2 Ph  1151 Me NH-3-pentyl 2-Me-4,6-(MeO).sub.2 Ph  1152 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  1153 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  1154 Me NHCH(CH.sub.2 OMe).sub.2 2-Me0-4-MePh  1155 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me0-4-MePh  1156 Me NHCH(Et)CH.sub.2 OMe 2-Me0-4-MePh  1157 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me0-4-MePh  1158 Me NEt.sub.2 2-Me0-4-MePh  1159 Me NH-3-pentyl 2-Me0-4-MePh  1160 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me0-4-MePh  1161 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me0-4-MePh  1162 Me NHCH(CH.sub.2 OMe).sub.2 2-Me0-4-MePh  1163 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me0-4-MePh  1164 Me NHCH(Et)CH.sub.2 OMe 2-Me0-4-MePh  1165 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me0-4-MePh  1166 Me NEt.sub.2 2-Me0-4-MePh  1167 Me NH-3-pentyl 2-Me0-4-MePh  1168 Me NHCH(CH.sub.2 OMe).sub.2 2-Me0-4-ClPh  1169 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me0-4-ClPh  1170 Me NHCH(Et)CH.sub.2 OMe 2-Me0-4-ClPh  1171 Me NEt.sub.2 2-Me0-4-ClPh  1172 Me NH-3-pentyl 2-Me0-4-ClPh__________________________________________________________________________</pre></p><p>The examples delineated in TABLE 8 may be prepared by the methods outlined in Examples 1A, 1B, 432, 433, 434. Commonly used abbreviations are: Ph is phenyl, Pr is propyl, Me is methyl, Et is ethyl, Bu is butyl, cPr is cyclopropyl, Ex is Example, EtOAc is ethyl acetate.</p><p><pre xml:space="preserve" listing-type="tabular"><!--Greenbook tabular data-->                                  TABLE 8__________________________________________________________________________  #STR47##   -Ex.   R  R.sup.3          Ar        mp (__________________________________________________________________________2000   Me N(CH.sub.2 CH.sub.2 OMe).sub.2                  2,4-Cl.sub.2 -Ph  2001 Me N(Bu)Et 2,4-Cl.sub.2 -Ph  2002 Me NHCH(Et)CH.sub.2 OMe 2,4-Cl.sub.2 -Ph  2003 Me N(Pr)CH.sub.2 CH.sub.2 CN 2,4-Cl.sub.2 -Ph  2004 Me NH-3-pentyl 2,4-Cl.sub.2 -Ph  2005 Me NHCH(CH.sub.2 OMe).sub.2 2,4-Cl.sub.2 -Ph  2006 Me NHCH(Et).sub.2 2,4-Me.sub.2 -Ph  2007 Me NHCH(CH.sub.2 OMe).sub.2 2,4-Me.sub.2 -Ph  2008 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4-Me.sub.2 -Ph  2009 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2,4-Me.sub.2 -Ph  2010 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl,4-MePh  2011 Me NHCH(CH.sub.2 OMe).sub.2 2-Cl,4-MePh  2012 Me NHCH(Et).sub.2 2-Cl,4-MePh  2013 Me NEt.sub.2 2,4-Me.sub.2 -Ph  2014 Me N(Pr)CH.sub.2 CH.sub.2 CN 2,4-Me.sub.2 -Ph  2015 Me N(Bu)CH.sub.2 CH.sub.2 CN 2,4-Me.sub.2 -Ph  2016 Me NHCH(Et)CH.sub.2 OMe 2,4-Me.sub.2 -Ph  2017 Me NHCH(Et).sub.2 2-Me,4-MeOPh  2018 Me NHCH(CH.sub.2 OMe).sub.2 2-Me,4-MeOPh  2019 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me,4-MeOPh 115-116.sup.a                             2020 Me (S)-NHCH(CH.sub.2 CH.sub.2                            OMe)- 2-Me,4-MeOPh  2021  (CH.sub.2 OMe)  2022 Me (S)-NHCH(CH.sub.2 CH.sub.2 OMe)- 2,4-Me.sub.2 -Ph  2023  (CH.sub.2 OMe)  2024 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me,4-ClPh  2025 Me NHEt 2,4-Me.sub.2 -Ph  2026 Me NHCH(Et).sub.2 2-Me,4-ClPh  2027 Me NHCH(CH.sub.2 OMe).sub.2 2-Me,4-ClPh  2028 Me N(Ac)Et 2,4-Me.sub.2 -Ph  2029 Me (S)-NHCH(CH.sub.2 CH.sub.2 OMe)- 2-Me,4-ClPh  2030  (CH.sub.2 OMe)  2031 Me N(Pr)CH.sub.2 CH.sub.2 CN 2-Me,4-MeOPh  2032 Me NEt.sub.2 2-Me,4-MeOPh  2033 Me (S)-NHCH(CH.sub.2 CH.sub.2 OMe)- 2-Cl,4-MePh  2034  (CH.sub.2 OMe)  2035 Me NEt.sub.2 2-Cl,4-MePh  2036 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me,4-MeOPh  2037 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl,4-MePh  2038 Me NHCH(Et)CH.sub.2 OMe 2-Me,4-MeOPh  2039 Me NHCH(Et)CH.sub.2 OMe 2-Cl,4-MePh  2040 Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4-MeOPh  2041 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4-MeOPh  2042 Me NHCH(Et)CH.sub.2 OMe 2-Cl-4-MeOPh  2043 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl-4-MeOPh  2044 Me NEt.sub.2 2-Cl-4-MeOPh  2045 Me NH-3-pentyl 2-Cl-4-MeOPh  2046 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Cl-4-MeOPh  2047 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Cl-4-MeOPh  2048 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Br-4-MeOPh  2049 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Br-4-MeOPh  2050 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  2051 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  2052 Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4,5-(MeO).sub.2 Ph  2053 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4,5-(MeO).sub.2 Ph  2054 Me NHCH(Et)CH.sub.2 OMe 2-Cl-4,5-(MeO).sub.2 Ph  2055 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl-4,5-(MeO).sub.2 Ph  2056 Me NEt.sub.2 2-Cl-4,5-(MeO).sub.2 Ph  2057 Me NH-3-pentyl 2-Cl-4,5-(MeO).sub.2 Ph  2058 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Cl-4,5-(MeO).sub.2 Ph  2059 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Cl-4,5-(MeO).sub.2 Ph  2060 Me NHCH(CH.sub.2 OMe).sub.2 2-Br-4,5-(MeO).sub.2 Ph  2061 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4,5-(MeO).sub.2 Ph  2062 Me NHCH(Et)CH.sub.2 OMe 2-Br-4,5-(MeO).sub.2 Ph  2063 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Br-4,5-(MeO).sub.2 Ph  2064 Me NEt.sub.2 2-Br-4,5-(MeO).sub.2 Ph  2065 Me NH-3-pentyl 2-Br-4,5-(MeO).sub.2 Ph  2066 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Br-4,5-(MeO).sub.2 Ph  2067 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Br-4,5-(MeO).sub.2 Ph  2068 Me NHCH(CH.sub.2 OMe).sub.2 2-Cl-4,6-(MeO).sub.2 Ph  2069 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4,6-(MeO).sub.2 Ph  2070 Me NHCH(Et)CH.sub.2 OMe 2-Cl-4,6-(MeO).sub.2 Ph  2071 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl-4,6-(MeO).sub.2 Ph  2072 Me NEt.sub.2 2-Cl-4,6-(MeO).sub.2 Ph  2073 Me NH-3-pentyl 2-Cl-4,6-(MeO).sub.2 Ph  2074 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Cl-4,6-(MeO).sub.2 Ph  2075 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Cl-4,6-(MeO).sub.2 Ph  2076 Me NHCH(CH.sub.2 OMe).sub.2 2-Me-4,6-(MeO).sub.2 Ph  2077 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me-4,6-(MeO).sub.2 Ph  2078 Me NHCH(Et)CH.sub.2 OMe 2-Me-4,6-(MeO).sub.2 Ph  2079 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me-4,6-(MeO).sub.2 Ph  2080 Me NEt.sub.2 2-Me-4,6-(MeO).sub.2 Ph  2081 Me NH-3-pentyl 2-Me-4,6-(MeO).sub.2 Ph  2082 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me-4,6-(MeO).sub.2 Ph  2083 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me-4,6-(MeO).sub.2 Ph  2084 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Br-4,6-(MeO).sub.2 Ph  2085 Me NEt.sub.2 2-Br-4,6-(MeO).sub.2 Ph  2086 Me NH-3-pentyl 2-Br-4,6-(MeO).sub.2 Ph  2087 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Br-4,6-(MeO).sub.2 Ph  2088 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Br-4,6-(MeO).sub.2 Ph  2089 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  2090 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  2091 Me NHCH(CH.sub.2 OMe).sub.2 2-Me0-4-MePh  2092 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me0-4-MePh  2093 Me NHCH(Et)CH.sub.2 OMe 2-Me0-4-MePh  2094 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me0-4-MePh  2095 Me NEt.sub.2 2-Me0-4-MePh  2096 Me NH-3-pentyl 2-Me0-4-MePh  2097 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me0-4-MePh  2098 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me0-4-MePh  2099 Me NHCH(CH.sub.2 OMe).sub.2 2-Me0-4-MePh  2100 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me0-4-MePh  2101 Me NHCH(Et)CH.sub.2 OMe 2-Me0-4-MePh  2102 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me0-4-MePh  2103 Me NEt.sub.2 2-Me0-4-MePh  2104 Me NH-3-pentyl 2-Me0-4-MePh  2105 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me0-4-MePh  2106 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me0-4-MePh  2107 Me NHCH(CH.sub.2 OMe).sub.2 2-Me0-4-ClPh  2108 Me N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me0-4-ClPh  2109 Me NHCH(Et)CH.sub.2 OMe 2-Me0-4-ClPh  2110 Me N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me0-4-ClPh  2111 Me NEt.sub.2 2-Me0-4-ClPh  2112 Me NH-3-pentyl 2-Me0-4-ClPh  2113 Me NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me0-4-ClPh  2114 Me NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me0-4-ClPh  2115 Cl N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4-Cl.sub.2 -Ph  2116 Cl N(Bu)Et 2,4-Cl.sub.2 -Ph  2117 Cl NHCH(Et)CH.sub.2 OMe 2,4-Cl.sub.2 -Ph  2118 Cl N(Pr)CH.sub.2 CH.sub.2 CN 2,4-Cl.sub.2 -Ph  2119 Cl NH-3-pentyl 2,4-Cl.sub.2 -Ph  2120 Cl NHCH(CH.sub.2 OMe).sub.2 2,4-Cl.sub.2 -Ph  2121 Cl NHCH(Et).sub.2 2,4-Me.sub.2 -Ph  2122 Cl NHCH(CH.sub.2 OMe).sub.2 2,4-Me.sub.2 -Ph  2123 Cl N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4-Me.sub.2 -Ph  2124 Cl N(c-Pr)CH.sub.2 CH.sub.2 CN 2,4-Me.sub.2 -Ph  2125 Cl N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl,4-MePh  2126 Cl NHCH(CH.sub.2 OMe).sub.2 2-Cl,4-MePh  2127 Cl NHCH(Et).sub.2 2-Cl,4-MePh  2128 Cl NEt.sub.2 2,4-Me.sub.2 -Ph  2129 Cl N(Pr)CH.sub.2 CH.sub.2 CN 2,4-Me.sub.2 -Ph  2130 Cl N(Bu)CH.sub.2 CH.sub.2 CN 2,4-Me.sub.2 -Ph  2131 Cl NHCH(Et)CH.sub.2 OMe 2,4-Me.sub.2 -Ph  2132 Cl NHCH(Et).sub.2 2-Me,4-MeOPh  2133 Cl NHCH(CH.sub.2 OMe).sub.2 2-Me,4-MeOPh 74-76.sup.b  2134 Cl N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me,4-MeOPh  2135 Cl (S)-NHCH(CH.sub.2 CH.sub.2 OMe)- 2-Me,4-MeOPh  2136  (CH.sub.2 OMe)  2137 Cl (S)-NHCH(CH.sub.2 CH.sub.2 OMe)- 2,4-Me.sub.2 -Ph  2138  (CH.sub.2 OMe)  2139 Cl N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me,4-ClPh  2140 Cl NHEt 2,4-Me.sub.2 -Ph  2141 Cl NHCH(Et).sub.2 2-Me,4-ClPh  2142 Cl NHCH(CH.sub.2 OMe).sub.2 2-Me,4-ClPh  2143 Cl N(Ac)Et 2,4-Me.sub.2 -Ph  2144 Cl (S)-NHCH(CH.sub.2 CH.sub.2 OMe)- 2-Me,4-ClPh  2145  (CH.sub.2 OMe)  2146 Cl N(Pr)CH.sub.2 CH.sub.2 CN 2-Me,4-MeOPh  2147 Cl NEt.sub.2 2-Me,4-MeOPh  2148 Cl (S)-NHCH(CH.sub.2 CH.sub.2 OMe)- 2-Cl,4-MePh  2149  (CH.sub.2 OMe)  2150 Cl NEt.sub.2 2-Cl,4-MePh  2151 Cl N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me,4-MeOPh  2152 Cl N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl,4-MePh  2153 Cl NHCH(Et)CH.sub.2 OMe 2-Me,4-MeOPh  2154 Cl NHCH(Et)CH.sub.2 OMe 2-Cl,4-MePh  2155 Cl NHCH(CH.sub.2 OMe).sub.2 2-Cl-4-MeOPh  2156 Cl N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4-MeOPh  2157 Cl NHCH(Et)CH.sub.2 OMe 2-Cl-4-MeOPh  2158 Cl N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl-4-MeOPh  2159 Cl NEt.sub.2 2-Cl-4-MeOPh  2160 Cl NH-3-pentyl 2-Cl-4-MeOPh  2161 Cl NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Cl-4-MeOPh  2162 Cl NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Cl-4-MeOPh  2163 Cl NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Br-4-MeOPh  2164 Cl NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Br-4-MeOPh  2165 Cl NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  2166 Cl NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  2167 Cl NHCH(CH.sub.2 OMe).sub.2 2-Cl-4,5-(MeO).sub.2 Ph  2168 Cl N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4,5-(MeO).sub.2 Ph  2169 Cl NHCH(Et)CH.sub.2 OMe 2-Cl-4,5-(MeO).sub.2 Ph  2170 Cl N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl-4,5-(MeO).sub.2 Ph  2171 Cl NEt.sub.2 2-Cl-4,5-(MeO).sub.2 Ph  2172 Cl NH-3-pentyl 2-Cl-4,5-(MeO).sub.2 Ph  2173 Cl NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Cl-4,5-(MeO).sub.2 Ph  2174 Cl NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Cl-4,5-(MeO).sub.2 Ph  2175 Cl NHCH(CH.sub.2 OMe).sub.2 2-Br-4,5-(MeO).sub.2 Ph  2176 Cl N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4,5-(MeO).sub.2 Ph  2177 Cl NHCH(Et)CH.sub.2 OMe 2-Br-4,5-(MeO).sub.2 Ph  2178 Cl N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Br-4,5-(MeO).sub.2 Ph  2179 Cl NEt.sub.2 2-Br-4,5-(MeO).sub.2 Ph  2180 Cl NH-3-pentyl 2-Br-4,5-(MeO).sub.2 Ph  2181 Cl NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Br-4,5-(MeO).sub.2 Ph  2182 Cl NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Br-4,5-(MeO).sub.2 Ph  2183 Cl NHCH(CH.sub.2 OMe).sub.2 2-Cl-4,6-(MeO).sub.2 Ph  2184 Cl N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4,6-(MeO).sub.2 Ph  2185 Cl NHCH(Et)CH.sub.2 OMe 2-Cl-4,6-(MeO).sub.2 Ph  2186 Cl N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl-4,6-(MeO).sub.2 Ph  2187 Cl NEt.sub.2 2-Cl-4,6-(MeO).sub.2 Ph  2188 Cl NH-3-pentyl 2-Cl-4,6-(MeO).sub.2 Ph  2189 Cl NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Cl-4,6-(MeO).sub.2 Ph  2190 Cl NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Cl-4,6-(MeO).sub.2 Ph  2191 Cl NHCH(CH.sub.2 OMe).sub.2 2-Me-4-6-(MeO).sub.2 Ph  2192 Cl N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me-4,6-(MeO).sub.2 Ph  2193 Cl NHCH(Et)CH.sub.2 OMe 2-Me-4,6-(MeO).sub.2 Ph  2194 Cl N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me-4,6-(MeO).sub.2 Ph  2195 Cl NEt.sub.2 2-Me-4,6-(MeO).sub.2 Ph  2196 Cl NH-3-pentyl 2-Me-4,6-(MeO).sub.2 Ph  2197 Cl NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me-4,6-(MeO).sub.2 Ph  2198 Cl NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me-4,6-(MeO).sub.2 Ph  2199 Cl N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Br-4,6-(MeO).sub.2 Ph  2200 Cl NEt.sub.2 2-Br-4,6-(MeO).sub.2 Ph  2201 Cl NH-3-pentyl 2-Br-4,6-(MeO).sub.2 Ph  2202 Cl NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Br-4,6-(MeO).sub.2 Ph  2203 Cl NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Br-4,6-(MeO).sub.2 Ph  2204 Cl NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  2205 Cl NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  2206 Cl NHCH(CH.sub.2 OMe).sub.2 2-Me0-4-MePh  2207 Cl N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me0-4-MePh  2208 Cl NHCH(Et)CH.sub.2 OMe 2-Me0-4-MePh  2209 Cl N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me0-4-MePh  2210 Cl NEt.sub.2 2-Me0-4-MePh  2211 Cl NH-3-pentyl 2-Me0-4-MePh  2212 Cl NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me0-4-MePh  2213 Cl NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me0-4-MePh  2214 Cl NHCH(CH.sub.2 OMe).sub.2 2-Me0-4-MePh  2215 Cl N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me0-4-MePh  2216 Cl NHCH(Et)CH.sub.2 OMe 2-Me0-4-MePh  2217 Cl N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me0-4-MePh  2218 Cl NEt.sub.2 2-Me0-4-MePh  2219 Cl NH-3-pentyl 2-Me0-4-MePh  2220 Cl NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me0-4-MePh  2221 Cl NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me0-4-MePh  2222 Cl NHCH(CH.sub.2 OMe).sub.2 2-Me0-4-ClPh  2223 Cl N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me0-4-ClPh  2224 Cl NHCH(Et)CH.sub.2 OMe 2-Me0-4-ClPh  2225 Cl N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me0-4-ClPh  2226 Cl NEt.sub.2 2-Me0-4-ClPh  2227 Cl NH-3-pentyl 2-Me0-4-ClPh  2228 Cl NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me0-4-ClPh  2229 Cl NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me0-4-ClPh  2230 F N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4-Cl.sub.2 -Ph  2231 F N(Bu)Et 2,4-Cl.sub.2 -Ph  2232 F NHCH(Et)CH.sub.2 OMe 2,4-Cl.sub.2 -Ph  2233 F N(Pr)CH.sub.2 CH.sub.2 CN 2,4-Cl.sub.2 -Ph  2234 F NH-3-pentyl 2,4-Cl.sub.2 -Ph  2235 F NHCH(CH.sub.2 OMe).sub.2 2,4-Cl.sub.2 -Ph  2236 F NHCH(Et).sub.2 2,4-Me.sub.2 -Ph  2237 F NHCH(CH.sub.2 OMe).sub.2 2,4-Me.sub.2 -Ph  2238 F N(CH.sub.2 CH.sub.2 OMe).sub.2 2,4-Me.sub.2 -Ph  2239 F N(c-Pr)CH.sub.2 CH.sub.2 CN 2,4-Me.sub.2 -Ph  2240 F N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl,4-MePh  2241 F NHCH(CH.sub.2 OMe).sub.2 2-Cl,4-MePh  2242 F NHCH(Et).sub.2 2-Cl,4-MePh  2243 F NEt.sub.2 2,4-Me.sub.2 -Ph  2244 F N(Pr)CH.sub.2 CH.sub.2 CN 2,4-Me.sub.2 -Ph  2245 F N(Bu)CH.sub.2 CH.sub.2 CN 2,4-Me.sub.2 -Ph  2246 F NHCH(Et)CH.sub.2 OMe 2,4-Me.sub.2 -Ph  2247 F NHCH(Et).sub.2 2-Me-4-MeOPh  2248 F NHCH(CH.sub.2 OMe).sub.2 2-Me-4-MeOPh  2249 F N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me-4-MeOPh  2250 F (S)-NHCH(CH.sub.2 CH.sub.2 OMe)- 2-Me-4-MeOPh  2251  (CH.sub.2 OMe)  2252 F (S)-NHCH(CH.sub.2 CH.sub.2 OMe)-  2,4-Me.sub.2 -Ph  2253  (CH.sub.2 OMe)  2254 F N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me,4-ClPh  2255 F NHEt 2,4-Me.sub.2 -Ph  2256 F NHCH(Et).sub.2 2-Me,4-ClPh  2257 F NHCH(CH.sub.2 OMe).sub.2 2-Me,4-ClPh  2258 F N(Ac)Et 2,4-Me.sub.2 -Ph  2259 F (S)-NHCH(CH.sub.2 CH.sub.2 OMe)- 2-Me,4-ClPh  2260  (CH.sub.2 OMe)  2261 F N(Pr)CH.sub.2 CH.sub.2 CN 2-Me,4-MeOPh  2262 F NEt.sub.2 2-Me,4-MeOPh  2263 F (S)-NHCH(CH.sub.2 CH.sub.2 OMe)- 2-Cl,4-MePh  2264  (CH.sub.2 OMe)  2265 F NEt.sub.2 2-Cl,4-MePh  2266 F N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me,4-MeOPh  2267 F N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl,4-MePh  2268 F NHCH(Et)CH.sub.2 OMe 2-Me,4-MeOPh  2269 F NHCH(Et)CH.sub.2 OMe 2-Cl,4-MePh  2270 F NHCH(CH.sub.2 OMe).sub.2 2-Cl-4-MeOPh  2271 F N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4-MeOPh  2272 F NHCH(Et)CH.sub.2 OMe 2-Cl-4-MeOPh  2273 F N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl-4-MeOPh  2274 F NEt.sub.2 2-Cl-4-MeOPh  2275 F NH-3-pentyl 2-Cl-4-MeOPh  2276 F NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Cl-4-MeOPh  2277 F NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Cl-4-MeOPh  2278 F NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Br-4-MeOPh  2279 F NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Br-4-MeOPh  2280 F NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  2281 F NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  2282 F NHCH(CH.sub.2 OMe).sub.2 2-Cl-4,5-(MeO).sub.2 Ph  2283 F N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4,5-(MeO).sub.2 Ph  2284 F NHCH(Et)CH.sub.2 OMe 2-Cl-4,5-(MeO).sub.2 Ph  2285 F N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl-4,5-(MeO).sub.2 Ph  2286 F NEt.sub.2 2-Cl-4,5-(MeO).sub.2 Ph  2287 F NH-3-pentyl 2-Cl-4,5-(MeO).sub.2 Ph  2288 F NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Cl-4,5-(MeO).sub.2 Ph  2289 F NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Cl-4,5-(MeO).sub.2 Ph  2290 F NHCH(CH.sub.2 OMe).sub.2 2-Br-4,5-(MeO).sub.2 Ph  2291 F N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Br-4,5-(MeO).sub.2 Ph  2292 F NHCH(Et)CH.sub.2 OMe 2-Br-4,5-(MeO).sub.2 Ph  2293 F N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Br-4,5-(MeO).sub.2 Ph  2294 F NEt.sub.2 2-Br-4,5-(MeO).sub.2 Ph  2295 F NH-3-pentyl 2-Br-4,5-(MeO).sub.2 Ph  2296 F NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Br-4-5-(MeO).sub.2 Ph  2297 F NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Br-4,5-(MeO).sub.2 Ph  2298 F NHCH(CH.sub.2 OMe).sub.2 2-Cl-4,6-(MeO).sub.2 Ph  2299 F N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Cl-4,6-(MeO).sub.2 Ph  2300 F NHCH(Et)CH.sub.2 OMe 2-Cl-4,6-(MeO).sub.2 Ph  2301 F N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Cl-4,6-(MeO).sub.2 Ph  2302 F NEt.sub.2 2-Cl-4,6-(MeO).sub.2 Ph  2303 F NH-3-pentyl 2-Cl-4,6-(MeO).sub.2 Ph  2304 F NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Cl-4,6-(MeO).sub.2 Ph  2305 F NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Cl-4,6-(MeO).sub.2 Ph  2306 F NHCH(CH.sub.2 OMe).sub.2 2-Me-4,6-(MeO).sub.2 Ph  2307 F N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me-4,6-(MeO).sub.2 Ph  2308 F NHCH(Et)CH.sub.2 OMe 2-Me-4,6-(MeO).sub.2 Ph  2309 F N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me-4,6-(MeO).sub.2 Ph  2310 F NEt.sub.2 2-Me-4,6-(MeO).sub.2 Ph  2311 F NH-3-pentyl 2-Me-4,6-(MeO).sub.2 Ph  2312 F NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me-4,6-(MeO).sub.2 Ph  2313 F NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me-4,6-(MeO).sub.2 Ph  2314 F N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Br-4,6-(MeO).sub.2 Ph  2315 F NEt.sub.2 2-Br-4,6-(MeO).sub.2 Ph  2316 F NH-3-pentyl 2-Br-4,6-(MeO).sub.2 Ph  2317 F NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Br-4,6-(MeO).sub.2 Ph  2318 F NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Br-4,6-(MeO).sub.2 Ph  2319 F NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  2320 F NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me-4-MeOPh  2321 F NHCH(CH.sub.2 OMe).sub.2  2-Me0-4-MePh  2322 F N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me0-4-MePh  2323 F NHCH(Et)CH.sub.2 OMe 2-Me0-4-MePh  2324 F N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me0-4-MePh  2325 F NEt.sub.2 2-Me0-4-MePh  2326 F NH-3-pentyl 2-Me0-4-MePh  2327 F NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me0-4-MePh  2328 F NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me0-4-MePh  2329 F NHCH(CH.sub.2 OMe).sub.2 2-Me0-4-MePh  2330 F N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me0-4-MePh  2331 F NHCH(Et)CH.sub.2 OMe 2-Me0-4-MePh  2332 F N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me0-4-MePh  2333 F NEt.sub.2 2-Me0-4-MePh  2334 F NH-3-pentyl 2-Me0-4-MePh  2335 F NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me0-4-MePh  2336 F NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me0-4-MePh  2337 F NHCH(CH.sub.2 OMe).sub.2 2-Me0-4-ClPh  2338 F N(CH.sub.2 CH.sub.2 OMe).sub.2 2-Me0-4-ClPh  2339 F NHCH(Et)CH.sub.2 OMe 2-Me0-4-ClPh  2340 F N(c-Pr)CH.sub.2 CH.sub.2 CN 2-Me0-4-ClPh  2341 F NEt.sub.2 2-Me0-4-ClPh  2342 F NH-3-pentyl 2-Me0-4-ClPh  2343 F NHCH(Et)CH.sub.2 CH.sub.2 OMe 2-Me0-4-ClPh  2344 F NHCH(Me)CH.sub.2 CH.sub.2 OMe 2-Me0-4-ClPh  2345 Me NMe(CH.sub.2 CH.sub.2 OMe) 2,4-Cl.sub.2 -Ph  2346 Me NEt(CH.sub.2 CH.sub.2 OMe) 2,4-Cl.sub.2 -Ph  2347 Me NPr(CH.sub.2 CH.sub.2 OMe) 2,4-Cl.sub.2 -Ph  2348 Me NH-2-butyl 2,4-Cl.sub.2 -Ph  2349 Me cyclobutylamino 2,4-Cl.sub.2 -Ph  2350 Me 2-ethylpiperidinyl 2,4-Cl.sub.2 -Ph  2351 Me NMe(propargyl) 2,4-Cl.sub.2 -Ph  2352 Me NEt(propargyl) 2,4-Cl.sub.2 -Ph  2353 Me NEtMe 2,4-Cl.sub.2 -Ph  2354 Me NEtPr 2,4-Cl.sub.2 -Ph  2355 Me NMeBu 2,4-Cl.sub.2 -Ph  2356 Me NMe(CH.sub.2 cPr) 2,4-Cl.sub.2 -Ph  2357 Me NEt (CH.sub.2 cPr) 2,4-Cl.sub.2 -Ph  2358 Me NPr(CH.sub.2 cPr) 2,4-Cl.sub.2 -Ph  2359 Me NMe(CH.sub.2 CH.sub.2 OMe) 2-Me-4-MeOPh  2360 Me NEt(CH.sub.2 CH.sub.2 OMe) 2-Me-4-MeOPh  2361 Me NPr(CH.sub.2 CH.sub.2 OMe) 2-Me-4-MeOPh  2362 Me NH-2-butyl 2-Me-4-MeOPh  2363 Me cyclobutylamino 2-Me-4-MeOPh  2364 Me 2-ethylpiperidinyl 2-Me-4-MeOPh  2365 Me NMe(propargyl) 2-Me-4-MeOPh  2366 Me NEt(propargyl) 2-Me-4-MeOPh  2367 Me NEtMe 2-Me-4-MeOPh  2368 Me NEtPr 2-Me-4-MeOPh  2360 Me NMeBu 2-Me-4-MeOPh  2370 Me NMe(CH.sub.2 cPr) 2-Me-4-MeOPh  2371 Me NEt(CH.sub.2 cPr) 2-Me-4-MeOPh  2372 Me NPr(CH.sub.2 cPr) 2-Me-4-MeOPh  2373 Me NMe(CH.sub.2 CH.sub.2 OMe) 2,4-Me.sub.2 -Ph  2374 Me NEt(CH.sub.2 CH.sub.2 OMe) 2,4-Me.sub.2 -Ph  2375 Me NPr(CH.sub.2 CH.sub.2 OMe) 2,4-Me.sub.2 -Ph  2376 Me NH-2-butyl 2,4-Me.sub.2 -Ph  2377 Me cyclobutylamino 2,4-Me.sub.2 -Ph  2378 Me 2-ethylpiperidinyl 2,4-Me.sub.2 -Ph  2379 Me NMe(propargyl) 2,4-Me.sub.2 -Ph  2380 Me NEt(propargyl) 2,4-Me.sub.2 -Ph  2381 Me NEtMe 2,4-Me.sub.2 -Ph  2382 Me NEtPr 2,4-Me.sub.2 -Ph  2383 Me NMeBu 2,4-Me.sub.2 -Ph  2384 Me NMe(CH.sub.2 cPr) 2,4-Me.sub.2 -Ph  2385 Me NEt(CH.sub.2 cPr) 2,4-Me.sub.2 -Ph  2386 Me NPr(CH.sub.2 cPr) 2,4-Me.sub.2 -Ph  2387 Me NMe(CH.sub.2 CH.sub.2 OMe) 2-Cl-4-MeOPh  2388 Me NEt(CH.sub.2 CH.sub.2 OMe) 2-Cl-4-MeOPh  2389 Me NPr(CH.sub.2 CH.sub.2 OMe) 2-Cl-4-MeOPh  2390 Me NH-2-butyl 2-Cl-4-MeOPh  2391 Me cyclobutylamino 2-Cl-4-MeOPh  2392 Me 2-ethylpiperidinyl 2-Cl-4-MeOPh  2393 Me NMe(propargyl) 2-Cl-4-MeOPh  2394 Me NEt(propargyl) 2-Cl-4-MeOPh  2395 Me NEtMe 2-Cl-4-MeOPh  2396 Me NEtPr 2-Cl-4-MeOPh  2397 Me NMeBu 2-Cl-4-MeOPh  2398 Me NMe(CH.sub.2 cPr) 2-Cl-4-MeOPh  2399 Me NEt(CH.sub.2 cPr) 2-Cl-4-MeOPh  2400 Me NPr(CH.sub.2 cPr) 2-Cl-4-MeOPh  2401 Me NMe(CH.sub.2 CH.sub.2 OMe) 2,5-Me.sub.2 -4-MeOPh  2402 Me NEt(CH.sub.2 CH.sub.2 OMe) 2,5-Me.sub.2 -4-MeOPh  2403 Me NPr(CH.sub.2 CH.sub.2 OMe) 2,5-Me.sub.2 -4-MeOPh  2404 Me NH-2-butyl 2,5-Me.sub.2 -4-MeOPh  2405 Me cyclobutylamino 2,5-Me.sub.2 -4-MeOPh  2406 Me 2-ethylpiperidinyl 2,5-Me.sub.2 -4-MeOPh  2407 Me NMe(propargyl) 2,5-Me.sub.2 -4-MeOPh  2408 Me NEt(propargyl) 2,5-Me.sub.2 -4-MeOPh  2409 Me NEtMe 2,5-Me.sub.2 -4-MeOPh  2410 Me NEtPr 2,5-Me.sub.2 -4-MeOPh  2411 Me NMeBu 2,5-Me.sub.2 -4-MeOPh  2412 Me NMe(CH.sub.2 cPr) 2,5-Me.sub.2 -4-MeOPh  2413 Me NEt(CH.sub.2 cPr) 2,5-Me.sub.2 -4-MeOPh  2414 Me NPr(CH.sub.2 cPr) 2,5-Me.sub.2 -4-MeOPh  2415 Cl NMe(CH.sub.2 CH.sub.2 OMe) 2,4-Cl.sub.2 -Ph  2416 Cl NEt(CH.sub.2 CH.sub.2 OMe) 2,4-Cl.sub.2 -Ph  2417 Cl NPr(CH.sub.2 CH.sub.2 OMe) 2,4-Cl.sub.2 -Ph  2418 Cl NH-2-butyl 2,4-Cl.sub.2 -Ph  2419 Cl cyclobutylamino 2,4-Cl.sub.2 -Ph  2420 Cl 2-ethylpiperidinyl 2,4-Cl.sub.2 -Ph  2421 Cl NMe(propargyl) 2,4-Cl.sub.2 -Ph  2422 Cl NEt(propargyl) 2,4-Cl.sub.2 -Ph  2423 Cl NEtMe 2,4-Cl.sub.2 -Ph  2424 Cl NEtPr 2,4-Cl.sub.2 -Ph  2425 Cl NMeBu 2,4-Cl.sub.2 -Ph  2426 Cl NMe(CH.sub.2 cPr) 2,4-Cl.sub.2 -Ph  2427 Cl NEt(CH.sub.2 cPr) 2,4-Cl.sub.2 -Ph  2428 Cl NPr(CH.sub.2 cPr) 2,4-Cl.sub.2 -Ph  2429 Cl NMe(CH.sub.2 CH.sub.2 OMe) 2-Me-4-MeOPh  2430 Cl NEt(CH.sub.2 CH.sub.2 OMe) 2-Me-4-MeOPh  2431 Cl NPr(CH.sub.2 CH.sub.2 OMe) 2-Me-4-MeOPh  2432 Cl NH-2-butyl 2-Me-4-MeOPh  2433 Cl cyclobutylamino 2-Me-4-MeOPh  2434 Cl 2-ethylpiperidinyl 2-Me-4-MeOPh  2435 Cl NMe(propargyl) 2-Me-4-MeOPh  2436 Cl NEt(propargyl) 2-Me-4-MeOPh  2437 Cl NEtMe 2-Me-4-MeOPh  2438 Cl NEtPr 2-Me-4-MeOPh  2439 Cl NMeBu 2-Me-4-MeOPh  2440 Cl NMe(CH.sub.2 cPr) 2-Me-4-MeOPh  2441 Cl NEt(CH.sub.2 cPr) 2-Me-4-MeOPh  2442 Cl NPr(CH.sub.2 cPr) 2-Me-4-MeOPh  2443 Cl NMe(CH.sub.2 CH.sub.2 OMe) 2,4-Me.sub.2 -Ph  2444 Cl NEt(CH.sub.2 CH.sub.2 OMe) 2,4-Me.sub.2 -Ph  2445 Cl NPr(CH.sub.2 CH.sub.2 OMe) 2,4-Me.sub.2 -Ph  2446 Cl NH-2-butyl 2,4-Me.sub.2 -Ph  2447 Cl cyclobutylamino 2,4-Me.sub.2 -Ph  2448 Cl 2-ethylpiperidinyl 2,4-Me.sub.2 -Ph  2449 Cl NMe(propargyl) 2,4-Me.sub.2 -Ph  2450 Cl NEt(propargyl) 2,4-Me.sub.2 -Ph  2451 Cl NEtMe 2,4-Me.sub.2 -Ph  2452 Cl NEtPr 2,4-Me.sub.2 -Ph  2453 Cl NMeBu 2,4-Me.sub.2 -Ph  2454 Cl NMe(CH.sub.2 cPr) 2,4-Me.sub.2 -Ph  2455 Cl NEt(CH.sub.2 cPr) 2,4-Me.sub.2 -Ph  2456 Cl NPr(CH2cPr) 2,4-Me.sub.2 -Ph  2457 Cl NMe(CH.sub.2 CH.sub.2 OMe) 2-Cl-4-MeOPh  2458 Cl NEt(CH.sub.2 CH.sub.2 OMe) 2-Cl-4-MeOPh  2459 Cl NPr(CH.sub.2 CH.sub.2 OMe) 2-Cl-4-MeOPh  2460 Cl NH-2-butyl 2-Cl-4-MeOPh  2461 Cl cyc1obutylamino 2-Cl-4-MeOPh  2462 Cl 2-ethylpiperidinyl 2-Cl-4-MeOPh  2463 Cl NMe(propargyl) 2-Cl-4-MeOPh  2464 Cl NEt(propargyl) 2-Cl-4-MeOPh  2465 Cl NEtMe 2-Cl-4-MeOPh  2466 Cl NEtPr 2-Cl-4-MeOPh  2467 Cl NMeBu 2-Cl-4-MeOPh  2468 Cl NMe(CH.sub.2 cPr) 2-Cl-4-MeOPh  2469 Cl NEt(CH.sub.2 cPr) 2-Cl-4-MeOPh  2470 Cl NPr(CH.sub.2 cPr) 2-Cl-4-MeOPh  2471 Cl NMe(CH.sub.2 CH.sub.2 OMe) 2,5-Me.sub.2 -4-MeOPh  2472 Cl NEt(CH.sub.2 CH.sub.2 OMe) 2,5-Me.sub.2 -4-MeOPh  2473 Cl NPr(CH.sub.2 CH.sub.2 OMe) 2,5-Me.sub.2 -4-MeOPh  2474 Cl NH-2-butyl 2,5-Me.sub.2 -4-MeOPh  2475 Cl cyclobutylamino 2,5-Me.sub.2 -4-MeOPh  2476 Cl 2-ethylpiperidinyl 2,5-Me.sub.2 -4-MeOPh  2477 Cl NMe(propargyl) 2,5-Me.sub.2 -4-MeOPh  2478 Cl NEt(propargyl) 2,5-Me.sub.2 -4-MeOPh  2479 Cl NEtMe 2,5-Me.sub.2 -4-MeOPh  2480 Cl NEtPr 2,5-Me.sub.2 -4-MeOPh  2481 Cl NMeBu 2,5-Me.sub.2 -4-MeOPh  2482 Cl NMe(CH.sub.2 cPr) 2,5-Me.sub.2 -4-MeOPh  2483 Cl NEt(CH.sub.2 cPr) 2,5-Me.sub.2 -4-MeOPh  2484 Cl NPr(CH.sub.2 cPr) 2,5-Me.sub.2 -4-MeOPh  2485 F NMe(CH.sub.2 CH.sub.2 OMe) 2,4-Cl.sub.2 -Ph  2486 F NEt(CH.sub.2 CH.sub.2 OMe) 2,4-Cl.sub.2 -Ph  2487 F NPr(CH.sub.2 CH.sub.2 OMe) 2,4-Cl.sub.2 -Ph  2488 F NH-2-butyl 2,4-Cl.sub.2 -Ph  2489 F cyclobutylamino 2,4-Cl.sub.2 -Ph  2490 F 2-ethylpiperidinyl 2,4-Cl.sub.2 -Ph  2491 F NMe(propargyl) 2,4-Cl.sub.2 -Ph  2492 F NEt(propargyl) 2,4-Cl.sub.2 -Ph  2493 F NEtMe 2,4-Cl.sub.2 -Ph  2494 F NEtPr 2,4-Cl.sub.2 -Ph  2495 F NMeBu 2,4-Cl.sub.2 -Ph  2496 F NMe(CH.sub.2 cPr) 2,4-Cl.sub.2 -Ph  2497 F NEt(CH.sub.2 cPr) 2,4-Cl.sub.2 -Ph  2498 F NPr(CH.sub.2 cPr) 2,4-Cl.sub.2 -Ph  2499 F NMe(CH.sub.2 CH.sub.2 OMe) 2-Me-4-MeOPh  2500 F NEt(CH.sub.2 CH.sub.2 OMe) 2-Me-4-MeOPh  2501 F NPr(CH.sub.2 CH.sub.2 OMe) 2-Me-4-MeOPh  2502 F NH-2-butyl 2-Me-4-MeOPh  2503 F cyclobutylamino 2-Me-4-MeOPh  2504 F 2-ethylpiperidinyl 2-Me-4-MeOPh  2505 F NMe(propargyl) 2-Me-4-MeOPh  2506 F NEt(propargyl) 2-Me-4-MeOPh  2507 F NEtMe 2-Me-4-MeOPh  2508 F NEtPr 2-Me-4-MeOPh  2509 F NMeBu 2-Me-4-MeOPh  2510 F NMe(CH.sub.2 cPr) 2-Me-4-MeOPh  2511 F NEt(CH.sub.2 cPr) 2-Me-4-MeOPh  2512 F NPr(CH.sub.2 cPr) 2-Me-4-MeOPh  2513 F NMe(CH.sub.2 CH.sub.2 OMe) 2,4-Me.sub.2 -Ph  2514 F NEt(CH.sub.2 CH.sub.2 OMe) 2,4-Me.sub.2 -Ph  2515 F NPr(CH.sub.2 CH.sub.2 OMe) 2,4-Me.sub.2 -Ph  2516 F NH-2-butyl 2,4-Me.sub.2 -Ph  2517 F cyclobutylamino 2,4-Me.sub.2 -Ph  2518 F 2-ethylpiperidinyl 2,4-Me.sub.2 -Ph  2519 F NMe(propargyl) 2,4-Me.sub.2 -Ph  2520 F NEt(propargyl) 2,4-Me.sub.2 -Ph  2521 F NEtMe 2,4-Me.sub.2 -Ph  2522 F NEtPr 2,4-Me.sub.2 -Ph  2523 F NMeBu 2,4-Me.sub.2 -Ph  2524 F NMe(CH.sub.2 cPr) 2,4-Me.sub.2 -Ph  2525 F NEt(CH.sub.2 cPr) 2,4-Me.sub.2 -Ph  2526 F NPr(CH.sub.2 cPr) 2,4-Me.sub.2 -Ph  2527 F NMe(CH.sub.2 CH.sub.2 OMe) 2-Cl-4-MeOPh  2528 F NEt(CH.sub.2 CH.sub.2 OMe) 2-Cl-4-MeOPh  2529 F NPr(CH.sub.2 CH.sub.2 OMe) 2-Cl-4-MeOPh  2530 F NH-2-butyl 2-Cl-4-MeOPh  2531 F cyclobutylamino 2-Cl-4-MeOPh  2532 F 2-ethylpiperidinyl 2-Cl-4-MeOPh  2533 F NMe(propargyl) 2-Cl-4-MeOPh  2534 F NEt(propargyl) 2-Cl-4-MeOPh  2535 F NEtMe 2-Cl-4-MeOPh  2536 F NEtPr 2-Cl-4-MeOPh  2537 F NMeBu 2-Cl-4-MeOPh  2538 F NMe(CH.sub.2 cPr) 2-Cl-4-MeOPh  2539 F NEt(CH.sub.2 cPr) 2-Cl-4-MeOPh  2540 F NPr(CH.sub.2 cPr) 2-Cl-4-MeOPh  2541 F NMe(CH.sub.2 CH.sub.2 OMe) 2,5-Me.sub.2 -4-MeOPh  2542 F NEt(CH.sub.2 CH.sub.2 OMe) 2,5-Me.sub.2 -4-MeOPh  2543 F NPr(CH.sub.2 CH.sub.2 OMe) 2,5-Me.sub.2 -4-MeOPh  2544 F NH-2-butyl 2,5-Me.sub.2 -4-MeOPh  2545 F cyclobutylamino 2,5-Me.sub.2 -4-MeOPh  2546 F 2-ethylpiperidinyl 2,5-Me.sub.2 -4-MeOPh  2547 F NMe(propargyl) 2,5-Me.sub.2 -4-MeOPh  2548 F NEt(propargyl) 2,5-Me.sub.2 -4-MeOPh  2549 F NEtMe 2,5-Me.sub.2 -4-MeOPh  2550 F NEtPr 2,5-Me.sub.2 -4-MeOPh  2551 F NMeBu 2,5-Me.sub.2 -4-MeOPh  2552 F NMe(CH.sub.2 cPr) 2,5-Me.sub.2 -4-MeOPh  2553 F NEt(CH.sub.2 cPr) 2,5-Me.sub.2 -4-MeOPh  2554 F NPr(CH.sub.2 cPr) 2,5-Me.sub.2 -4-MeOPh__________________________________________________________________________ .sup.a) CI-HRMS: Calcd: 367.2498; Found: 367.2468 (M + H).sup.+- .sup.b) CIHRMS: Calcd: 387.1952; Found: 387.1939 (M + H).sup.+-</pre></p><heading>Utility</heading><p>CRF-R1 Receptor Binding Assay for the Evaluation of Biological Activity</p><p>The following is a description of the isolation of cell membranes containing cloned human CRF-R1 receptors for use in the standard binding assay as well as a description of the assay itself.</p><p>Messenger RNA was isolated from human hippocampus. The mRNA was reverse transcribed using oligo (dt) 12-18 and the coding region was amplified by PCR from start to stop codons The resulting PCR fragment was cloned into the EcoRV site of pGEMV, from whence the insert was reclaimed using XhoI+XbaI and cloned into the XhoI+XbaI sites of vector pm3ar (which contains a CMV promoter, the SV40 `t` splice and early poly A signals, an Epstein-Barr viral origin of replication, and a hygromycin selectable marker). The resulting expression vector, called phchCRFR was transfected in 293EBNA cells and cells retaining the episome were selected in the presence of 400 μM hygromycin. Cells surviving 4 weeks of selection in hygromycin were pooled, adapted to growth in suspension and used to generate membranes for the binding assay described below. Individual aliquots containing approximately 1 were then centrifuged to form a pellet and frozen.</p><p>For the binding assay a frozen pellet described above containing 293EBNA cells transfected with hCRFR1 receptors is homogenized in 10 ml of ice cold tissue buffer (50 mM HEPES buffer pH 7.0, containing 10 mM MgCl.sub.2, 2 mM EGTA, 1 μg/l aprotinin, 1 μg/ml leupeptin and 1 μg/ml pepstatin). The homogenate is centrifuged at 40,000 12 min and the resulting pellet rehomogenized in 10 ml of tissue buffer. After another centrifugation at 40,000 resuspended to a protein concentration of 360 μg/ml to be used in the assay.</p><p>Binding assays are performed in 96 well plates; each well having a 300 μl capacity. To each well is added 50 μl of test drug dilutions (final concentration of drugs range from 10-.sup.10 -10-.sup.5 M), 100 μl of .sup.125 I-ovine-CRF (.sup.125,-o-CRF) (final concentration 150 pM) and 150 μl of the cell homogenate described above. Plates are then allowed to incubate at room temperature for 2 hours before filtering the incubate over GF/F filters (presoaked with 0.3% polyethyleneimine) using an appropriate cell harvester. Filters are rinsed 2 times with ice cold assay buffer before removing individual filters and assessing them for radioactivity on a gamma counter.</p><p>Curves of the inhibition of .sup.125 I-o-CRF binding to cell membranes at various dilutions of test drug are analyzed by the iterative curve fitting program LIGAND [P. J. Munson and D. Rodbard, Anal. Biochem. 107:220 (1980), which provides Ki values for inhibition which are then used to assess biological activity.</p><p>A compound is considered to be active if it has a K.sub.i value of less than about 10000 mM for the inhibition of CRF.</p><p>Inhibition of CRF-Stimulated Adenylate Cyclase Activity</p><p>Inhibition of CRF-stimulated adenylate cyclase activity can be performed as described by G. Battaglia et al. Synapse 1:572 (1987). Briefly, assays are carried out at 37 mM Tris-HCl (pH 7.4 at 37 BSA, 1 mM isobutylmethylxanthine (IBMX), 250 units/ml phosphocreatine kinase, 5 mM creatine phosphate, 100 mM guanosine 5'-triphosphate, 100 nM oCRF, antagonist peptides (concentration range 10.sup.-9 to 10.sup.-6 m) and 0.8 mg original wet weight tissue (approximately 40-60 mg protein). Reactions are initiated by the addition of 1 mM ATP/.sup.32 P]ATP (approximately 2-4 mCi/tube) and terminated by the addition of 100 ml of 50 mM Tris-HCL, 45 mM ATP and 2% sodium dodecyl sulfate. In order to monitor the recovery of cAMP, 1 μl of [.sup.3 H]cAMP (approximately 40,000 dpm) is added to each tube prior to separation. The separation of [.sup.32 P]cAMP from [.sup.32 P]ATP is performed by sequential elution over Dowex and alumina columns.</p><p>In vivo Biological Assay</p><p>The in vivo activity of the compounds of the present invention can be assessed using any one of the biological assays available and accepted within the art. Illustrative of these tests include the Acoustic Startle Assay, the Stair Climbing Test, and the Chronic Administration Assay. These and other models useful for the testing of compounds of the present invention have been outlined in C. W. Berridge and A. J. Dunn Brain Research Reviews 15:71 (1990). Compounds may be tested in any species of rodent or small mammal.</p><p>Compounds of this invention have utility in the treatment of inbalances associated with abnormal levels of corticotropin releasing factor in patients suffering from depression, affective disorders, and/or anxiety.</p><p>Compounds of this invention can be administered to treat these abnormalities by means that produce contact of the active agent with the agent's site of action in the body of a mammal. The compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals either as individual therapeutic agent or in combination of therapeutic agents. They can be administered alone, but will generally be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.</p><p>The dosage administered will vary depending on the use and known factors such as pharmacodynamic character of the particular agent, and its mode and route of administration; the recipient's age, weight, and health; nature and extent of symptoms; kind of concurrent treatment; frequency of treatment; and desired effect. For use in the treatment of said diseases or conditions, the compounds of this invention can be orally administered daily at a dosage of the active ingredient of 0.002 to 200 mg/kg of body weight. Ordinarily, a dose of 0.01 to 10 mg/kg in divided doses one to four times a day, or in sustained release formulation will be effective in obtaining the desired pharmacological effect.</p><p>Dosage forms (compositions) suitable for administration contain from about 1 mg to about 100 mg of active ingredient per unit. In these pharmaceutical compositions, the active ingredient will ordinarily be present in an amount of about 0.5 to 95% by weight based on the total weight of the composition.</p><p>The active ingredient can be administered orally is solid dosage forms, such as capsules, tablets and powders; or in liquid forms such as elixirs, syrups, and/or suspensions. The compounds of this invention can also be administered parenterally in sterile liquid dose formulations.</p><p>Gelatin capsules can be used to contain the active ingredient and a suitable carrier such as but not limited to lactose, starch, magnesium stearate, steric acid, or cellulose derivatives. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of time. Compressed tablets can be sugar-coated or film-coated to mask any unpleasant taste, or used to protect the active ingredients from the atmosphere, or to allow selective disintegration of the tablet in the gastrointestinal tract.</p><p>Liquid dose forms for oral administration can contain coloring or flavoring agents to increase patient acceptance.</p><p>In general, water, pharmaceutically acceptable oils, saline, aqueous dextrose (glucose), and related sugar solutions and glycols, such as propylene glycol or polyethylene glycol, are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, butter substances. Antioxidizing agents, such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or in combination, are suitable stabilizing agents. Also used are citric acid and its salts, and EDTA. In addition, parenteral solutions can contain preservatives such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.</p><p>Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences", A. Osol, a standard reference in the field.</p><p>Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows:</p><heading>Capsules</heading><p>A large number of units capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 mg of powdered active ingredient, 150 mg lactose, 50 mg cellulose, and 6 mg magnesium stearate.</p><heading>Soft Gelatin Capsules</heading><p>A mixture of active ingredient in a digestible oil such as soybean, cottonseed oil, or olive oil is prepared and injected by means of a positive displacement was pumped into gelatin to form soft gelatin capsules containing 100 mg of the active ingredient. The capsules were washed and dried.</p><heading>Tablets</heading><p>A large number of tablets are prepared by conventional procedures so that the dosage unit was 100 mg active ingredient, 0.2 mg of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch, and 98.8 mg lactose. Appropriate coatings may be applied to increase palatability or delayed adsorption.</p><p>The compounds of this invention may also be used as reagents or standards in the biochemical study of neurological function, dysfunction, and disease.</p><p>Although the present invention has been described and exemplified in terms of certain preferred embodiments, other embodiments will be apparent to those skilled in the art. The invention is, therefore, not limited to the particular embodiments described and exemplified, but is capable of modification or variation without departing from the spirit of the invention, the full scope of which is delineated by the appended claims.</p></description><claims lang="EN" load-source="us" status="new"><claim-statement>What is claimed is:</claim-statement><claim num="1"><claim-text>1. A compound of Formulae (1) or (2): ##STR48## and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein:<claim-text>Z is N or CR.sup.2 ;</claim-text><claim-text>Ar is selected from phenyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, benzothienyl, benzofuranyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, indanyl, 1,2-benzopyranyl, 3,4-dihydro-1,2-benzopyranyl, tetralinyl, each Ar optionally substituted with 1 to 5 R.sup.4 groups and each Ar is attached to an unsaturated carbon atom;</claim-text><claim-text>R is independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.7 cycloalkylalkyl, halo, CN, C.sub.1 -C.sub.4 haloalkyl;</claim-text><claim-text>R.sup.1 is independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, halo, CN, C.sub.1 -C.sub.4 haloalkyl, C.sub.1 -C.sub.12 hydroxyalkyl, C.sub.2 -C.sub.12 alkoxyalkyl, C.sub.2 -C.sub.10 cyanoalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, NR.sup.9 R.sup.10, C.sub.1 -C.sub.4 alkyl-NR.sup.9 R.sup.10, NR.sup.9 COR.sup.10, OR.sup.11, SH or S(O).sub.n R.sup.12 ;</claim-text><claim-text>R.sup.2 is selected from H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, C.sub.1 -C.sub.4 hydroxyalkyl, halo, CN, --NR.sup.6 R.sup.7, NR.sup.9 COR.sup.10, --NR.sup.6 S(O).sub.n R.sup.7, S(O).sub.n NR.sup.6 R.sup.7, C.sub.1 -C.sub.4 haloalkyl, --OR.sup.7, SH or --S(O).sub.n R.sup.12 ;</claim-text><claim-text>R.sup.3 is selected from:<claim-text>--H, OR.sup.7, SH, S(O).sub.n R.sup.13, COR.sup.7, CO.sub.2 R.sup.7, OC(O)R.sup.13, NR.sup.8 COR.sup.7, N(COR.sup.7).sub.2, NR.sup.8 CONR.sup.6 R.sup.7, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.6 R.sup.7, NR.sup.6a R.sup.7a, N(OR.sup.7)R.sup.6, CONR.sup.6 R.sup.7, aryl, heteroaryl and heterocyclyl, or</claim-text><claim-text>--C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.5 -C.sub.8 cycloalkenyl, C.sub.4 -C.sub.12 cycloalkylalkyl or C.sub.6 -C.sub.10 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl and heterocyclyl;</claim-text></claim-text><claim-text>R.sup.4 is independently selected at each occurrence from:<claim-text>C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, NO.sub.2, halo, CN, C.sub.1 -C.sub.4 haloalkyl, NR.sup.6 R.sup.7, NR.sup.8 COR.sup.7, NR.sup.8 CO.sub.2 R.sup.7, COR.sup.7, OR.sup.7, CONR.sup.6 R.sup.7, CO(NOR.sup.9)R.sup.7, CO.sub.2 R.sup.7, or S(O).sub.n R.sup.7, where each such C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.6 cycloalkyl and C.sub.4 -C.sub.12 cycloalkylalkyl are optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, NO.sub.2, halo, CN, NR.sup.6 R.sup.7, NR.sup.8 COR.sup.7, NR.sup.8 CO.sub.2 R.sup.7, COR.sup.7 OR.sup.7, CONR.sup.6 R.sup.7, CO.sub.2 R.sup.7, CO(NOR.sup.9)R.sup.7, or S(O).sub.n R.sup.7 ;</claim-text></claim-text><claim-text>R.sup.6, R7, R.sup.6a and R.sup.7a are independently selected at each occurrence from:<claim-text>--H,</claim-text><claim-text>--C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.1 -C.sub.10 haloalkyl with 1-10 halogens, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, C.sub.5 -C.sub.10 cycloalkenyl, or C.sub.6 -C.sub.14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl,</claim-text><claim-text>-aryl, aryl(C.sub.1 -C.sub.4 alkyl), heteroaryl, heteroaryl(C.sub.1 -C.sub.4 alkyl), heterocyclyl or heterocyclyl(C.sub.1 -C.sub.4 alkyl),<claim-text>alternatively, NR.sup.6 R.sup.7 and NR.sup.6a R.sup.7a are independently piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine, each optionally substituted with 1-3 C.sub.1 -C.sub.4 alkyl groups;</claim-text></claim-text></claim-text><claim-text>R.sup.8 is independently selected at each occurrence from H or C.sub.1 -C.sub.4 alkyl;</claim-text><claim-text>R.sup.9 and R.sup.10 are independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, or C.sub.3 -C.sub.6 cycloalkyl;</claim-text><claim-text>R.sup.11 is selected from H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, or C.sub.3 -C.sub.6 cycloalkyl;</claim-text><claim-text>R.sup.12 is C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 haloalkyl;</claim-text><claim-text>R.sup.13 is selected from C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, aryl, aryl(C.sub.1 -C.sub.4 alkyl)-, heteroaryl or heteroaryl(C.sub.1 -C.sub.4 alkyl)-;</claim-text><claim-text>R.sup.14 is selected from C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, or C.sub.4 -C.sub.12 cycloalkylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, and C.sub.1 -C.sub.6 alkylthio, C.sub.1 -C.sub.6 alkylsulfinyl and C.sub.1 -C.sub.6 alkylsulfonyl;</claim-text><claim-text>R.sup.15 and R.sup.16 are independently selected at each occurrence from H, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.10 cycloalkyl, C.sub.4 -C.sub.16 cycloalkylalkyl, except that for S(O).sub.n R.sup.15, R.sup.15 cannot be H;</claim-text><claim-text>aryl is phenyl or naphthyl, each optionally substituted with 1 to 5 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.16 R.sup.15, and CONR.sup.16 R.sup.15 ;</claim-text><claim-text>heteroaryl is pyridyl, pyrimidinyl, triazinyl, furanyl, pyranyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, isoxazolyl, pyrazolyl, 2,3-dihydrobenzothienyl or 2,3-dihydrobenzofuranyl, each being optionally substituted with 1 to 5 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, --COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.16 R.sup.15, and CONR.sup.16 R.sup.15 ;</claim-text><claim-text>heterocyclyl is saturated or partially saturated heteroaryl, optionally substituted with 1 to 5 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.15 R.sup.16, and CONR.sup.16 R.sup.15 ;</claim-text><claim-text>n is independently at each occurrence 0, 1 or 2;</claim-text><claim-text>with the provisos that:<claim-text>(1) when Z is CR.sup.2, then R.sup.2 is not --NR.sup.6 SO.sub.2 R.sup.7 or --SO.sub.2 NR.sup.6 R.sup.7 ;</claim-text><claim-text>(2) when Z is CR.sup.2 and R.sup.2 is H, phenyl or alkyl and R.sup.3 is NR.sup.8 COR.sup.7 and Ar is phenyl or phenyl substituted with phenylthio, then R.sup.7 is not aryl, aryl(C.sub.1 -C.sub.4 alkyl), heteroaryl, heteroaryl(C.sub.1 -C.sub.4 alkyl), heterocyclyl or heterocycly(C.sub.1 -C.sub.4 alkyl);</claim-text><claim-text>(3) when Z is CR.sup.2 and R.sup.2 is H or alkyl and Ar is phenyl and R.sup.3 is SR.sup.13 or NR.sup.6a R.sup.7a, then R.sup.13 is not aryl or heteroaryl and R.sup.6a and R.sup.7a are not H or aryl; or</claim-text><claim-text>(4) when Z is CR.sup.2 and R.sup.1 is OR.sup.11 and R.sup.2 is H and R.sup.3 is OR.sup.7 and R.sup.7 and R.sup.11 are both H, then Ar is not phenyl, p-Br-phenyl, p-Cl-phenyl, p-NHCOCH.sub.3 -phenyl, p-CH.sub.3 -phenyl, pyridyl or naphthyl;</claim-text><claim-text>(5) when Z is CR.sup.2 and R.sup.2 is H and Ar is unsubstituted phenyl and R.sup.3 is CH.sub.3, C.sub.2 H.sub.5, CF.sub.3 or C.sub.6 H.sub.4 F, then R.sub.1 is not CF.sub.3 or C.sub.2 F.sub.5 ;</claim-text><claim-text>(6) when R is H and Z is CR.sup.2 and R.sup.2 is OH and R.sup.1 and R.sup.3 are H, then Ar is not phenyl;</claim-text><claim-text>(7) when R is H and Z is CR.sup.2 and R.sup.2 is OH or NH.sub.2 and R.sup.1 and R.sup.3 are CH.sub.3, then Ar is not 4-phenyl-3-cyano-2-aminopyrid-2-yl; and</claim-text><claim-text>(7) when R is H and Z is CR.sup.2 and R.sup.1 and R.sup.2 are CH.sub.3 and Ar is 2-methyl-4-methoxyphenyl, then R.sup.3 is not 3-pentylamino.</claim-text></claim-text></claim-text></claim><claim num="2"><claim-text>2. A compound of claim 1 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, each optionally substituted with 1 to 4 R.sup.4 substituents.</claim-text></claim><claim num="3"><claim-text>3. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1.</claim-text></claim><claim num="4"><claim-text>4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 2.</claim-text></claim><claim num="5"><claim-text>5. A compound of Formula (2) of claim 1 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof.</claim-text></claim><claim num="6"><claim-text>6. A compound of claim 5 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R.sup.4 substituents.</claim-text></claim><claim num="7"><claim-text>7. A compound of claim 5 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein R.sup.3 is NR.sup.6a R.sup.7a or OR.sup.7.</claim-text></claim><claim num="8"><claim-text>8. A compound of claim 5 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R.sup.4 substituents, and R.sup.3 is NR.sup.6a R.sup.7a or OR.sup.7.</claim-text></claim><claim num="9"><claim-text>9. A compound of Formula (1) of claim 1 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein Z is CR.sup.2.</claim-text></claim><claim num="10"><claim-text>10. A compound of claim 9 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl and each Ar is optionally substituted with 1 to 4 R.sup.4 substituents.</claim-text></claim><claim num="11"><claim-text>11. A compound of claim 9 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein R.sup.3 is NR.sup.6a R.sup.7a or OR.sup.7.</claim-text></claim><claim num="12"><claim-text>12. A compound of claim 9 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R.sup.4 substituents, and R.sup.3 is NR.sup.6a R.sup.7a or OR.sup.7.</claim-text></claim><claim num="13"><claim-text>13. A compound of claim 12 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein R.sup.6a and R.sup.7a are independently H or C.sub.1 -C.sub.10 alkyl, and each such C.sub.1 -C.sub.10 alkyl is optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, R.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl.</claim-text></claim><claim num="14"><claim-text>14. A compound of claim 9 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein<claim-text>--Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, and each Ar is optionally substituted with 1 to 4 R.sup.4 substituents,</claim-text><claim-text>--R.sup.3 is NR.sup.6a R.sup.7a or OR.sup.7 and</claim-text><claim-text>--R.sup.1 and R.sup.2 are independently selected from H, C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl.</claim-text></claim-text></claim><claim num="15"><claim-text>15. A compound of claim 14 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein R.sup.6a and R.sup.7a are independently H or C.sub.1 -C.sub.10 alkyl, and each such C.sub.1 -C.sub.10 alkyl is optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, R.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl.</claim-text></claim><claim num="16"><claim-text>16. A compound of Formula (51) ##STR49## and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof selected from the group consisting of:</claim-text></claim><claim num="17"><claim-text>17. A compound of Formula (70) ##STR50## and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof selected from the group consisting of:</claim-text></claim><claim num="18"><claim-text>18. A compound of claim 16 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof, wherein said compound is selected from: 7-(diethylamino)-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl-[1,5-a]-pyrazolopyrimidine and 7-(N-(3-cyanopropyl)-N-propylamino)-2,5-dimethyl-3-(2,4-dimethylphenyl)-[1,5-a]-pyrazolopyrimidine.</claim-text></claim><claim num="19"><claim-text>19. A compound of claims 1, 5 and 9 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein: R.sup.1 is not H and R.sup.1 is independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, halo, CN, C.sub.1 -C.sub.4 haloalkyl, C.sub.1 -C.sub.12 hydroxyalkyl, C.sub.2 -C.sub.12 alkoxyalkyl, C.sub.2 -C.sub.10 cyanoalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, NR.sup.9 R.sup.10, C.sub.1 -C.sub.4 alkyl-NR.sup.9 R.sup.10, NR.sup.9 COR.sup.10, OR.sup.11, SH or S(O).sub.n R.sup.12.</claim-text></claim><claim num="20"><claim-text>20. A compound of claims 1, 5 and 9 and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof wherein R.sup.1 is H.</claim-text></claim><claim num="21"><claim-text>21. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claims 5, 9, 16 and 17.</claim-text></claim><claim num="22"><claim-text>22. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 19.</claim-text></claim><claim num="23"><claim-text>23. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 20.</claim-text></claim><claim num="24"><claim-text>24. A method of treating anxiety in mammals, comprising administering to the mammal a therapeutically effective amount of a compound of Formulae (1) or (2): ##STR51## and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof, wherein:<claim-text>Z is N or CR.sup.2 ;</claim-text><claim-text>Ar is selected from phenyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, benzothienyl, benzofuranyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, indanyl, 1,2-benzopyranyl, 3,4-dihydro-1,2-benzopyranyl, tetralinyl, each Ar optionally substituted with 1 to 5 R.sup.4 groups and each Ar is attached to an unsaturated carbon atom;</claim-text><claim-text>R is independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.7 cycloalkylalkyl, halo, CN, C.sub.1 -C.sub.4 haloalkyl;</claim-text><claim-text>R.sup.1 is independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, halo, CN, C.sub.1 -C.sub.4 haloalkyl, C.sub.1 -C.sub.12 hydroxyalkyl, C.sub.2 -C.sub.12 alkoxyalkyl, C.sub.2-C.sub.10 cyanoalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, NR.sup.9 R.sup.10, C.sub.1 -C.sub.4 alkyl-NR.sup.9 R.sup.10, NR.sup.9 COR.sup.10, OR.sup.11, SH or S(O).sub.n R.sup.12 ;</claim-text><claim-text>R.sup.2 is selected from H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.10 cycloaluylalkyl C.sub.1 -C.sub.4 hydroxyalkyl, halo, CN, --NR.sup.6 R.sup.7, NR.sup.9 COR.sup.10, --NR.sup.6 S(O).sub.n R.sup.7, S(O).sub.n NR.sup.6 R.sup.7, C.sub.1 -C.sub.4 haloalkyl, --OR.sup.7, SH or --S(O).sub.n R.sup.12 ;</claim-text><claim-text>R.sup.3 is selected from:<claim-text>--H, OR.sup.7, SH, S(O).sub.n R.sup.13, COR.sup.7, CO.sub.2 R.sup.7, OC(O)R.sup.13, NR.sup.8 COR.sup.7, N(COR.sup.7).sub.2, NR.sup.8 CONR.sup.6 R.sup.7, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.6 R.sup.7, NR.sup.6a R.sup.7a, N(OR.sup.7)R.sup.6, CONR.sup.6 R.sup.7, aryl, heteroaryl and heterocyclyl, or</claim-text><claim-text>--C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.5 -C.sub.8 cycloalkenyl, C.sub.4 -C.sub.12 cycloalkylalkyl or C.sub.6 -C.sub.10 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl and heterocyclyl;</claim-text></claim-text><claim-text>R.sup.4 is independently selected at each occurrence from: C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, NO.sub.2, halo, CN, C.sub.1 -C.sub.4 haloalkyl, NR.sup.6 R.sup.7, NR.sup.8 COR.sup.7, NR.sup.8 CO.sub.2 R.sup.7, COR.sup.7, OR.sup.7, CONR.sup.6 R.sup.7, CO(NOR.sup.9)R.sup.7, CO.sub.2 R.sup.7, or S(O).sub.n R.sup.7, where each such C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.6 cycloalkyl and C.sub.4 -C.sub.12 cycloalkylalkyl are optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, NO.sub.2, halo, CN, NR.sup.6 R.sup.7, NR.sup.8 COR.sup.7, NR.sup.8 CO.sub.2 R.sup.7, COR.sup.7 OR.sup.7, CONR.sup.6 R.sup.7, CO.sub.2 R.sup.7, CO(NOR.sup.9)R.sup.7, or S(O).sub.n R.sup.7 ;</claim-text><claim-text>R.sup.6, R.sup.7, R.sup.6a and R.sup.7a are independently selected at each occurrence from:<claim-text>--H,</claim-text><claim-text>--C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.1 -C.sub.10 haloalkyl with 1-10 halogens, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, C.sub.5 -C.sub.10 cycloalkenyl, or C.sub.6 -C.sub.14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl,</claim-text><claim-text>-aryl, aryl(C.sub.1 -C.sub.4 alkyl), heteroaryl, heteroaryl (C.sub.1 -C.sub.4 alkyl), heterocyclyl or heterocyclyl (C.sub.1 -C.sub.4 alkyl);<claim-text>alternatively, NR.sup.6 R.sup.7 and NR.sup.6a R.sup.7a are independently piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine, each optionally substituted with 1-3 C.sub.1 -C.sub.4 alkyl groups;</claim-text></claim-text></claim-text><claim-text>R.sup.8 is independently selected at each occurrence from H or C.sub.1 -C.sub.4 alkyl;</claim-text><claim-text>R.sup.9 and R.sup.10 are independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, or C.sub.3 -C.sub.6 cycloalkyl;</claim-text><claim-text>R.sup.11 is selected from H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, or C.sub.3 -C.sub.6 cycloalkyl;</claim-text><claim-text>R.sup.12 is C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 haloalkyl;</claim-text><claim-text>R.sup.13 is selected from C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, aryl, aryl (C.sub.1 -C.sub.4 alkyl)-, heteroaryl or heteroaryl(C.sub.1 -C.sub.4 alkyl)-;</claim-text><claim-text>R.sup.14 is selected from C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, or C.sub.4 -C.sub.12 cycloalkylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, and C.sub.1 -C.sub.6 alkylthio, C.sub.1 -C.sub.6 alkylsulfinyl and C.sub.1 -C.sub.6 alkylsulfonyl;</claim-text><claim-text>R.sup.15 and R.sup.16 are independently selected at each occurrence from H, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.10 cycloalkyl, C.sub.4 -C.sub.16 cycloalkylalkyl, except that for S(O).sub.n R.sup.15, R.sup.15 cannot be H;</claim-text><claim-text>aryl is phenyl or naphthyl, each optionally substituted with 1 to 5 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15,SH, S(O).sub.n R.sup.15, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.16 R.sup.15, and CONR.sup.16 R.sup.15 ;</claim-text><claim-text>heteroaryl is pyridyl, pyrimidinyl, triazinyl, furanyl, pyranyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, isoxazolyl, pyrazolyl, 2,3-dihydrobenzothienyl or 2,3-dihydrobenzofuranyl, each being optionally substituted with 1 to 5 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, --COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.16 R.sup.15, and CONR.sup.16 R.sup.15 ;</claim-text><claim-text>heterocyclyl is saturated or partially saturated heteroaryl, optionally substituted with 1 to 5 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.15 R.sup.16, and CONR.sup.16 R.sup.15 ;</claim-text><claim-text>n is independently at each occurrence 0, 1 or 2.</claim-text></claim-text></claim><claim num="25"><claim-text>25. A method of treating depression in mammals, comprising administering to the mammal a therapeutically effective amount of a compound of Formulae (1) or (2): ##STR52## and isomers thereof, stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, and pharmaceutically acceptable salt forms thereof, wherein:<claim-text>Z is N or CR.sup.2 ;</claim-text><claim-text>Ar is selected from phenyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, furanyl, thienyl, benzothienyl, benzofuranyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, indanyl, 1,2-benzopyranyl, 3,4-dihydro-1,2-benzopyranyl, tetralinyl, each Ar optionally substituted with 1 to 5 R.sup.4 groups and each Ar is attached to an unsaturated carbon atom;</claim-text><claim-text>R is independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.7 cycloalkylalkyl, halo, CN, C.sub.1 -C.sub.4 haloalkyl;</claim-text><claim-text>R.sup.1 is independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, halo, CN, C.sub.1 -C.sub.4 haloalkyl, C.sub.1 -C.sub.12 hydroxyalkyl, C.sub.2 -C.sub.12 alkoxyalkyl, C.sub.2 -C.sub.10 cyanoalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, NR.sup.9 R.sup.10, C.sub.1 -C.sub.4 alkyl-NR.sup.9 R.sup.10, NR.sup.9 COR.sup.10, OR.sup.11, SH or S(O).sub.n R.sup.12 ;</claim-text><claim-text>R.sup.2 is selected from H, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.10 cycloalkylalkyl, C.sub.1 -C.sub.4 hydroxyalkyl, halo, CN, --NR.sup.6 R.sup.7, NR.sup.9 COR.sup.10, --NR.sup.6 S(O).sub.n R.sup.7, S(O).sub.n NR.sup.6 R.sup.7, C.sub.1 -C.sub.4 haloalkyl, --OR.sup.7, SH or --S(O).sub.n R.sup.12 ;</claim-text><claim-text>R.sup.3 is selected from:<claim-text>--H, OR.sup.7, SH, S(O).sub.n R.sup.13, COR.sup.7, CO.sub.2 R.sup.7, OC(O)R.sup.13, NR.sup.8 COR.sup.7, N(COR.sup.7).sub.2, NR.sup.8 CONR.sup.6 R.sup.7, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.6 R.sup.7, NR.sup.6a R.sup.7a, N(OR.sup.7)R.sup.6, CONR.sup.6 R.sup.7, aryl, heteroaryl and heterocyclyl, or</claim-text><claim-text>--C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.5 -C.sub.8 cycloalkenyl, C.sub.4 -C.sub.12 cycloalkylalkyl or C.sub.6 -C.sub.10 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl and heterocyclyl;</claim-text></claim-text><claim-text>R.sup.4 is independently selected at each occurrence from:<claim-text>C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, NO.sub.2, halo, CN, C.sub.1 -C.sub.4 haloalkyl, NR.sup.6 R.sup.7, NR.sup.8 COR.sup.7, NR.sup.8 CO.sub.2 R.sup.7, COR.sup.7, OR.sup.7, CONR.sup.6 R.sup.7, CO(NOR.sup.9)R.sup.7, CO.sub.2 R.sup.7, or S(O).sub.n R.sup.7, where each such C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.10 alkenyl, C.sub.2 -C.sub.10 alkynyl, C.sub.3 -C.sub.6 cycloalkyl and C.sub.4 -C.sub.12 cycloalkylalkyl are optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.4 alkyl, NO.sub.2, halo, CN, NR.sup.6 R.sup.7, NR.sup.8 COR.sup.7, NR.sup.8 CO.sub.2 R.sup.7, COR.sup.7 OR.sup.7, CONR.sup.6 R.sup.7, CO.sub.2 R.sup.7, CO(NOR.sup.9)R.sup.7, or S(O).sub.n R.sup.7 ;</claim-text></claim-text><claim-text>R.sup.6, R.sup.7, R.sup.6a and R.sup.7a are independently selected at each occurrence from:<claim-text>--H,</claim-text><claim-text>--C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.1 -C.sub.10 haloalkyl with 1-10 halogens, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, C.sub.5 -C.sub.10 cycloalkenyl, or C.sub.6 -C.sub.14 cycloalkenylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.13, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.13, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.13, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, aryl, heteroaryl or heterocyclyl,</claim-text><claim-text>-aryl, aryl(C.sub.1 -C.sub.4 alkyl), heteroaryl, heteroaryl (C.sub.1 -C.sub.4 alkyl), heterocyclyl or heterocyclyl (C.sub.1 -C.sub.4 alkyl);<claim-text>alternatively, NR.sup.6 R.sup.7 and NR.sup.6a R.sup.7a are independently piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine or thiomorpholine, each optionally substituted with 1-3 C.sub.1 -C.sub.4 alkyl groups;</claim-text></claim-text></claim-text><claim-text>R.sup.8 is independently selected at each occurrence from H or C.sub.1 -C.sub.4 alkyl;</claim-text><claim-text>R.sup.9 and R.sup.10 are independently selected at each occurrence from H, C.sub.1 -C.sub.4 alkyl, or C.sub.3 -C.sub.6 cycloalkyl;</claim-text><claim-text>R.sup.11 is selected from H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, or C.sub.3 -C.sub.6 cycloalkyl;</claim-text><claim-text>R.sup.12 is C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 haloalkyl;</claim-text><claim-text>R.sup.13 is selected from C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.2 -C.sub.8 alkoxyalkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.4 -C.sub.12 cycloalkylalkyl, aryl, aryl (C.sub.1 -C.sub.4 alkyl)-, heteroaryl or heteroaryl (C.sub.1 -C.sub.4 alkyl)-;</claim-text><claim-text>R.sup.14 is selected from C.sub.1 -C.sub.10 alkyl, C.sub.3 -C.sub.10 alkenyl, C.sub.3 -C.sub.10 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, or C.sub.4 -C.sub.12 cycloalkylalkyl, each optionally substituted with 1 to 3 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.16 R.sup.15, CONR.sup.16 R.sup.15, and C.sub.1 -C.sub.6 alkylthio, C.sub.1 -C.sub.6 alkylsulfinyl and C.sub.1 -C.sub.6 alkylsulfonyl;</claim-text><claim-text>R.sup.15 and R.sup.16 are independently selected at each occurrence from H, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.10 cycloalkyl, C.sub.4 -C.sub.16 cycloalkylalkyl, except that for S(O).sub.n R.sup.15, R.sup.15 cannot be H;</claim-text><claim-text>aryl is phenyl or naphthyl, each optionally substituted with 1 to 5 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15,SH, S(O).sub.n R.sup.15, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.16 R.sup.15, and CONR.sup.16 R.sup.15 ;</claim-text><claim-text>heteroaryl is pyridyl, pyrimidinyl, triazinyl, furanyl, pyranyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, isoxazolyl, pyrazolyl, 2,3-dihydrobenzothienyl or 2,3-dihydrobenzofuranyl, each being optionally substituted with 1 to 5 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, --COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.16 R.sup.15, and CONR.sup.16 R.sup.15 ;</claim-text><claim-text>heterocyclyl is saturated or partially saturated heteroaryl, optionally substituted with 1 to 5 substituents independently selected at each occurrence from C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, halo, C.sub.1 -C.sub.4 haloalkyl, cyano, OR.sup.15, SH, S(O).sub.n R.sup.15, COR.sup.15, CO.sub.2 R.sup.15, OC(O)R.sup.15, NR.sup.8 COR.sup.15, N(COR.sup.15).sub.2, NR.sup.8 CONR.sup.16 R.sup.15, NR.sup.8 CO.sub.2 R.sup.15, NR.sup.15 R.sup.16, and CONR.sup.16 R.sup.15 ;</claim-text><claim-text>n is independently at each occurrence 0, 1 or 2.</claim-text></claim-text></claim><claim num="26"><claim-text>26. A method of treating anxiety in mammals, comprising administering to the mammal a therapeutically effective amount of a compound of claim 1, 5, 9, 16, 17, 19 and 20.</claim-text></claim><claim num="27"><claim-text>27. A method of treating depression in mammals, comprising administering to the mammal a therapeutically effective amount of a compound of claim 1, 5, 9, 16, 17, 19 and 20.</claim-text></claim><claim num="28"><claim-text>28. A method of claims 24 or 25 wherein, in the compound of Formulae (1) or (2), Ar is phenyl, pyridyl or 2,3-dihydrobenzofuranyl, each optionally substituted with 1 to 4 R.sup.4 substituents.</claim-text></claim></claims><copyright>User acknowledges that Matrixware and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement set forth at http://www.matrixware.com/legal/marec/data_licence.html</copyright></patent-document>